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factor VIIa (rFVIIa) therapeutic efficacy. We then extended this mechanistic investigation of rFVIIa to flow
assays where clotting is initiated by collagen and immobilized lipidated tissue factor to evaluate the role of the
intrinsic tenase in conjunction with exogenous rFVIIa when surface-triggered extrinsic pathway is present.
Finally, we continued to assess coagulopathic patients by first mimicking resuscitation-driven hemodilution,
hyperfibrinolysis, and plasmin-inhibitor therapy under flow. We then evaluated downregulation of platelet
function in whole blood from trauma patients during the acute phase of trauma-induced coagulopathy. The
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in advancing our knowledge of clinical and pathological disorders such as myocardial infracts, hemophilia, and
deep vein thrombosis. Beyond this work, microfluidic platforms in hemostasis and thrombosis can potentially
be used as drug screening platforms for antiplatelet or clotting factor therapies, or a point of care diagnostic
test for bleeding and pin-pointing the therapeutic index of novel biopharmaceutics.
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ABSTRACT 
 
MICROFLUIDIC APPROACHES TO THROMBOSIS AND HEMOSTASIS: A 
GLOBAL INVESTIGATION OF ANTIPLATELET THERAPEUTICS AND THE 
ASSESSMENT OF BLEEDING AND COAGULOPATHY IN HEMOPHILIC AND 
TRAUMA PATIENTS 
 
Ruizhi (Richard) Li 
Scott L. Diamond 
 
Current in vitro or ex vivo models of hemostasis and thrombosis fail to recapitulate the 
hemodynamic conditions and biorheologic phenomena found throughout the vasculature. 
Microfluidic technology enables physiologic hemodynamics for the study of platelet 
deposition and coagulation using minimum volumes of human whole blood. This 
dissertation describes the application of microfluidic assays, the manipulation of surface-
patterned procoagulant and sub-endothelial proteins, anti-coagulation, and flow conditions 
to investigate platelet function and coagulation under flow. First, we demonstrate a novel 
method to assess the in vivo or in vitro therapeutic efficacy of anti-platelet therapies on 
platelet aggregates adhering to collagen type I surfaces. We phenotyped individual healthy 
donor platelet function responses to in vivo or in vitro aspirin, a common antiplatelet 
therapy over collagen type I surfaces at venous shear rates. Utilizing the same flow assay, we 
also characterized mechanism-based resistance to aspirin conferred by non-steroidal anti-
inflammatory drugs. Furthermore, we have also developed a new model to assess the 
intrinsic pathway of coagulation under flow on collagen type I surfaces and investigated the 
role of the intrinsic pathway in recombinant coagulation factor VIIa (rFVIIa) therapeutic 
efficacy. We then extended this mechanistic investigation of rFVIIa to flow assays where 
clotting is initiated by collagen and immobilized lipidated tissue factor to evaluate the role of 
the intrinsic tenase in conjunction with exogenous rFVIIa when surface-triggered extrinsic 
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pathway is present. Finally, we continued to assess coagulopathic patients by first mimicking 
resuscitation-driven hemodilution, hyperfibrinolysis, and plasmin-inhibitor therapy under 
flow. We then evaluated downregulation of platelet function in whole blood from trauma 
patients during the acute phase of trauma-induced coagulopathy.  The development of 
microfluidics, microfabrication, and its applications in hemostasis and thrombosis is essential 
in advancing our knowledge of clinical and pathological disorders such as myocardial 
infracts, hemophilia, and deep vein thrombosis.  Beyond this work, microfluidic platforms in 
hemostasis and thrombosis can potentially be used as drug screening platforms for 
antiplatelet or clotting factor therapies, or a point of care diagnostic test for bleeding and 
pin-pointing the therapeutic index of novel biopharmaceutics.  
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1 INTRODUCTION TO PLATELETS, BLOOD COAGULATION, 
AND MICROFLUIDICS 
1.1 Hemostasis and the Role of Platelets  
 Human blood is primarily comprised of plasma proteins, platelets, red blood cells, 
and white blood cells. In human whole blood, platelets are the primary anucleate cells that 
are responsible for hemostasis, more commonly described as the physiologic balance 
between bleeding and excessive blood clotting (thrombosis). Healthy whole blood on 
average contains 150,000 – 400,000 platelets per microliter[1]. These anucleate cells stay in a 
quiescent state circulating the blood vasculature patrolling the human body for vessel wall 
damage and exposure of the subendothelium. Once damage occurs to the vessel wall, tissue 
factor (TF) is exposed and the coagulation cascade (to be described in detail later) is 
triggered. This cascade produces a potent serine protease thrombin (IIa) which activates 
platelets[2]. The final downstream product of the cascade is fibrin, which is a fibrous 
biopolymer network that stabilizes and seals a blood clot[3].   
Platelets are able to remain in a quiescent state as they are inhibited by chemical 
mediators from the endothelium, prostacyclin (PGI2) and nitric oxide (NO2)[4]. Additionally, 
platelets have numerous receptors and respond to activating stimuli such as collagen, von 
Willebrand Factor (vWF), epinephrine, and histamine[4]. In the presence of these agonists, 
platelet become activated through a series of transmembrane receptors on their surface. This 
then results in an increase in intracellular calcium that cause changes in platelet morphology 
and the platelet cytoskeleton[5]. In addition to platelet shape change, platelet activation also 
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results in the secretion of additional agonists from platelet alpha and dense granules. These 
granules are packaged prior to platelet release by megakaryocytes during 
megakaryopoiesis[6].  Secretion of these agonists [Adenosine Diphosphate (ADP), 
Thromboxane A2 (TXA2)] results in both autocrine and paracrine signaling which are 
biochemical signaling processes important for the recruitment of additional platelets to the 
site of injury and the stabilization of previously deposited platelets during blood clotting.  
1.2 Thrombosis  
 Once the delicate balance of blood clotting is perturbed, excessive clot growth or 
thrombosis then occurs. Thrombosis is the cessation of blood flow through a vessel due to 
an occlusive blood clot. Two clinically-relevant types of thrombosis are clots that emanate 
from the venous circulation or clots that emanate from the arterial circulation of the 
vasculature.  The most prevalent venous thrombosis is deep vein thrombosis (DVT). Deep 
vein thrombosis usually occurs due to continuous immobilization, surgery, or heart 
failure[7]. Medical treatment for DVT consists of anticoagulant drugs such as heparin or 
vitamin K antagonists[7]. Arterial thrombosis is pathologically different from venous 
thrombosis and occurs within arterioles[8]. A prime example of arterial thrombosis is 
myocardial infarction (MI), otherwise commonly known as a heart attack. This sudden 
occlusive event prevents blood flow to the heart. The major causes of MI are usually genetic 
risk factors, atherosclerotic plaque build-up and rupture, or a combination of high blood 
pressure, cholesterol and obesity[8]. Common treatment for arterial thrombosis includes 
antiplatelet therapies, drug-eluting stents, and bypass surgery. A major concern with venous 
and arterial thrombosis is the risk of thromboembolism. Thromboembolism is a scenario 
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where an occlusive clot dislodges from the injury site and eventually travels downstream and 
becomes lodged in another vascular bed. Thromboembolism is a major concern with 
patients who have DVT or have experienced acute MI. Thrombus dislodgement followed by 
adherence either in the lungs or brain could put an individual at risk for pulmonary 
embolism or stroke. The investigation of the biophysical and biochemical characteristics of 
venous and arterial thrombi is on-going and much additional research is still needed[9]. 
1.3 Hemostatic clot growth under flow: platelet adhesion biology & 
receptor interactions  
 Hemostastic clot growth under physiologic flow environments occurs in three stages, 
initial platelet adherence to subendothelial proteins, growth of the clot through autocrine 
and paracrine signaling, and stabilization of the platelet aggregate (Figure 1-1). Platelets 
initially adhere to either collagen or vWF at the site of injury. This initial adhesion is 
mediated through platelet receptors α2β1 and glycoprotein VI (GPVI) for collagen and 
glycoprotein IB (GPIB) for vWF respectively[10]. Beyond this initial monolayer of platelets 
adhered to collagen and vWF, local platelet secretion of agonists ADP and TXA2 help 
activate more platelets and recruits those additional platelets to the site of injury[11]. 
Furthermore, platelet calcium levels Ca2+ rise due to its release from intracellular stores. 
Rising Ca2+ levels results in platelet integrin αIIbβ3 activation. Platelet integrin αIIbβ3 is a major 
integrin involved in platelet aggregation, it undergoes a conformational change which then 
facilitates its binding to fibrinogen, a major plasma protein in blood and vWF[12]. The high 
copy number of platelet αIIbβ3 and multiple binding sites on fibrinogen and vWF for αIIbβ3 
then ensure platelet aggregation, extension of the hemostatic blood clot and the cessation of 
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bleeding. This is further supported by platelet mechanosensing as increases in platelet 
activation and changes in the local flow environment results in single platelet and platelet 
aggregate contraction that secures the clot against the vessel wall and stops bleeding[13,14].  
 
Figure 1-1 Hemostatic Plug Formation, Aggregation, and Contraction 
 
 (a) Circulating platelets are kept quiescent by PGI2 and NO released from endothelial cells. (b & c) At sites of 
vessel injury, platelets adhere to proteins of the exposed subendothelium through interactions with collagen, 
vWF through their receptors integrin α2β1 and GPIb respectively. Agonists, ADP and thrombin then cause 
platelet shape change. (d) Activated platelets release ADP and fibrinogen from their intracellular granules. ADP 
and TXA2 recruits additional platelets to the site of injury through autocrine and paracrine signaling. (e) Platelet 
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αIIbβ3 becomes engaged and activated platelets bind fibrinogen or vWF resulting in platelet aggregation. (f) Clot 
contraction then leads to a stable thrombus under flow.  
 
 A final important role of platelets during blood clotting is the ability of their 
phospholipid membrane surfaces to support coagulation. The surface of activated platelets 
becomes negatively charged due to phosphatidylserine (PS) and phosphatidycholine (PC) 
exposure as these phospholipids are transferred from the inner leaflet of the platelet 
membrane to the outer leaflet of the platelet membrane[15]. This negatively charged surface 
then provides a surface for the adherence of plasma proteins which then can support the 
coagulation cascade[16].  
1.4 Coagulation 
 Blood coagulation is a series of biochemical, enzymatic pathways that is governed by 
zymogens, serine proteases, and enzymes. This serious of reactions results in generation of a 
master enzyme, thrombin and the formation of a biopolymer network, fibrin, which then 
stabilizes the clot.  The coagulation cascade is divided into two pathways, the contact 
(intrinsic) pathway and the tissue factor (extrinsic) pathway. These two pathways converge to 
the formation of clotting factor Xa (FXa). The subsequent steps following FXa generation 
are known as the “common pathway”. This leads to the formation of thrombin. Thrombin 
then acts on fibrinogen to convert fibrinogen into fibrin monomer which then polymerize 
into fibrin. Fibrin fibers stabilize the loose platelet aggregate. These pathways occur in the 
presence of serine protease inhibitors that limit the activity of active proteases. The 
coagulation cascade is schematically depicted in.  
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Figure 1-2 Schematic Depiction of the Coagulation Cascade  
 
The coagulation cascade involves a series of sequential plasma reactions that lead to the generation of 
thrombin. The cascade is triggered either by exposure of TF at the site of injury (extrinsic pathway) or by 
exposure to negatively charged surfaces and activation of FXII (intrinsic pathway). Both pathways lead to 
thrombin formation and then fibrin production.  
 
In in vivo scenarios, the extrinsic pathway is the predominant trigger of the 
coagulation cascade. This involves the exposure of TF at the site of vascular injury. TF is 
commonly expressed by smooth muscle cells and fibroblasts. TF exposure to flowing blood 
in vivo then allows binding of activated soluble clotting factor seven (FVIIa). FVII is a 
member of the vitamin K-dependent clotting factors, the others are FIX, FIX, and proteins 
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C and S[18]. Most coagulation factors have gamma-carboxyglutamic acid residues in the N-
terminal region (Gla-domain) of their protein structure which then enables them to bind 
calcium and assemble on the phospholipid surfaces of platelets. Once the TF/FVIIa 
complex forms it can activate FIX via limited proteolysis. However, TF/FVIIa complex can 
directly activate FX and this is a heavily favored pathway in vivo. Once FIX is activated, it 
can also activate FX as long as FVIIIa is present. Factor VIIIa is the cofactor for FIXa and 
the assembly of these two active factors together to promote FXa generation is known as the 
‘intrinsic tenase’ complex’. As all serine proteases and clotting cofactors in the coagulation 
cascade exist as zymogens in the plasma component of whole blood, it is surprising how 
such potent biocatalytic reactions can be triggered via the ensemble of these inert precursors. 
However, previous studies have shown that sub-nanomolar concentrations of FVIIa does 
exist in circulation while active forms of other clotting factors are even more miniscule in 
comparison. Exposure of TF to this small but nevertheless potent amount of FVIIa then 
sets up autocatalytic feedback where VII bound to TF is activated. Furthermore, other 
clotting enzymes can also activate FVII which thus makes the coagulation cascade a network 
of self-amplifying, feedforward, and feedback reactions.  
 In a traditional sense, the other arm of the coagulation cascade is the ‘intrinsic’ 
pathway. Its name is derived from the ‘intrinsic’ ability of blood to clot when placed in a 
glass tube. Specifically speaking, blood derived from the human blood tends to clot in vitro 
when in direct contact with negatively charged surfaces. Non-physiologic surfaces for 
contact activation of blood include glass, clay, and kaolin, while physiologic substrates for 
contact activation include DNA, RNA, and histones. The contact pathway has been viewed 
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previously as non-physiologic as severe deficiencies in the most upstream source of this 
pathway(FXII) causes no severe bleeding defect[19]. In fact, studies have shown inadequate 
levels of FXII may actually result in increased risk of thrombosis[20]. However, recent in 
vivo models have shown that mice deficient in FXII have a tendency to form unstable 
thrombi, thus suggesting that this previously overlooked part of the coagulation cascade may 
have an important physiologic role. The intrinsic pathway is activated once zymogen FXII 
comes into contact with negatively charged surfaces. The heavy chain of FXII is the portion 
that binds to negatively charged surfaces which then leads to increases in local enzyme 
concentration, autoactivation, and activation of FXI. Then FIX is activated by dimerized 
FXIa.  
 Nevertheless both the intrinsic and extrinsic pathway converge to FXa generation. 
Factor Xa along with its cofactor FVa converts prothrombin into thrombin. Factor Xa 
assembly with FVa in the presence of calcium on a phospholipid surface results in a 300,000 
fold increase in thrombin generation as compared to FXa alone. Thrombin is central to the 
formation of the haemostatic blood clot as it controls its own generation and inhibition by 
acting on numerous substrates such as fibrinogen, FV, FVIII, FIX, platelet receptors, 
protein S, and protein C. One major role of thrombin is its cleavage of fibrinogen, a heavily 
abundant protein in both plasma and platelet granules. Thrombin cleavage of fibrinopeptide 
A and B of fibrinogen results in a self-association and restructuring of fibrin monomers[21]. 
The progressive lengthening of initial fibrin monomers into dimers and beyond occurs 
initially through half overlap of fibrin monomers which then forms long, thin fibrin strands. 
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Factor XIIIa can then crosslink these loose fibrin strands and confers degradation by 
plasmin.    
1.5 Anticoagulation for in vitro and ex vivo research 
1.5.1 Citrate or Ethylenediaminetetraacetic acid (EDTA)  
Citrate or EDTA are potent calcium chelators that can completely inhibit thrombin 
production and platelet adhesion under flow. Thus these reagents are ideally used for pure 
biorheological studies of platelet/red blood cell interaction under flow. The addition of 
exogenous Ca2+ for recalcification can recover extracellular calcium levels, however EDTA 
tends to destroy αIIbβ3 function and citrate also significantly impairs αIIbβ3 after 
recalcification[22]. Basic scientific and clinical studies of TF or contact pathway triggered 
coagulation predominantly uses citrate as an anticoagulant. However, it is important to note 
that FXIIa can be generated in the absence of calcium.  
1.5.2 Corn Trypsin Inhibitor (CTI) 
CTI is an intrinsic pathway inhibitor which when used in the 20-120 µg/ml range 
can inhibit the activity of βFXIIa, the soluble cleavage product formed from surface-bound 
αFXIIa. As CTI does not inhibit αFXIIa, it can provide approximately 30-60 min of 
inhibition of the contact pathway without interfering with the cation levels required for 
extrinsic pathway medicated coagulation. Thus high exogenous concentrations of CTI are 
commonly used to test TF-initiated coagulation under flow given that blood can be tested in 
vitro immediately following phlebotomy. Furthermore, recent studies have shown that a low 
level of CTI (4 µg/ml) can partially delay the contact pathway allowing study of FXIIa and 
its subsequent reactions ex vivo provided that blood is perfused ex vivo within 5-15 minutes 
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of phlebotomy[23,24].  Other reagents have also been used to control in vitro contact 
activation. Monoclonal function-blocking antibodies have been used against FXIIa and 
FXIa[25]. Infestin-4 has been used to antagonize FXIIa, while domains from protease nexin-
2 have been used to inhibit FXIa[26–28].  
1.5.3 FPR-Chloromethylketone (PPACK), Direct FXa inhibitors, Heparin  
PPACK is a small molecule inhibitor of thrombin. PPACK (100 µM) provides strong 
and irreversible inhibition of thrombin for in vitro studies of platelet function. This 
approach is useful to solely examine platelet activation, adhesion, aggregation, and function 
in the absence of thrombin and fibrin. Furthermore, with the advent of novel oral direct 
FXa inhibitors (apixaban), these new anticoagulants can be used in vitro for direct inhibition 
of FXa. The use of apixaban (0.25 – 1 µM) becomes particularly useful when examining the 
effect of exogenously added thrombin on platelet activation and intracellular calcium 
signaling[29].  
1.6 Microfluidic Technology  
1.6.1 Motivation 
Microfluidic technology was invented due to a need in industrial applications and 
academic laboratories to minimize reagent usage, evaluate novel drug therapeutic efficacy 
and toxicity, and increase throughput while maintaining the physiologic conditions in which 
most biological systems exist. Since blood flow occurs in a closed, high pressure, 
continuously circulating system, in vitro or ex vivo models that can capture the 
hemodynamics and flow characteristics offer better opportunities to accurately investigate 
the biological phenomena that occurs in vivo during thrombus formation. Furthermore, 
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current in vivo animal models of hemostatic and vascular injury are still not well-understood 
and the small volumes of blood collected from difficult to breed genetically modified 
animals mandates a low volume test of hemostasis and thrombosis[30,31].  
Several previous technologies have been used to study the hemostatic process under 
flow ex vivo. Such technologies include parallel plate flow chambers, capillary flow 
chambers, and cone and plate viscometers. These technologies all have their own pitfalls 
with respect to volume requirements, experimental control and physiologic hemodynamics. 
By coupling very well-established micropatterning techniques with soft photolithography, 
microfluidic assays can be developed for whole blood perfusion over well-defined 
biomimetic injuries. With control over flow conditions, micropatterned protein/enzyme 
surface composition and inlet blood biochemistry, thrombi can be formed in vitro and 
examined with real time epifluorescence microscopy by a host of monoclonal antibodies, 
novel biosensors, and fluorescently conjugated peptides or proteins. Finally, the ability to 
measure multiple outputs in real-time with various fluorescent probes from a single blood 
sample over the course of an experiment provides control and reproducibility critical to the 
variable nature of hemostatic studies. This could serve as a basis for future automated 
preclinical diagnostic platforms.  
 A thorough discussion of PDMS and microcontact printing techniques is out of the 
scope of this dissertation and extensive reviews can be found elsewhere[32]. Generally 
speaking, microfluidic devices are made out of polydimethylsiloxane (PDMS) that was cured 
over master molds fabricated by photolithographic techniques. In brief, a photoresistive 
substrate is spin-coated onto a silicon wafer in a process known as spin-coating. This process 
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enables substrate adherence to the wafer to a height that will represent the microfluidic 
channel depth. The spin-coated wafer is then brought into close contact with a high-
resolution transparency of the desired microfluidic geometry and channel device. UV light is 
then shun on the sample which then cross-links the photo-resistive substrate. Unexposed 
photoresist is then removed with a developing solution. This master mold can then be used 
to make PDMS casts of the microfluidic devices.   
1.6.2 Microfluidic open systems for the study of hemostasis and thrombosis: Focal 
Injury Models, High Throughput Testing  
Open microfluidic systems allow for exchange with the outside environment and 
offer excellent spatial and temporal control of the flow regime, surface protein/enzyme 
concentration, and perfused blood biochemistry. Such flow systems allow for high replicate 
testing of clotting events in vitro and utilizes low volumes of blood (< 1 ml). Microfluidic 
assays provide control of local flow environments by perfusion of whole blood over well-
defined geometries and excellent command of sample flow rates via pre-programed syringe 
pumps that can also be automated via external LABVIEW interface[13]. Physiological 
venous (100-800 s-1) and arterial shear rates (1000-2000 s-1) can be used in microfluidic 
devices, and pathological shear rates (10,000-200,000 s-1) have also been investigated too. 
Most microfluidic devices set-ups are single path perfusions and for square rectangular 
channels, the x-directed velocity field for steady flow over a domain of –w/2 y w/2 and 0 z 
h is given by  
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(Equation 1-1)  
 
PDMS allows for the creation of rectangular flow channels with microscopic features down 
to approximately 3 µm. Microcontact stamping has also allowed microprinting of proteins or 
lipids on various substrates down to a spatial resolution of < 1 µm. Neeves et al. have 
previously demonstrated the use of micropatterned collagen surfaces in a PDMS 
microchannel[33]. Collagen Type I was patterned onto a glass slide using a single channel 
device that was then removed to allow placement of a second 13 channel flow device[33]. 
The resulting protocol was an assay of thrombi formed over 13 individual flow paths each 
with a precisely patterned injury site where collagen was exposed to the flowing blood. 
Maloney et al. further advanced this design by making an 8-channel device through which 
blood was perfused by withdrawal through a single outlet[34]. Furthermore, Colace et al. also 
improved the biological complexity of the surface trigger in this model 8-channel 
microfluidic system. With regards to micropatterning, microchannels are usually filled with a 
protein of interest and rinsed with physiologic buffer before sample perfusion. Colace et al. 
used this technique to generate thrombogenic surfaces of collagen and immobilized TF in 
PDMS microchannels[35]. Briefly, Colace et al. modified the TF-bearing liposomes 
described by Smith et al. to produce TF-bearing biotinylated liposomal constructs which 
then could be bound to a collagen surface via biotinylated anti-collagen antibody and 
14 
 
streptavidin[36]. Such techniques are vital to study the simultaneous effect of platelet 
deposition and thrombin production under flow and characterize the roles of thrombin in 
platelet adhesion and fibrin generation in platelet plug formation[37]. Finally, it is important 
to note that the use of external syringe pumps only generates constant flow rate 
environments. Under these flow conditions, growing thrombi only obstruct the flow as large 
pressure drops develop eventually leading the partial and complete embolism of clots as even 
occlusive structures under flow cannot stop a syringe pump. Thus Colace et al. used the 8-
channel device previously described to create a constant pressure drop flow regime by 
developing thrombi in four of eight channels which then diverted flow to the other four 
bifurcated channels due to the unreactive EDTA-treated blood that was being perfused 
simultaneously[37]. This was verified computationally with fluid dynamics simulations 
showing a drastic difference between clots formed in the presence or absence of fibrin.  
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2 MICROFLUIDIC ASSAY OF PLATELET DEPOSITION ON 
COLLAGEN BY PERFUSION OF WHOLE BLOOD FROM 
HEALTHY INDIVIDUALS TAKING ASPIRIN 
2.1 Introduction 
Antiplatelet therapies are commonly used in the acute treatment of coronary diseases 
and long-term prevention of cardiovascular events[38]. Inhibition of platelet cyclooxygenase-
1 (COX-1) by aspirin (acetylsalicylic acid, ASA) and the subsequent attenuation of 
thromboxane A2 (TXA2) production causes a decrease in secondary platelet aggregation and 
reduces excessive thrombus formation[39]. ASA does not severely reduce the primary 
platelet response to the damaged vessel wall needed for homeostasis. Currently, about 50 
million patients in the United States take ASA at typical doses of 81 or 325-mg per day to 
reduce cardiovascular risks[40]. 
Aspirin reduces the activation of platelets by irreversibly acetylating serine 529 of 
cycloxygenase-1 and therefore reducing TXA2 production[39]. The inhibition of COX-1 is 
irreversible and permanent for the lifetime of platelets because platelets lack the synthetic 
machinery to produce new protein[41]. Recently, the bleeding risks associated with aspirin 
led to the development of anti-inflammatory drugs selective for COX-2.  Several COX-2 
selective inhibitors cause less gastrointestinal side effects than traditional non-steroidal anti-
inflammatory drugs[42], but they cause cardiovascular risks via inhibition of COX-2 
dependent endothelial prostacyclin. All approved COX-2 inhibitors have either been 
withdrawn or their prescription restricted[43].  
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However, with regards to COX-1 inhibitors, patients show a marked variability in 
laboratory responses to aspirin.  Depending on the platelet function test, aspirin resistance 
has been reported in 5-60% of patients[44–46].  Failure to actually take the pill is a well-
documented cause of apparent “aspirin resistance”[47,48]. Mutations in the thromboxane 
receptor would also cause aspirin insensitivity, but such mutations result in a modest 
bleeding phenotype that would be a contraindication for aspirin therapy[49]. Patients may 
also fail to benefit from aspirin therapy owing to increased platelet turnover, increased 
sensitivity to ADP and collagen[41], or increased COX-1 synthesis. However, an association 
between aspirin resistance detected by a laboratory test in patients and a higher vascular 
event rate in a group of resistant individuals has yet to be convincingly shown[50,51].   
Determination of the anti-platelet effectiveness of pharmacological agents often 
occurs in closed systems, with or without flow.  Measurement of platelet calcium 
mobilization upon TP stimulation is an example of a closed system with no flow[5].  Platelet 
aggregometry is a closed system with a poorly defined flow field. The efficacy of 
pharmacological agents in closed systems may not always predict anti-platelet therapeutic 
benefits under flow conditions. For example, apyrase is a potent inhibitor in a tube but can 
potentiate thrombosis under flow due to the dynamics of local levels of ATP and ADP in a 
concentration boundary layer[34]. During platelet deposition under flow conditions, the 
platelet deposit can reach platelet densities that are 50 to 200-fold greater than that of 
platelet rich plasma.  Because of this dense platelet deposit, the potency of pharmacological 
agents may depend on the local concentration of platelet release products that occur under 
flow conditions[52]. The advent of microfluidic technology has enabled such platelet 
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deposits to be built under flow[34,53].Microfluidic patterning techniques allow for spatially 
confined injury models distinct from current technologies such as perfusion of whole blood 
through coated glass capillary flow chambers or parallel plate flow chambers. Furthermore, 
microfluidic devices recreate the progression of signaling and thrombotic pathways as they 
progress from a surface trigger, i.e. collagen and/or thrombin produced at the wall to 
secondary aggregation processes driven by ADP and TXA2[37,52]. Here we investigated the 
utility of an 8-channel microfluidic device in assessing ASA phenotype using fluorescently 
labeled platelets with ASA added to whole blood in vitro, either before ASA intake or at 24 h 
after ASA intake by healthy individuals. We show a novel method to measure residual COX-
1 function and evaluation of the COX-1 mediated thromboxane A2 pathway in a 
microfluidic platelet function test under venous flow conditions.  
 
2.2 Materials and Methods 
2.2.1 Blood Collection, Labeling, and Drug Administration 
Blood was collected at 0 h and 26 h by venipuncture from 28 healthy subjects (18-55 
years), who self-reported non-smoking, free from oral medication and abstained from, 
caffeine, alcohol, and high fat food for 24 h prior to the study and throughout the duration 
of the study. All volunteers received a 325-mg loading dose of aspirin by mouth at 2 h. 
Subjects returned after a 2 week washout period for a third blood draw (Figure 2-1A). For 
arterial flow studies, blood was collected by venipuncture from 4 healthy individuals who 
were free of oral medication for 10 days and self-reported free from disease or bleeding 
disorders. All blood samples were drawn into H-D-Phe-Pro-Arg-chloromethylketone (100 
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µM PPACK final concentration, Haematologic Technologies). PPACK is a potent active site 
inhibitor of thrombin that irreversibly and specifically inactivates thrombin. All volunteers 
provided informed consent in accordance with IRB approval and the Declaration of 
Helsinki. The blood was treated with PE Mouse Anti-Human CD61 (αIIbβ3) antibody (BD 
Biosciences) in a ratio of 1:50. PPACK-treated whole blood was perfused through the 
microfluidic device within 1 h of phlebotomy. For in vitro additions to whole blood, 
acetylsalicylic acid (Sigma Aldrich) was dissolved in DMSO at 500 mM.  Dilutions of ASA 
were then made to the desired final concentration in HBS within 1 h of the test. Final ASA 
concentrations used were: 0 µM, 0.05 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM, 500 µM (final 
0.1 % DMSO in all samples). Blood was incubated for 30 min in ASA before initiation of 
the assay.  
2.2.2 Fabrication of microfluidic devices, platelet deposition, and real-time imaging   
Microfluidic devices were fabricated in poly(dimethylsioxane) (PDMS, Sylgard 184, 
Ellsworth Adhesives) according to previously described techniques[34]. The device was fed 
by 8 distinct wells, with perfusion by withdrawal into a syringe pump (Harvard Apparatus) 
from a single outlet (Figure 2-1B). The channels were spaced in close proximity to allow all 
channels to be imaged simultaneously with a 2X objective lens using an inverted microscope 
(IX81, Olympus America) equipped with a charge-coupled camera (Hamamatsu). A custom 
stage insert held 3 microfluidic devices allowing 24 simultaneous clotting events to be 
imaged in 15 sec intervals. A micropatterning device with a single channel (5 cm x 250 µm x 
50 µm) was used for patterning collagen. Equine fibrillar collagen type 1 (Chronopar, 
Chronolog) was diluted to 250 µg/mL in isotonic glucose solution (Chronopar, Chronolog). 
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Prior to perfusion, channels were blocked with 0.5% bovine serum albumin (BSA) in 2-[4-
(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffered saline (HBS, 20 
mmol/L HEPES, 160 mmol/L NaCl, pH 7.5) for 30 min. Samples were perfused at an 
initial venous wall shear rate of 200 s-1 (2 µL/min per channel) for 5 min. For arterial studies, 
an initial wall shear rate of 1000 s-1 (10 µL/min per channel) was used for 5 min. The 
respective shear rates for venous and arterial studies were established previously in other 
assays with the same microfluidic device[34,37].   
2.2.3 IC50 Calculation and ASA Sensitivity     
Background-corrected fluorescence values were fit with a four parameter dose-
response curve ((Equation 2-1): 
(Equation 2-1)                              
𝑭𝑰 = 𝑨 +
𝑨−𝑩
𝟏+𝟏𝟎[(𝑳𝒐𝒈 𝑰𝑪𝟓𝟎−𝑪)∙𝑫]
 
 
with C representing the ASA concentration, FI the background corrected fluorescence of the 
corresponding region of interest, A and B the minimum and maximum intensities, 
respectively, and D the Hill coefficient. The data were fit using a log(inhibitor) vs. response 
routine by GraphPad Prism 5.00 (GraphPad Software).  Analysis of platelet deposition and 
total platelet accumulation on collagen was also calculated using the change in the 
background-corrected fluorescence values over time between time intervals 60 to 150 sec for 
collagen deposition and 150 to 300 sec for TXA2-dependent secondary aggregation (F’ = ∆ 
F/∆ t between 60-150 sec or 150-300 sec). A ratio of these two slopes (R-value) was then 
taken as an internally normalized value for each subject with R > 1 when secondary 
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aggregation was prominent and R < 1 when secondary aggregation was attenuated relative to 
the primary response to collagen (primary deposition) (Figure 8-2, Table 6).   
 
Figure 2-1 ASA phenotyping protocol and quantification of ASA concentration-
response 
(A), Study protocol. Blood samples were taken at t = 0 h and t = 26 h with ASA administration to each healthy 
donor at t = 2 h, followed by a second blood draw 2 weeks later. For each blood sample, increasing amounts of 
in vitro ASA was added to PPACK-inhibited WB prior to microfluidic testing (3 replicate tests per blood 
sample). (B), Photograph of the 8-channel microfluidic device with the micropatterned collagen strip digitally 
indicated. (C & D), Epifluoresence images of fluorescently labeled platelet accumulation on the collagen and 
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platelet interaction zone with various in vitro ASA concentrations, either in randomized positions (C) or ordered 
by ASA concentration (D). (E), Platelet fluorescence values over time for each in vitro ASA concentration. (F), 
Schematic summary of secondary platelet aggregation and definition of R value on the basis of platelet 
deposition rates (F’).  
2.3 Results 
 A protocol was established (Figure 2-1A) for the recruitment of healthy 
donors (n = 28, Table 1) to obtain 3 venous blood samples. Relevant characteristics of the 
subjects are reported (Table 1). The first blood sample was collected at t = 0 h, followed by 
ASA ingestion at t = 2 h, and collection of a second sample at t = 26 h, 24 h after in vivo 
ingestion of 325-mg of ASA by all subjects (Period 1). A third venous sample was collected 
after a 2 week washout period at t = 0 h (Period 2). With each of the 3 blood samples 
obtained from each donor during Period 1 and 2, ASA was added in vitro at increasing doses 
from 0 to 500 µM ASA prior to running the 300 sec microfluidic test (8 doses run in 
triplicate per blood draw at an initial wall shear rate of 200 s-1), for a total of 2304 individual 
clotting events. All results shown are an average of triplicate measurements. 
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Subject 
ID 
Age BMI Gender 
Platelet Count 
Period 1                                    
(x1000 
platelets/µL) 
Platelet Count 
Period 2                                                           
(x1000 
platelets/µL) 
%
Hematocrit 
217 25 27.08 M 190 187 43 
246 30 24.28 F 183 171 36 
272 22 21.65 F 280 275 39 
259 43 20.14 M 220 247 39 
262 37 24.18 M 274 233 41 
225 31 24.47 F 216 217 36 
250 44 24.77 F 227 216 38 
241 26 19.47 F 204 227 40 
283 37 28.28 F 206 176 38 
268 31 27.59 M 293 262 44 
203 33 29.71 M 216 226 44 
248 33 20.84 F 300 288 38 
239 52 24.58 F 225 301 37 
216 27 24.98 F 182 195 36 
226 51 23.51 F 226 222 34 
235 21 20.73 F 189 216 36 
238 26 17.54 F 150 183 37 
240 48 31.79 M 182 149 40 
255 25 20.02 F 183 181 44 
212 29 23.92 M 272 191 44 
231 35 27.33 M 209 209 45 
243 23 19.46 F 235 230 40 
278 22 20.37 F 261 258 36 
293 37 20.59 F 283 285 39 
253 44 26.18 M 224 245 46 
256 29 19.12 M 176 176 40 
277 25 20.34 F 196 182 36 
282 44 28.52 M 243 234 45 
Average 
33 ± 
9 
23.62 
± 
3.70 11M/17F 223 ± 40 220 ± 39 40 ± 3.5 
 
Table 1. Donor Attributes 
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Healthy subject age, BMI, gender, platelet count for period 1 and 2, and %Hematocrit were measured and data 
is presented above.  
 
2.3.1 IC50 for ASA during thrombosis under flow 
Ex vivo addition of ASA to whole blood was tested in the device in a concentration-
dependent manner to calculate IC50 values for collagen induced platelet deposition (Figure 
2-1). In each experiment, a total of 24 simultaneously forming thrombi were imaged in real 
time. Fluorescently labeled platelets aggregated only at the site of micropatterned collagen, 
with no platelet deposition upstream or downstream of the micropatterned collagen (Figure 
2-1C,D).  Platelet adhesion due to collagen occurred within 60 sec and secondary platelet 
accumulation/aggregation continued after 150 sec of perfusion (Figure 2-1E, Figure 8-2). 
Inhibition of secondary platelet adhesion by ASA was measured through the R-value 
(Figure 2-1F). Determination of platelet surface fluorescence at 300 sec (FI300s) allowed a 
measurement of an IC50 of 22 µM ASA (Figure 2-2AFigure 2-1) for an in vitro ASA 
incubation time of 30 min for Subject 272. The collagen-induced platelet activation was 
temporally separated and preceded the ASA-sensitive deposition regime. A dose-dependent 
decrease in platelet deposition rate (F’ from 150 to 300 sec) was observed with increasing 
ASA concentration while the initial platelet deposition rate (F’ between 60 and 150 s) was 
ASA insensitive (Figure 2-2B). Finally, internal normalization (Figure 2-2C) of late stage 
F'150-300s divided by early stage F'60-150s provides a R-value of 1.0 near the ASA  IC50 of 10 µM. 
This R value showed more dynamic range and sensitivity related to secondary platelet 
aggregation due to TXA2 release causing a minor left shift in the IC50 value to 10 µM. The 
ASA dose-response was also obtained by in vitro addition of ASA to whole blood 24 h after a 
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single 325-mg dose was ingested by subjects. Representative subject 255 lacked response to 
in vitro addition of ASA demonstrating strong inhibition of platelet COX-1 activity by the 
325 mg dose (Figure 2-2D).    
 
Figure 2-2 Platelet deposition from PPACK-inhibited WB treated with increasing in 
vitro ASA at 200 s-1 initial wall shear rate over fibrillar collagen for period 1 (t= 0 h, no 
ASA ingestion). 
(A), Representative IC50 curve for in vitro ASA dose-response. (B), In order to separate COX-1 mediated 
TXA2 production from the platelet-collagen response, F’ = ΔF/Δt was calculated for the initial time interval of 
60 to 150 sec and secondary aggregation platelet deposition rate was calculated during the time interval of 150 
to 300 sec. Initial platelet deposition rate from 60 to 150 sec was ASA-insensitive. (C), Normalization of 
subject response to in vitro ASA using the R-value. (D), In vitro addition of ASA at 26 h (open circle) had no 
efficacy after donors took ASA (325mg) at 2 h 
25 
 
2.3.2 Microfluidic ASA Phenotyping and in vitro addition of aspirin after oral 
administration 
Microfluidic phenotyping of whole blood 24-h after a single 325-mg dose was 
ingested showed that 27 of 28 subjects had some reduction in total platelet accumulation 
relative to total platelet accumulation measured in blood prior to ASA ingestion (Figure 
2-3A).  Only Donor 253 displayed a slight increase in platelet deposit size, which was not 
statistically significant.  Marked inter-subject variation in the amount of baseline platelet 
deposition was observed, with FI300s values ranging from below 4000 to above 12000 FI.  
However, the microfluidic assay detected the decrease in total platelet accumulation 
following in vivo ASA ingestion. Platelet deposition from blood obtained 24 h after ASA 
ingestion (no additional in vitro ASA added) was inhibited relative to the platelet deposition 
measured for blood prior to ASA ingestion (Figure 2-3B). The degree of inhibition of 
platelet deposition for these 28 subjects at 24 h after ASA dosage ranged from 10 to 90 % 
(45 % ± 23%; P < 0.001, n = 28) (Figure 2-3B). When comparing each subject at 26 h to 
their response at 0 h, subjects with ≥ 25 % inhibition (16 of 28 subjects) displayed 
statistically significant inhibition (Figure 2-3B, P < 0.05). In comparing platelet deposition 
(FI300s) in response to in vitro 500 µM ASA addition relative to in vitro 0 µM ASA addition, the 
in vitro addition of high dose ASA was very potent in blood obtained from subjects prior to 
ASA ingestion where 24 of 28 subjects responded to in vitro ASA addition (Figure 2-3C, solid 
bar).  Only 4 of 28 subjects (Donors 217, 250, 240, 253) lacked significant inhibition with in 
vitro ASA addition to blood obtained prior to in vivo ASA ingestion.  In contrast, only 7 
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subjects of 28 displayed sensitivity to in vitro 500 µM ASA addition 24 h after ASA ingestion 
(Figure 2-3C, open bar). 
 
 
Figure 2-3 Microfluidic ASA Phenotyping of donors  
(A), Ingestion of ASA at t = 2 h resulted in smaller platelet deposits compared to the response obtained from 
blood prior to ASA ingestion at t = 0 h (28 donors). *P < 0.05, relative to each donor at t = 0 h. Percent 
inhibition of platelet deposition as a measure of in vivo ASA efficacy at 26 h, as assessed by 8-channel 
microfluidic assay. *P < 0.05, relative to each donor at t = 0 h.  (B). Comparison of high dose in vitro addition 
of 500 µM ASA measured for whole blood obtained before (t = 0 h) or 26 h after oral ASA administration (t = 
2 h) (C). Data are mean ± SD (3 replicates).   
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2.3.3 Microfluidic Assay for measuring platelet deposition in the presence of aspirin 
For the 28 healthy donors with platelet counts in the normal range, no correlation 
between the extent of platelet deposition on collagen and platelet count was observed 
(Figure 2-4A). Subject platelet counts were highly correlated between period 1 and period 2, 
indicating the ability of the body to tightly regulate total platelet count (Figure 2-4B). Total 
platelet deposition (FI300s) showed a weak but positive correlation between period 1 and 
period 2 (Figure 2-4C).  
Using the R-value as a normalized metric of secondary aggregation for each subject, 
22 of 28 subjects had R > 1 in Period 1 and 23 of 28 subjects had R > 1 in Period 2 (Figure 
2-4D).  Interestingly, only 2 of 28 subjects had R < 1 in both trial periods (Figure 2-4D, 
lower left quadrant), suggesting that almost all donors have a secondary aggregation response 
(i.e. R > 1) that was detectable in a microfluidic assay when aspirin was absent. All 28 
cohorts as a group had an average R = 1.21 ± 0.34 and 1.16 ± 0.22 in period 1, 0 h and 
period 2, 0 h respectively from 168 determinations of this metric displaying sensitivity and 
specificity to score secondary aggregation upon no in vitro ASA treatment in this microfluidic 
assay (P < 0.05, n = 28). In contrast, with 500 µM ASA added in vitro, only 3 of 28 donors 
displayed R(500 µM ASA) > 1 in both Period 1 and 2 (Figure 2-4E) demonstrating that 
almost all subjects had platelet function that were sensitive to inhibition by ASA.  With 
respect to the in vivo activity of ASA, 21 out of 28 subjects had R < 1 at 24 h after ingestion 
of a 325-mg dose (no ASA added in vitro) (Figure 2-4F).  In these subjects, the addition of 
500 µM ASA in vitro did not further inhibit platelet function since the platelets had already 
been inhibited by ASA in vivo.  Interestingly, the 7 of 28 subjects who had R>1 following 
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ASA ingestion also displayed insensitivity following in vitro ASA addition (upper right quadrant, 
Figure 2-4F).    
A detailed Receiver-Operator Curve (ROC) analysis (Figure 8-3, Figure 8-4Figure 
8-3) indicated that an R-value = 1 cut-off resulted in a true positive rate of 71 % (sensitivity) 
and a false positive rate of 36 % (or 64 % specificity) when comparing donors pre and post-
ASA ingestion.  Similarly, when comparing donors pre and post in vitro ASA addition, the R-
value = 1 cut-off resulted in a true positive rate of 75 % (sensitivity) and a false positive rate 
of 33 % (or 67 % specificity). 
 
Figure 2-4 Microfluidic assay characterization of in vitro ASA response: R value 
(A), Final thrombus size measured by final platelet fluorescence without in vitro ASA at t = 300 sec vs. donor 
platelet count in period 1 (no ASA ingestion). (B), Donor platelet count in period 1 vs. donor platelet count in 
period 2 after 2-week ASA washout period. (C), Final thrombus size without in vitro ASA addition at t = 300 
sec in period 1 vs. final thrombus size without in vitro ASA addition at t = 300 sec in period 2. (D), R value for 
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secondary platelet aggregation (no ASA ingestion; no in vitro ASA added) in both periods. (E), R value for high-
dose in vitro ASA inhibition of secondary platelet aggregation in both periods 1 and 2 (no ASA ingestion) (F), R 
value for high-dose in vitro ASA addition vs zero in vitro ASA addition in period 1 in blood exposed in vivo to 
ASA (ASA ingestion at 2 h). 
2.3.4 Effect of in vitro ASA at arterial flow conditions 
ASA is used to reduce the incidence of arterial thrombosis. In these microfluidic 
assays, we have observed that arterial shear rates of 1000 to 2000 sec-1 cause unstable 
thrombi with pronounced embolism, especially when thrombin or fibrin is absent (19).  This 
is especially relevant for experiments conducted at constant flow rate (as opposed to 
constant pressure drop) where clot growth can cause high shear stresses to occur as the clot 
partially occludes the flow path.  To investigate the pharmacological potency of ASA at 
arterial shear rates, IC50 curves were calculated using the same microfluidic assay by 
measuring platelet accumulation on collagen under the influence of in vitro ASA addition at 
1000 s-1. Comparison of the same 4 donors who did not participate in the study protocol 
previously mentioned at both venous (Figure 2-5A) and arterial (Figure 2-5B) shear rates 
indicate the efficacy of ASA under both flow conditions.  The slightly lower IC50 at 1000 s
-1, 
although not significantly different, compared to the value found at venous shear rate may 
be due to the reduced levels of TXA2 in the boundary layer at higher shear rates[34].  Further 
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work will be necessary to determine if the IC50 depends on wall shear rate.  
 
Figure 2-5 Response to in vitro ASA dosing: a comparison of venous vs. arterial 
initial wall shear rate  
Representative IC50 curves for ASA at venous (A) and arterial (B) wall shear rates (4 donors). A total of 9 
microfluidic assays were run at each initial wall shear rate for the 4 donors.  
 
2.4 Discussion 
We demonstrated that whole blood microfluidic assays and the data generated from 
these assays can produce an aspirin dose-response curve under flow conditions based upon: 
final platelet fluorescence (FI300s in Figure 2-2A), platelet deposition rate between 150 and 
300 sec (F'300-150s in Figure 2-2B), or the R-value which is a normalized metric of secondary 
platelet aggregation (Figure 2-2C).  For each of these metrics, the IC50 of aspirin was 
between 10 and 20 µM which is quite consistent with the known Kd = 4.5 µM of ASA 
against COX-1 [54]. The effect of COX-1 inhibition on donor platelet function after 150 sec 
in this flow assay is consistent with previous findings in the same microfluidic device and a 
multi-scale neural network and Monte Carlo simulation of platelet deposition under flow 
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[52]. Furthermore, this onset of action of ASA is consistent with aggregometry results 
showing action of COX-1 inhibitors at the later stages after primary aggregation [55]. The 
assay partially detected the in vivo efficacy of ASA ingestion on platelet COX-1 when whole 
blood was tested ex vivo (Figure 2-3).  Lack of statistical significance of in vivo modulation of 
platelet COX-1 activity due to ASA ingestion in 12 of the 28 subjects tested could be 
attributed to varying interdonor functionality of TP, P2Y1, and P2Y12 receptors. Interdonor 
changes in P2Y1 and P2Y12 receptor response modulate ADP flux from the growing 
thrombus under flow conditions hence causing variations in total platelet accumulation and 
the R value. Healthy subjects who ingested 325-mg ASA displayed 45 % smaller platelet 
deposits on average when the blood was tested 24 h after dosing (Figure 2-3B).  Whereas 
healthy donors have platelets that display thromboxane-dependent secondary aggregation in 
the flow assay (only 2 of 28 donors had R < 1; Figure 2-4D), healthy donors have platelets 
that respond to ASA administered ex vivo (only 3 of 28 donors had R > 1 in duplicate tests of 
500 µM ASA added ex vivo; Figure 2-4E).  
These microfluidic assays bring together contributions from platelet collagen signaling, 
granule release, ADP signaling, thromboxane synthesis, and adhesion strength under flow 
conditions. Thus, the pharmacological effects of COX-1 inhibition were investigated under 
far more complex conditions than an assay that measures thromboxane synthesis.  While the 
effects of aspirin ingestion or in vitro aspirin addition are clearly detectable in our assay, the 
capabilities of this microfluidic assay to detect "aspirin resistance" for patients with 
cardiovascular diseases remains unknown, as this study was limited to healthy subjects.   
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Several platelet function tests currently exist, however these technologies that assess 
aspirin sensitivity in whole blood have limitations, especially with regards to running a dose-
response assay requiring multiple tests. Dose-response assays are fundamental 
pharmacological tools to quantify drug potency or remaining enzyme activity.  The Platelet 
Function Analyzer (PFA-100) and VerifyNow are tests used to assess inhibition of platelet 
function by aspirin using whole blood. PFA-100 deploys a cartridge to create flow and 
measure puncture closure time with an activating coating of collagen/ADP or 
collagen/epinephrine [56]. The assay is highly dependent on plasma vWF, high shear stress, 
and epinephrine thus presenting difficulties in isolating the inhibitory effects of aspirin [57]. 
VerifyNow Aspirin is a point of care assay utilizing whole blood in standard cartridges 
containing a preparation of human fibrinogen-coated beads and arachidonic acid as agonists 
[56]. VerifyNow Aspirin is an assay based on light transmittance but lacks a hemodynamic 
flow field. Most recently development of a perfusion chamber allows for study of ASA 
dependent changes in platelet deposition [58]. Our methodology is distinct from Stephens et 
al. where whole blood was perfused through an entire glass capillary coated with human type 
III fibrillar collagen at 1000 or 1500 sec-1.  A collagen-coated capillary creates a long distance 
of many centimeters of collagen for platelets to activate, adhere, embolize, and recapture on 
the surface.  Platelet deposition is a function of distance from the entrance in this assay due 
to boundary layer depletion of platelets over the long length of collagen.  Since only one 
capillary is run at a time, dose-response testing is particularly cumbersome.  In contrast, our 
8-channel microfluidic perfusion of whole blood over fibrillar collagen exposes platelets to a 
spatially-confined 250 µm long "injury" site where all the data is collected with no 
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dependence on distance down the microfluidic channel.   The 8-channel microfluidic device 
facilitated the ex vivo testing of anti-platelet drugs in a dose-dependent manner over a large 
cohort of healthy donors.  
The biology of thrombosis includes the interaction of platelets with potent vessel wall-
derived stimuli including collagen and thrombin.  As a layer of platelets becomes activated 
on collagen, they recruit additional platelets via release of ADP and TXA2.  By targeting the 
secondary wave of platelet recruitment with P2Y12 antagonists and/or cyclooxgenase-1 
inhibitors, an anti-thrombotic effect is achieved with reduced risk of bleeding in comparison 
to other antithrombotic therapies that target biologically active clotting factors like warfarin.  
Few assays recreate the sequential process of collagen adhesion followed by the release of 
autocrine factors.  Since platelet recruitment, adhesion, and the convective-diffusion of 
autocrine agents are dictated by prevailing hemodynamic conditions [34], microfluidic assays 
partially recreate the disease environment in which anti-platelet agents must act.  We 
demonstrate the use of microfluidic assays to evaluate healthy subject response to aspirin. 
Supplemental discussion about this chapter, including additional discussion topics and data, 
is presented in the appendix of this dissertation.  
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3 DETECTION OF PLATELET SENSITIVITY TO INHIBITORS 
OF COX-1, P2Y1, and P2Y12 USING A WHOLE BLOOD 
MICROFLUIDIC ASSAY 
3.1 Introduction 
Antiplatelet therapies are used in a variety of clinical settings from management of 
unstable angina to risk reduction of myocardial infarction or stroke. Aspirin is used by over 
50 million patients in the United States to reduce the risk of cardiovascular events[40]. 
Aspirin irreversibly acetylates serine 529 of cyclooxygenase-1 (COX-1), blocking the enzyme 
active site for arachidonic acid and inhibiting the generation of prostaglandin H2 and thus 
thromboxane A2 (TXA2) production from platelets[59]. Inhibition of platelet TXA2 synthesis 
prevents platelet activation through the platelet TXA2 receptor (TP), a receptor encoded by 
the TBXA2R gene.    
In addition to TXA2, adenosine disphosphate (ADP) receptors are another target of 
antiplatelet therapies. The platelet plasma membrane contains two ADP receptors, P2Y1 and 
P2Y12, which are purinergic G protein coupled receptors. P2Y1 is linked to Gq and ADP 
signaling through this pathway results in rapid Ca2+ mobilization and platelet shape change 
[11,60]. P2Y12 is linked to a Gi protein. ADP binding to P2Y12 inhibits adenylate cyclase and 
stabilizes secondary platelet aggregation. Current therapies that target the P2Y12 receptor 
range from prodrugs that irreversibly antagonize the P2Y12 receptor to direct, reversible 
antagonists[60,61]. The thienopyridines clopidogrel and prasugrel are examples of the 
former, while ticagrelor is an example of the latter.  Currently, no P2Y1 antagonists are on 
the United States drug market, however, combined P2Y1 and P2Y12 antagonists are in 
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development[62]. To mimic the action of P2Y1 and P2Y12 antiplatelet therapies ex vivo, 2'-
deoxy-N6-methyl adenosine 3',5'-diphosphate (MRS 2179) and 2-methylthioadenosine 5-
monophosphate (2MeSAMP) are used in this study as highly selective P2Y1 and P2Y12 
antagonists, respectively.  
Targeting signaling pathways such as TXA2 production and ADP/P2Y12 signaling 
reduces secondary platelet aggregation while not severely altering primary hemostasis. 
However, the delicate balance between preventing excessive clotting and increasing bleeding 
risks requires careful monitoring of antiplatelet therapies. The evaluation of the effect of 
pharmacological agents on platelet function often rely on tests with poorly defined fluid 
mechanics and flow fields (eg. aggregometry) that fail to replicate platelet adhesive 
mechanisms under realistic and well geometrically-defined hemodynamic conditions. Under 
flow conditions, the efficacy of pharmacological agents greatly depend on granule release, 
platelet-platelet contacts, and convective removal of autocrinic agonists from the injury site. 
Microfluidic devices can recreate the hemodynamic conditions required to study anti-platelet 
agents.  These devices offer spatially controlled focal injuries with collagen or collagen with 
tissue factor bearing surfaces[35,37].  Microfluidic devices have also been used to study clot 
contraction and clot permeability with precise control of wall shear stress and transthrombus 
pressure gradients [13,63].  In fact, the core-shell hierarchy of clots observed in vivo 
following laser injury [9] can be replicated in vitro with such devices[63]. 
Here we continue the development of microfluidic assay metrics found previously[64] 
and extend these metrics to examine two ADP antagonists and validate this assay for 
detection of anti-platelet therapies through Receiver-Operator Characteristic (ROC) analysis. 
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For flow assays to become a relevant clinical tool a large cohort of healthy donors must be 
tested with respect to response to antiplatelet agents. Toward that goal, we tested healthy 
subject platelet function with 38 donors and 66 independent blood draws (2 combined 
studies) following ex vivo addition of ASA.  While coagulation assays can rely on stable 
pooled plasma for calibration, live platelet function assays have no available standard to 
calibrate the assay.  We sought to define a self-normalized parameter, the R-value, to score 
platelet accumulation on collagen surfaces from a single blood sample test without reference 
to a prior test value or calibration fluid.   
 
3.2 Materials and Methods 
3.2.1 Blood collection, labeling, and antiplatelet agents  
Blood was collected via venipuncture from 11 healthy subjects who self-reported as 
non-smoking, free of oral medication, and abstained from alcohol 48 h prior to donation. All 
subjects were free from illness and bleeding disorders. Blood samples were drawn into H-D-
Phe-Pro-Arg-chloromethylketone (100 µM PPACK final concentration, Haematologic 
Technologies). All volunteers provided informed consent in accordance with IRB approval 
and the Declaration of Helsinki. Whole blood was treated with Phycoerythrin (PE) Mouse 
Anti-Human CD61 (αIIbβ3) antibody (BD Biosciences) in a ratio of (1:50) 7 min prior to 
perfusion. This antibody has no effect on platelet αIIbβ3 function in this microfluidic flow 
assay.  PPACK-treated whole blood was perfused through the device within 25 min of 
phlebotomy. Blood was incubated with vehicle (0.1% DMSO final concentration) or 
indicated concentrations of ASA, 2MeSAMP, MRS 2179, or combined 2MeSAMP and MRS 
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2179 20 min prior to the assay. This time scale is consistent with previous studies done with 
these compounds[34,52,64].  Acetylsalicylic acid (ASA, Sigma Aldrich) was dissolved in 
DMSO at 500 mM, 2-methylthioadenosine 5′-monophosphate triethylammonium salt 
hydrate (2MeSAMP, Sigma Aldrich) was dissolved in HEPES buffered saline (HBS, 20 mM 
HEPES, 160 mM NaCl, pH 7.5) at 1 mM/L, and 2'-deoxy-N6-methyladenosine 3', 5'-
bisphosphate ammonium salt (MRS 2179, Tocris Bioscience) at 0.1 mM in HBS. A dilution 
of ASA was then made to the desired final concentration in HBS within 1 h of the test. Final 
concentrations of antiplatelet therapies used were: 500 µM ASA, 100 µM 2MeSAMP, and 10 
µM MRS 2179, well in excess of their IC50s in the assay of 10-20 µM ASA, 2.56 µM 
2MeSAMP, and 0.23 µM MRS 2179 respectively[34,64].  Antiplatelet agent concentrations 
were used well in excess of their respective IC50 values to completely antagonize ADP 
receptors or abate COX-1 derived TXA2. 
3.2.2 Microfluidic devices and real time platelet deposition imaging  
Microfluidic devices were fabricated in polydimethylsiloxane (PDMS, Sylgard 184, 
Ellsworth Adhesives) according to previously described techniques [34,64]. The microfluidic 
device has 8 parallel channels (250 µm wide by 60 µm high) that converge to a common 
outlet(Figure 3-1A). The device was fed by 8 distinct wells, with perfusion achieved by 
withdrawal into a single syringe pump (Harvard Apparatus). The channels run 
perpendicularly over a 250 µm long stripe of patterned equine fibrillar collagen type 1 
(Chronopar, Chronolog). Channels were spaced in close proximity to image all 8 eight 
channels simultaneously with a 2X objective lens using an inverted microscope (IX81, 
Olympus America Inc.) equipped with a CCD camera (ORCA-ER, Hamamatsu). A custom 
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stage insert held 3 microfluidic devices allowing formation of 24 simultaneous thrombi to be 
imaged in 15 sec intervals. Prior to microfluidic assay, all channels were blocked with 0.5% 
bovine serum albumin (BSA) in HBS buffer. Blood samples were perfused at an initial 
venous wall shear rate of 200 s-1 for 5 min (2 L/min per channel).  
3.2.3 Platelet accumulation analysis  
Background corrected fluorescence values were measured using MATLAB 
(MathWorks) as previously described [34]. Briefly, all eight platelet deposits on a single 
microfluidic device were identified and corrected with their corresponding background 
regions downstream of each platelet deposit by a custom MATLAB script.  To calculate 
overall percent inhibition after a 300 s perfusion, platelet fluorescence values were 
normalized to each donor's baseline platelet adhesion to collagen (FI300s(Drug)/FI300s). 
Additionally, a R-value for ASA (RCOX) was defined as a ratio of platelet deposition rates that 
normalized the late stage platelet deposition rate (F'300-150s) to early stage deposition rate (F'150-
60s) for all ex vivo ASA additions, as previously established[64].  The RCOX value is an internal 
intradonor standard to score secondary aggregation due to TXA2 secretion, with values of 
RCOX > 1 indicating when secondary platelet aggregation was prominent and RCOX < 1 when 
secondary aggregation was attenuated by ex vivo ASA treatment (Figure 3-1C). In a 
previous work, a dose-dependent decrease in the rate of secondary platelet aggregation was 
found with increasing ex vivo ASA concentrations whereas the initial platelet deposition rate 
on collagen was unaffected by ASA. We now define an additional intradonor normalization 
metric RP2Y as a ratio of platelet deposition rates normalizing late stage secondary platelet 
aggregation rate due to ADP release (F'300-105s) to earlier stage platelet deposition rate (F'105-60s) 
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(Figure 3-1D).  The temporal onset for RP2Y was based on previous work[52] establishing 
that the effect of ADP antagonism occurred after 100 sec, as was later confirmed in platelet 
dynamic traces for ADP antagonists for the 11 donors in this present study (Figure 3-1B). 
Finally, sensitivity and specificity for detection of ASA, 2MeSAMP, or MRS 2179 
was found through Receiver Operator Characteristic (ROC) analysis[65]. ROC curves were 
generated to detect the presence of each drug in the microfluidic assay through evaluation of 
the true positive and false positive fractions and the area under the curve (AUC) [65]. In this 
analysis, for each antiplatelet therapy tested, ROC curves were generated comparing 10 
average R-values, one from each of the 10 healthy subjects with no ex vivo inhibition to 10 
average measurements of the R-value for each anti-platelet drug tested. 
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Figure 3-1 Eight-channel device, measured platelet fluorescence dynamics, and RCOX, 
RP2Y schematic summaries.  
(A), Photograph of the 8-channel microfluidic device, the device is fed by 8 wells converging into a single 
outlet. (B), Platelet fluorescence values over time in the presence of aspirin, 2MeSAMP, and MRS 2179. Error 
bars indicate standard deviation from 6 measurements at each time point. (C), Graphic representation of RCOX 
based on a ratio of platelet deposition rates (F') of secondary platelet aggregation to initial platelet deposition 
on collagen. (D), Graphic representation of RP2Y. 
 
3.3 Results 
Ex vivo testing of anti-platelet agents occurred in duplicate on 3 separate microfluidic 
devices run simultaneously. For 11 subjects, a total of 432 individual thrombi were formed 
under flow on collagen, resulting in 108 events each for 3 individual conditions (control, 
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2MeSAMP, and MRS 2179), 60 events for ex vivo ASA addition, and 48 events for ex vivo 
addition of 2MeSAMP and MRS 2179. Statistical analysis was conducted to evaluate 
intradonor variations for duplicate control conditions on a single microfluidic device or 3 
devices run simultaneously (6 conditions). Total platelet accumulation (FI300s) and secondary 
aggregation [RCOX(0)] values for whole blood perfusion with vehicle buffer were tabulated 
from 11 blood samples and the coefficient of variation for each donor defined as standard 
deviation divided by the mean was found (Table 7, Table 8). Coefficients of variation for 
FI300s ranged from 5.3% to 35.8% (mean = 13.1%) for replicate channels on a single device 
while values varied from 5.3% to 24.4% for triplicate microfluidic testing (mean = 16.3%). 
For RCOX (0), coefficient of variation values were all < 20% for a single microfluidic device 
or triplicate device testing with the exception of donor 4 and donor 10.  In 3 comparisons 
evaluating ex vivo ASA efficacy (Figure 3-5), prior supplementary data for 28 individuals 
[64] obtained in the same manner as this study was combined with data from 10 subjects 
from this work. Only 1 subject partook in both studies.   
Platelets adhere substantially to the localized collagen surface within 1 minute and 
subsequent secondary platelet accumulation via platelet-platelet interactions over the 300 s 
perfusion time has been well-established in previous studies [34,52]. Growth in platelet 
coverage occurs in two dimensions on the collagen surface between 60 -105 sec. After 105 
sec, thrombus growth continues in the third dimension and thrombus height under flow 
increases significantly due to secondary platelet-platelet aggregation mediated by soluble 
agonists such as ADP and TXA2 at approximately 105 s and 150 s, respectively.  
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3.3.1 Platelet inhibition by ASA, 2MeSAMP, and MRS 2179 
Platelet adhesion and subsequent secondary platelet aggregation were significantly 
reduced upon ex vivo addition of ASA, 2MeSAMP, or MRS 2179 (Figure 3-1B). Using RCOX 
or RP2Y (Figure 3-1C, D), 8 out of 10 subjects displayed significant secondary platelet 
aggregation [R(0 drug) > 1] before ex vivo drug addition (Figure 3-2A-C).  In contrast, 9 
out of 10 subjects had RCOX < 1 upon ex vivo treatment with ASA (Figure 3-2A). 
Furthermore, 9 out of 10 subjects had RP2Y < 1 with ex vivo 2MeSAMP addition, 
demonstrating that most subjects had secondary platelet aggregation and primary platelet 
deposition that was sensitive to P2Y12 antagonism (Figure 3-2B). RP2Y was less reliable in 
scoring MRS 2179 inhibition of P2Y1 with only 6 out of 10 subjects having RP2Y < 1 (Figure 
3-2C), in part (ironically) due to the high potency of MRS 2179 in reducing Ca2+ 
mobilization through P2Y1 signaling. Hence MRS 2179 drastically reduces primary platelet 
deposition in comparison to 2MeSAMP, thus the associated difficulty of taking a ratio of 
two small numbers as both primary platelet deposition and secondary platelet aggregation 
rate were inhibited by MRS 2179.  
ROC curves were generated to examine the inhibitory effects of ASA, 2MeSAMP, 
and MRS 2179 in this assay (Figure 3-2D-F).  In comparing 10 measurements of RCOX(0) 
(true full COX-1 activity, true full P2Y12 and P2Y1 function) to 10 measurements of RCOX 
(500 µM ASA) (true full COX-1 inhibition), the ROC curve had an AUC of 0.874 (Figure 
3-2D). Comparison of 10 RP2Y values at baseline to 10 RP2Y(100 µM 2MeSAMP) (true full 
P2Y12 antagonism) gave an ROC curve AUC of 0.966 (Figure 3-2E). Finally, in comparing 
the same 10 baseline RP2Y values to RP2Y(10 µM MRS 2179) an ROC curve AUC of 0.889 was 
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obtained. Calculated ROC AUC values indicate excellent diagnostic discrimination between 
populations upon ex vivo treatment with ASA, 2MeSAMP, or MRS 2179. ASA, 2MeSAMP, 
or MRS 2179 all decreased total platelet accumulation at 300 sec when normalized against 
baseline collagen response reaching statistical significance for the entire cohort (p < 0.01, n 
= 10 subjects) and each antiplatelet agent (Figure 3-3). The % inhibition of platelet function 
was much greater for 2MeSAMP and MRS 2179 than ASA. However, the effect of ex vivo 
2MeSAMP and MRS 2179 were not statistically different from each other. While the % 
inhibition is very useful for measuring drug potency following ex vivo drug addition, it 
requires reference to a separate untreated blood sample which may not necessarily be 
available clinically with patients.  In contrast, the R-value is self-normalized and can be used 
for a single blood sample obtained from a patient without the need to reference to a prior 
blood test to obtain % inhibition. 
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Figure 3-2 Microfluidic assay sensitivity and specificity of RCOX and RP2Y to detect 
inhibition of primary platelet adhesion to collagen or secondary platelet aggregation 
(A), Rcox for ex vivo ASA addition. (B), RP2Y for ex vivo 2MeSAMP addition. (C), RP2Y for ex vivo MRS 2179 
addition. (D) ROC curve for detection of ex vivo ASA addition. (E), ROC curve for detection of ex vivo 
2MeSAMP addition. (F), ROC curve for detection of ex vivo MRS 2179 addition. Error bars indicate standard 
deviation from 6 measurements of RCOX or RP2Y for each donor. Dashed lines are 95% confidence intervals. 
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Figure 3-3 Effect of ex vivo ASA, 2MeSAMP, or MRS2179 on final platelet aggregate 
size normalized by baseline platelet aggregate size formed on collagen.  
Ex vivo addition of ASA, 2MeSAMP, or MRS2179 resulted in smaller final platelet aggregate size compared to 
response measured with no drug (p < 0.01, n = 10 donors) 
 
3.3.2 Platelet inhibition by combined 2MeSAMP and MRS 2179 ex vivo addition 
To investigate the effects of combined P2Y1 and P2Y12 inhibition by MRS 2179 and 
2MeSAMP respectively, 7 of the 10 subjects from the above study of ex vivo addition of 
either P2Y1, P2Y12, or COX-1 inhibitor alone were re-enrolled along with new subject #11.  
Platelet fluorescence traces over time representing thrombus buildup during the microfluidic 
assay were reduced in the case of combined P2Y1 and P2Y12 inhibition of platelet function in 
comparison to ex vivo P2Y1 or P2Y12 inhibition alone (Figure 3-4A). Using MRS 2179 and 
2MeSAMP together, both primary deposition rate and secondary platelet aggregation rates 
were strongly reduced when compared to control or when MRS 2179 or 2MeSAMP were 
used individually to inhibit platelet function (Figure 3-4A).  
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Combined ex vivo addition of 2MeSAMP and MRS 2179 dramatically reduced total platelet 
accumulation at 300 sec when normalized against control platelet response to collagen 
(Figure 3-4B). The platelet mass at the end of 300 sec due to combined P2Y1 and P2Y12 
inhibition was significantly smaller than the platelet masses due to single P2Y1 or P2Y12 
inhibition (p < 0.001, n = 8 subjects) (Figure 3-4B). Because the primary deposition rate 
was so strongly attenuated, RP2Y was not suited to score combined P2Y1 and P2Y12 inhibition 
(Figure 3-4C). This is due to the high efficacy of combined MRS 2179 and 2MeSAMP 
treatment on the primary platelet deposition rate on collagen in this microfluidic thrombosis 
model. The primary deposition rate becomes exceedingly low once ADP is completely 
attenuated under flow conditions through inhibiting both P2Y12 and P2Y1 signaling 
pathways. ADP is a potent modulator of platelet recruitment to the initial monolayer of 
platelets adherent to collagen. The R-value was originally intended to score secondary 
aggregation, hence the difficulties in using RP2Y to detect a ratio of platelet deposition rates 
over the two temporal ranges.  
 
Figure 3-4 Effect of combined ex vivo addition of 2MeSAMP and MRS2179 on 
platelet function in comparison to ex vivo addition of 2MeSAMP or MRS2179 alone.  
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(A) Platelet fluorescence dynamics over time in the presence of ex vivo 2MeSAMP, MRS 2179, or combined 
2MeSAMP and MRS 2179. (B) Ex vivo addition of 2MeSAMP and MRS 2179 reduced final thrombus size 
more significantly than 2MeSAMP or MRS 2179 treatment alone when normalized against final control 
thrombus size over collagen (p < 0.01, n = 8 donors). (C) RP2Y for combined ex vivo 2MeSAMP and MRS 
2179 addition. Error bars indicate standard deviation for 6 measurements of RP2Y for each donor.  
 
3.3.3 Statistics of platelet phenotyping with microfluidics using ASA 
Finally, we incorporate and quantify historical supplementary data from a previous 
work [64] into this study with intent to show the full distribution of microfluidic platelet 
function metrics (total platelet accumulation, primary and secondary platelet deposition rates, 
RCOX). Distribution of these metrics is optimal with maximum data in assessing the 
capabilities of this microfluidic assay to detect the inhibitory effects of ex vivo ASA on 
platelet function.  
Microfluidic phenotyping of 37 donors, 10 from the current study and 28 from a 
previous study [64] showed a broad distribution of primary platelet deposition rates on 
collagen with no ex vivo ASA treatment (Figure 3-5A). Late stage secondary platelet 
aggregation also distributed broadly (Figure 3-5A).  Binning of total platelet accumulation 
showed varied inter-subject platelet function response to collagen with FI300s values ranging 
from 2,000 to 16,000 (Figure 3-5B). Interestingly, the 10 healthy subjects from this study 
exhibited FI300s values all below 6000 while the larger unique subset of 28 subjects from the 
previous study showed a wider range of FI300s values. The stochastic Gaussian-like 
distribution of RCOX(0) values centered above 1 indicated that RCOX was a robust 
measurement of secondary platelet aggregation response in untreated whole blood (Figure 
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3-5C). The use of RCOX = 1 as the decision value was previously reported as the microfluidic 
assay for detection of in vivo and ex vivo ASA had high discrimination (high true positive 
rate with low false positive rate) at this anchoring point [64].  In a total of 66 determinations 
of RCOX(0), 52 measurements were above the RCOX = 1 cutoff demonstrating a majority of 
donors had a strong secondary platelet aggregation response in the assay.  Observation of 14 
values of RCOX < 1 indicate some donors lack detectable secondary aggregation by this assay, 
a phenomena potentially attributable to low levels of released ADP and TXA2 in the 
boundary layer formed above the platelet deposit [52]. In contrast, with 500 µM ASA added 
ex vivo, 49 of 66 determinations of RCOX < 1 demonstrated that most subjects had platelets 
that were sensitive to ASA inhibition of platelet TXA2 production (Figure 3-5C). The 17 
determinations of RCOX where RCOX > 1 with 500 µM ASA added ex vivo could be due to 
non COX-1 mediated ASA effects on platelets when they are activated by collagen with 
autocrinic ADP present [66].  Such blood samples may be worthy of further study with 
respect to the phenotype of functional insensitivity to ASA despite COX-1 acetylation.  A 
notable left shift of the distribution away from RCOX(0) was evident for the 66 
determinations of RCOX(500 µM ASA) (Figure 3-5C).  
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Figure 3-5 Distribution of microfluidic metrics in the assessment of platelet adhesion 
to collagen and ASA’s inhibition of platelet function under flow.  
(A), Binning of primary and secondary platelet deposition rates. (B), Binning of final platelet accumulation as 
measured by platelet fluorescence at t = 300s (FI300s). (C), Binning of RCOX values in assessment of the effect of 
ASA on secondary platelet aggregation in the microfluidic perfusion assay.  
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3.4 Discussion 
We demonstrated the utility of whole blood microfluidic assays run on an 8-channel 
microfluidic device to assess the effect of various anti-platelet agents on platelet function 
under flow. We extended from a previous study [64] the RCOX value, a normalized metric to 
detect reduction in secondary platelet aggregation due to ex vivo ASA addition (Figure 
3-1C). We now define RP2Y a ratio of secondary platelet aggregation rate to primary platelet 
deposition rate (with a different temporal profile than RCOX) to quantify P2Y1 and P2Y12 
antagonists (Figure 3-2). Examination of RP2Y and ROC curve testing establish 2MeSAMP 
and MRS 2179 as potent anti-platelet drugs that target both initial platelet adhesion to 
collagen and secondary platelet aggregation by attenuating the autocrine ADP pathway 
(Figure 3-6). 
 
 
Figure 3-6 Effect of P2Y1, P2Y12 antagonists and ASA on primary platelet adhesion to 
collagen and secondary platelet aggregation due to ADP and thromboxane autocrine 
and paracrine signaling.  
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COX-1 inhibitor ASA reduced secondary aggregation between 150 and 300 s without an effect on primary 
platelet deposition to collagen from 60 to 150 s.  2MeSAMP and MRS 2179 reduced primary deposition 
between 60 and 105 s and secondary platelet aggregation between 105 and 300 s. Time intervals marked are 
indicators for RCOX and RP2Y, 60- 150 sec & 150 sec-300 sec and 60-105 sec & 105 sec-300 sec respectively. X-
axis is not to scale.  
 
The effect of ASA on secondary platelet-platelet interactions has been well-
characterized in platelet aggregometry [55]. Under flow, ADP and TXA2 are complex and 
interacting modulators since both can become elevated in a concentration boundary layer 
[52]. Additionally, RP2Y was shown to be unsuited to score the potency of combined P2Y1 
and P2Y12 antagonism of platelet function because primary deposition rate was so strongly 
inhibited in this microfluidic thrombosis model. Measured platelet fluorescence dynamics 
and normalization of final platelet mass against control platelet masses formed over collagen 
for 8 healthy donors showed ex vivo dual treatment with P2Y12 and P2Y1 inhibitors to be 
significantly more potent than single ex vivo P2Y1 or P2Y12 antagonism (Figure 3-4B).  
We report findings with some similarities and differences to the prior flow studies of 
Lucitt et al. [67] and Mendolicchio et al. [68].   Lucitt et al. found no effect on the rate of 
platelet coverage of the collagen surface with in vitro ASA addition at 1500 s-1.   However, 
percent surface coverage may be a less sensitive measure of secondary aggregation which 
also increases the height of platelet deposits.  Menolicchio et al. also reported a limited 
reduction of platelet aggregate growth above the layer of platelets adherent to collagen with 
in vitro addition ASA at 1500 s-1.   Since there was no thrombin/fibrin generation allowed in 
Lucitt [67] who used 300 ATU hirudin or Menolicchio [68] who used 68 USP heparin, 
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arterial shear rates of 1500 s-1 may limit the detection of ASA action because thrombin/fibrin 
dramatically stabilize the platelet deposit at arterial conditions[37]. As a platelet deposit 
grows in height in a flow channel, the shear rates become exceedingly high during a constant 
flow rate perfusion and embolization is likely, especially at an initial arterial wall shear rates, 
with or without fibrin present[37]. At the venous shear rate used with antiplatelet agents in 
the present study, partially occlusive deposits formed in the absence of thrombin/fibrin are 
more reliably measured since there is no embolization, even under constant flow conditions. 
In prior work, we have shown that the IC50 of ASA measured at venous shear rates was quite 
similar to that measured at arterial shear rates [64]. In addition, the IC50 of 2MeSAMP and 
MRS 2179 at venous wall shear rates were also on the same order of magnitude to that 
found at arterial shear rates (1000s-1) (Figure 8-5).  
Lucitt et al. also reported an effect of in vitro 2MeSAMP on initial platelet 
recruitment on collagen surfaces delaying the time to reach 2.5% platelet surface coverage to 
56 sec as compared to 33 sec for the control case in an 8 min assay at 1500 s-1. Lucitt et al. 
found that in vitro ASA had no effect on this initial stage of platelet adhesion. We report 
findings consistent with Lucitt et al. but at 200 s-1. We found that ASA does not affect 
primary platelet deposition to collagen (F'150-60s), while 2MeSAMP and MRS 2179 inhibit 
primary platelet response to collagen (F'105-60s) but more significantly affects secondary 
platelet aggregation (F'300-105s) requiring RP2Y as a new internally normalized metric to 
characterize platelet response to ADP antagonists under flow. ADP antagonists were found 
to inhibit platelet function by ~ 105 sec as compared to ~ 150 sec due to ASA inhibition of 
TXA2 release. Also, Lucitt et al. determined 2MeSAMP significantly reduced the rate of 
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platelet aggregate formation on collagen by impairing recruitment of additional platelets. 
Menolicchio et al. reported marked reduction of platelet aggregation above the initial platelet 
surface on collagen due to in vitro addition of 2MeSAMP. Both report these results at 1500s-
1. This is consistent with our findings at 200s-1 with RP2Y and ROC curves detecting 
significant impairment of secondary platelet aggregation due to either 2MeSAMP or MRS 
2179.   
Monitoring of P2Y12 inhibition by clopidogrel or other P2Y12 antagonists can be 
achieved through assays such as vasodilator-stimulated phosphoprotein phosphorylation 
(VASP), turbidometric platelet aggregometry, or the VerifyNow P2Y12 test.  Although 
platelet aggregometry remains the gold standard for platelet function testing, several 
disadvantages exist such as poor reproducibility, high sample volume, and complex sample 
preparation[44]. Turbidometric platelet aggregometry testing uses ADP induced platelet 
aggregation to measure the effect of clopidogrel. However, ADP can illicit platelet 
aggregation through P2Y1 while VASP requires flow cytometry and an experienced 
technician[44].  Point of care assays are especially advantageous in clinical settings as they 
enable immediate decision making for dosing of antiplatelet drugs. The VerifyNOW P2Y12 
is the only device that meets the various constraints to be considered a point of care assay.  
Interestingly, in comparing the clinical utility of this microfluidic assay to the VerifyNow 
P2Y12 system, ROC curve AUC values were strikingly similar.  A ROC curve value of 0.929 
was found in the assessment of the VerifyNow P2Y12 assay to detect antiplatelet effects 
during clopidogrel therapy, comparable to the 0.966 value found for 2MeSAMP in this 
study[69].  
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With regards to microfluidic flow assays, microfluidic chambers often utilize a single 
flow path comprised of a millimeter length collagen coated cover slip or capillary tube 
enabling platelets to tether, activate, and re-adhere along the entire length[67].  With such 
long zones available for adhesion, the platelet coverage is often a function of distance along 
the collagen. The current microfluidic injury model exposes platelets to a narrow 250 µm 
long collagen strip with no dependency on distance down the "injury" site as the image 
capture zone is the entire prothrombotic surface. Furthermore, the type of collagen used as 
the adhesive substrate impacts platelet-surface interactions. Previous reports utilize bovine 
soluble collagen type I, porcine type I collagen, or equine tendon fibrillar type I 
collagen[13,37]. The equine fibrillar type I collagen used in this study is a thoroughly 
established prothrombogenic surface as a recent study examined sources of variability over 
this collagen type in microfluidic flow assays for n = 104 healthy donors[70].    
Several previous flow systems have been examined for the detection of P2Y1, P2Y12 
antagonists and COX-1 effects under various shear rates[67,68,71]. However, distinct in our 
studies are the eight channels comprising this single microfluidic device capable of 
performing dose-response experiments for 8 different concentrations on a single antiplatelet 
agent or high throughput testing of three antiplatelet agents in duplicate with simultaneous 
testing across three devices. Single channel platelet function measurements make dose 
response testing and high replicate testing of multiple drugs cumbersome. Dose dependent 
testing of the inhibitory effects of antiplatelet therapies on platelet function is crucial in 
narrowing the therapeutic window for these drugs. This would be an additional step towards 
personalized medicine in a clinical setting.      
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While antiplatelet agents are used for the prevention of arterial thrombosis, the 
monitoring of antiplatelet agents in anticoagulated whole blood (that lacks fibrin 
stabilization) is perhaps most precisely detected at venous shear rate, especially when 
constant flowrate perfusion is used.   The action of antiplatelet agents on thrombus build-up 
in the presence of fibrin generation at arterial shear rates remains an area of active 
investigation. Such arterial thrombosis studies will be best conducted under microfluidic 
conditions of constant pressure drop (not constant flow rate) where channel occlusion is a 
natural and important endpoint to the experiment [37].  Further work would be required to 
examine whether the presence of thrombin and fibrin in this microfluidic thrombosis model 
affects the inhibitory capabilities of 2MeSAMP and MRS 2179 on platelet function and as 
well as the compounds' respective IC50 values at venous and arterial wall shear rates. A 
constant pressure drop microfluidic thrombosis model at initial arterial wall shear rates 
would be more physiologically relevant. This could be a future avenue to investigate the 
efficacy of P2Y1 and P2Y12 inhibitors over increasingly complex surface triggered 
prothrombogenic surfaces such as lipidated recombinant tissue factor on collagen[35].      
The 8-channel microfluidic phenotyping of healthy subject response to anti-platelet 
therapies in this study was able to reproduce the biochemical signaling pathways and 
transport processes under which antiplatelet therapies must act. Quantification through 
platelet deposition rates, total platelet fluorescence and the all encompassing R value self-
normalizes donors without requiring donor specific measurements of vWF levels, platelet 
count, and hemoatocrit. However, quantification of secondary platelet aggregation using RP2Y 
or RCOX has not been tested with patients on clopidogrel or combined clopidogrel and 
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aspirin regiments. Translation of these values to quantify patients treated for coronary heart 
disease remains an area of future study. This work represents another step towards a 
functional high throughput point of care platelet function assay to detect patient-specific 
response to various antiplatelet therapies.  
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4 MICROFLUIDIC ASSAY OF HEMOPHILIC BLOOD 
CLOTTING: DEFICITS IN PLATELET AND FIBRIN 
DEPOSITION AT LOW FACTOR LEVELS AND 
POTENTIATION OF rFVIIa-INDUCED FIBRIN DEPOSITION 
BY THE CONTACT PATHWAY 
4.1 Introduction 
Hemophilia A and B are X-linked genetic disorders resulting in deficiencies of 
coagulation factor VIII (FVIII) or FIX, respectively[72]. The inheritance of FXI deficiency, 
also known as hemophilia C, is autosomal, and mostly leads to a bleeding risk during 
trauma[73]. Bypass therapies are used when neutralizing antibodies develop against FVIII, 
FIX, or less commonly FXI in hemophilic patients. Bypass therapies, including activated 
prothrombin complex concentrates (aPCC) and recombinant factor FVIIa (rFVIIa) supplant 
FXa generation from the intrinsic tenase (FIXa/FVIIIa) by increasing prothrombinase levels 
or activating FX on the platelet surface that then leads to thrombin generation[74]. 
Evaluations of responses to infused rFVIIa in hemophilia A and B patients reveal 
phenotypic differences in the drug's capacity to restore hemostasis[75]. Previous studies 
show that addition of rFVIIa to washed platelets increases platelet adhesion and aggregation 
to collagen at arterial shear rates attributable to the binding of rFVIIa to activated 
platelets[76]. Others showed a significant decrease in lag time and an increase in total fibrin 
deposition[77]. However, the effect of rFVIIa on fibrin generation under flow conditions 
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and the potential role of the contact pathway in rFVIIa efficacy has not yet been 
investigated.  
Recent developments in microfluidics have allowed low volume, high-throughput 
hemostatic assessment of platelet function[23,64,78]. We have previously described a 
microfluidic model evaluating contact pathway-driven coagulation using whole blood (WB) 
from patients with congenital bleeding disorders perfused over collagen without exogenously 
added tissue factor[23]. Platelet and fibrin deposition in WB from patients with FVIII and 
FIX-deficiencies displayed deficits in both platelet and fibrin deposition at <1% critical 
factor level activity[23].  
In the current study, the efficacy of rFVIIa was tested in high and low corn trypsin 
inhibitor (CTI, 4 or 40 µg/ml) inhibited WB from healthy or clotting factor-deficient 
hemophilia patients. CTI is a potent and selective inhibitor of βFXIIa[79]. Normal or 
hemophilic WB was perfused over collagen type I surfaces at an initial venous wall shear rate 
of 100s-1. We observed rFVIIa potentiation of platelet adhesion to collagen in hemophilic 
patients and healthy donors independent of CTI. However, with strong inhibition of the 
contact pathway (high CTI), exogenous rFVIIa was unable to rescue fibrin generation in 
cases of severe or moderate factor-deficiencies. The low levels of thrombin generated by 
rFVIIa alone indicate a novel role for the contact pathway in potentiating platelet-rFVIIa 
function. Thus in the absence of exogenous tissue factor, rFVIIa promotes platelet 
deposition on collagen by production of "signaling" levels of thrombin, but does not rescue 
fibrin deposition to normal levels unless the contact pathway participates.  
59 
 
4.2 Materials and Methods  
4.2.1 Blood collection, labelling, rFVIIa addition and patient recruitment 
Blood was drawn from healthy donors (n = 10) and coagulopathic patients (n = 8) 
under Internal Review Board approval of the University of Pennsylvania. Information 
regarding patient sex, age, bleeding phenotype, and recent therapy was collected(Table 2). 
Laboratory testing of hemophilic patients included a platelet count, residual coagulation 
factor activity, prothrombin time (PT), and activated partial thromboplastin time (aPTT). 
Residual FVIII, FIX, or FXI activity were measured in Hemophilia A and VWD disease, 
Hemophilia B, and Hemophilia C diagnoses respectively. The aPTT test assesses contact 
pathway function by measuring the time to clot formation in platelet-poor plasma in the 
presence of contact activators. aPTT values (reference range: 20.9-34.4 sec) were negatively 
correlated with residual factor activity levels as previously established[23]. Healthy donors 
were self-reported free of oral medication for 7 days and abstained from alcohol 48 h prior 
to blood donations. 
Patient 
ID# Diagnosis 
Residual 
Coagulation 
Factor %* 
aPTT 
(Sec) 
Platelets 
(103/µL) 
Timing 
of Most 
Recent 
Therapy  
Replacement 
Therapy Dosage 
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 Moderate 
Hemophilia C 3% 58.7 274 None N/A 
51 Severe Hemophilia A <1% 78.6 233  1 wk 35 IU/kg rFVIII  
52 Severe Hemophilia A 15% 43.5 204 20 hr 26 IU/kg rFVIII  
53 Severe Hemophilia A 15% 39.9 239 24 hr 30 IU/kg rFVIII  
54 
Moderate Hemophilia 
B 5% 48.2 250 30 hr 50 IU/kg rFIX  
55 Severe Hemophilia A 3% 51.8 201  4 days 30 IU/kg rFVIII  
56 
Moderate Hemophilia 
A 10% 46 333 4 wk 51 IU/kg rFVIII 
57 Severe Hemophilia A 9 57.1 145 3 days 27 IU/kg rFVIII 
Table 2. Eight patients were examined with respect to ex vivo rFVIIa addition in the 
microfluidic hemostasis model with high or low CTI-inhibited WB.  
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Time since last hemostatic therapy, % residual coagulation factor activity, PTT, and platelet count are as 
reported. *Reflects in some cases recent administration of factor concentrate. 
 
WB was drawn into 4 µg/ml and 40 µg/ml CTI (Haematologic Technologies, Essex 
Junction, VT) containing polypropylene test tubes, a material which minimally activates the 
contact pathway.  A low 4 µg/ml CTI is a concentration sufficient to prevent visible clotting 
in the test tube for approximately 30 min but insufficient to completely inhibit contact 
pathway activation at the micropatterned microfluidic injury site[23]. A high 40 µg/ml CTI 
concentration, while not perfect in abolishing contact activation, will prevent visible clotting 
for 60 to 120 min allowing studies of TF-dependent extrinsic pathway with minimal 
participation of the contact pathway[35,37,80]. Both concentrations of CTI allow sufficient 
time for completion of all assays with no clotting in the 35 µL entrance reservoirs of the 
microfluidic devices. 
Blood samples were treated with 0.125 µg/ml fluorescently conjugated non-function 
blocking anti-CD41a antibody (clone VI-PL2, Becton Dickson, Franklin Lakes, NJ, 0.125 
µg/ml final concentration) to label platelets and fluorescently conjugated anti-fibrin antibody 
(clone T2G1, Dr. Mortimer Poncz laboratory, Children's Hospital of Philadelphia, 0.5 µg/ml 
final concentration) to label fibrin. WB samples were also treated with vehicle HEPES 
buffered saline (HBS, 20 mM HEPES, 160 mM NaCl, pH 7.5) or indicated concentrations 
of rFVIIa. Recombinant FVIIa (NovonSeven, Novo Nordisk, Plainsboro NJ, 1 mg/ml final 
concentration) was reconstituted in histidine diluent. A dilution of rFVIIa was made to the 
final desired concentration in HBS within 1 hr of the assays. Whole blood perfusion in 
microfluidic devices started within 15 min of venipuncture.  
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4.2.2 Microfluidic haemostasis model 
Microfluidic devices were fabricated in polydimethylsiloxane (PDMS, Sylgard 184, 
Ellsworth Adhesives) according to previously described techniques[33,34]. The 8-channel 
microfluidic device has 8 channels fed by 8 wells with perfusion by withdrawal from a single 
outlet into a syringe pump (PHD 2000, Harvard Apparatus, Holliston, MA). The channels 
(250 µm by 60 µm) run perpendicularly over a 250 µm wide strip of patterned equine fibrillar 
collagen type I (Chronopar, Chronolog). A custom stage insert held two microfluidic devices 
allowing replicate testing of 4 conditions at each concentration of CTI in 60 sec intervals. 
Microfluidic devices were mounted on an inverted microscope (IX81, Olympus, Center 
Valley, PA). Microfluidic channels were spaced in close proximity to allow two channels to 
be imaged simultaneously with a 10X objective lens equipped with a CCD camera (ORCA-
ER, Hamamatsu, Bridgewater, NJ). Prior to initiation of the flow assay, all channels were 
blocked with 0.5% bovine serum albumin (BSA) in HBS buffer. Blood samples were 
perfused at an initial local wall shear rate of 100s-1 (1 µL/min per channel) for 15 min. In 
constant flow rate mode, the local wall shear rate monotonically increases as thrombi grow 
to the channel height[37].  
4.2.3 Platelet and fibrin accumulation analysis  
Platelet and fibrin fluorescence intensities, which are proportional to the total platelet 
and fibrin masses respectively were measured in 60 sec intervals for 15 min through Image J 
software (Image J, NIH, Bethesda, MD). The initial image was taken as background and 
subsequent images were background corrected. Platelet and fibrin masses were measured in 
an area comprising of 70% center zone of the 250 µm by 250 µm collagen surface due to the 
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slightly non-uniform shear profiles along the side of the microfludic channels[33]. Platelet 
adhesion and fibrin formation was not observed upstream or downstream of the collagen 
strip prior to full channel occlusion.  Statistical significance was assessed using a two tailed 
Student's t test.  
 
4.3 Results 
4.3.1 Exogenous rFVIIa enhances platelet adhesion to collagen, but does not restore 
fibrin generation in a moderately FXI-deficient patient 
The hemostatic effect of rFVIIa was evaluated by ex vivo addition to the WB of 
hemophilic patients. High or low CTI-treated WB from a moderately FXI-deficient patient 
(#50) with 3% FXI activity produced no detectable levels of fibrin (Figure 4-1B,D). As 
expected, high or low CTI had little effect on fibrin generation, which was already strongly 
attenuated in this patient because of the FXI deficiency. In the flow assay over collagen, 
fibrin generation is dependent on contact pathway engagement (FXIIa→FXIa) which is 
nearly absent in this patient. Fibrin generation due to the contact pathway was confirmed 
with perfusion of low CTI-treated recalcified healthy pooled plasma or factor-deficient 
plasma over collagen (Figure 8-6).   
Exogenous rFVIIa addition increased platelet deposition on collagen at high and low 
CTI (Figure 4-1A,C). However, ex vivo supplementation with rFVIIa failed to rescue fibrin 
formation at either CTI concentration (Figure 4-1B,D). Without contact pathway 
engagement (high CTI and FXI deficiency), rFVIIa strongly promoted platelet deposition 
with little effect on fibrin production. To rule out inhibition of rFVIIa function by CTI, a 
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fluorogenic substrate for FVIIa was tested with rFVIIa and high or low CTI showing no 
effect of CTI on rFVIIa function (Figure 8-7).   
 
 
Figure 4-1 Moderately FXI-deficient (3%) patient #50 response to exogenous rFVIIa  
(A & B), Platelet and fibrin fluorescence at various exogenous rFVIIa concentrations in high CTI (40 µg/ml). 
(C & D), Platelet and fibrin fluorescence with ex vivo rFVIIa addition in low CTI (4 µg/ml). Shaded traces are 
the standard deviation of two clotting events measured in 60 sec intervals over 15 min. Insert: 8-channel 
microfluidic device with location of the collagen strip as indicated.  
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4.3.2 Exogenous rFVIIa enhances platelet adhesion to collagen, but does not restore 
fibrin generation in a severely FVIII-deficient patient 
WB from a severely FVIII-deficient patient (#51; <1% FVIII) tested at one week following 
administration of FVIII concentrate, showed a deficit in fibrin production that was not 
rescued by rFVIIa at either CTI concentration. Recombinant FVIIa enhanced platelet 
deposition but had no effect on fibrin production (Figure 4-2). Despite FXa generation due 
to rFVIIa binding to activated platelets, insufficient thrombin was produced to cause robust 
fibrin formation. Robust fibrin formation, especially in the absence of exogenous tissue 
factor, requires intrinsic tenase formation (FIXa/FVIIIa) which clearly did not occur with 
<1% FVIII levels. The level of CTI had no effect since the contact pathway can proceed 
downstream from FXIIa to FIXa but will not result in sufficient intrinsic tenase.    
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Figure 4-2 Severely FVIII-deficient (<1%) patient #51 response to exogenous rFVIIa  
(A & B), Platelet and fibrin fluorescence over time in high CTI at indicated concentrations of ex vivo rFVIIa. 
(C & D), Platelet and fibrin fluorescence over time in low CTI at indicated concentrations of ex vivo rFVIIa. 
Timing of recent hemostatic therapy is as indicated. Shaded traces are the standard deviation of two clotting 
events measured in 60 sec intervals over 15 min.  
 
4.3.3 Moderate deficiency of FVIII or FIX allows rFVIIa to enhance platelet and 
fibrin generation when the contact pathway is available  
In high CTI, rFVIIa augmented platelet deposition in a severely FVIII-deficient 
patient (#55; 3% FVIII) who was treated with FVIII concentrate 4 days prior to testing 
(Figure 4-3A, upper left). However, ex vivo rFVIIa addition again did not produce 
substantial fibrin accumulation with strong inhibition of the contact pathway (Figure 4-3A, 
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lower left). In contrast, fibrin generation occurred upon addition of rFVIIa at low CTI 
(Figure 4-3A, lower right). Contact pathway engagement (FXIIa→FXIa→FIXa) and 
intrinsic tenase assembly was productive enough to make sufficient thrombin to generate 
fibrin when rFVIIa was used at a 3% FVIII deficiency.  
Similarly, a moderately FIX-deficient patient (#54; 5%) displayed nearly identical 
results as patient (#55) (Figure 4-3B). Recombinant FVIIa potently amplified platelet 
deposition in either CTI concentration (Figure 4-3, upper panels) whereas fibrin formation 
was highly dependent on contact pathway activity (low versus high CTI; Figure 4-3, lower 
panels). A similar role for the contact pathway was discovered when two additional severely 
FVIII-deficient patients treated with FVIII concentrate were tested (#57 & 56) (Figure 8-8). 
In three of these patients a peak in platelet deposition as measured by platelet fluorescence 
with contact pathway engagement and rFVIIa was found at 7-11 min followed by a drastic 
dip in the signal(Patient #54,57,56). This is due to downstream movement of the platelet-
fibrin aggregates past the collagen surface as the clots formed under a constant flow regime 
cannot stop flow driven by a syringe pump.  
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Figure 4-3 Effect of ex vivo rFVIIa in severely FVIII-deficient patient #55 and 
moderately FIX-deficient patient #54 after recovery of critical factor levels to 3 and 
5% respectively 
(A), Platelet and fibrin fluorescence over time in high or low CTI-inhibited WB for patient #55. (B), Platelet 
and fibrin fluorescence in high or low CTI-inhibited WB for patient #54.  Timing of recent hemostatic therapy 
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is as indicated. Shaded traces are the standard deviation of two clotting events measured in 60 sec intervals over 
15 min. Dashed lines indicate full channel occlusion. 
 
4.3.4 Recovery of FVIII levels to 15% in patients allows rFVIIa to potentiate both 
platelet and fibrin deposition with less requirement for the contact pathway  
When severely FVIII-deficient patients (#53 and #52) were recently treated (<24 hr) 
with therapy to increase their FVIII levels to 15%, exogenous rFVIIa addition caused 
substantial increases in platelet deposition and fibrin generation. The two FVIII-deficient 
patients displayed identical responses to rFVIIa. Increases in platelet deposition, fibrin 
initiation, and fibrin generation were measured in both patients; concentration dependent 
increases in platelet and fibrin accumulation were statistically significant at 4 nM rFVIIa  
(Figure 4-4). As residual clotting factor levels reach 15%, a level clinically considered as a 
mild deficiency, the influence of FXIIa was less prominent. However, the effects of FXIIa 
were still detectable as fibrin was generated faster and more abundantly in low CTI 
compared to high CTI in both patients (Figure 4-4A, B, lower panels).  
In examining total platelet accumulation at 15 min (or prior to full channel 
occlusion), rFVIIa increased final platelet accumulation independent of CTI in all 8 patients 
(#50-57) (Figure 4-5A).  Recombinant FVIIa showed robust effects on total fibrin 
accumulation with contact pathway-initiated coagulation at low CTI and >3% factor levels 
and minimum effect with strong inhibition of the contact pathway (high CTI) or at <3% 
factor levels (Figure 4-5B). The levels of fibrin production in FVIII or FIX-deficient 
patients in low CTI and the lack of fibrin generation in high CTI with rFVIIa indicate a 
novel role for contact pathway potentiation of platelet-rFVIIa function.   
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Figure 4-4 Effect of ex vivo rFVIIa in 2 severely FVIII-deficient patients after 
recovery of FVIII activity to 15% 
(A), Platelet and fibrin fluorescence dynamics in high or low CTI-inhibited WB for severely FVIII deficient 
patient #53. (B), Platelet and fibrin fluorescence dynamics in low or high CTI inhibited WB for severely 
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FVIII-deficient patient #52. Timing of recent hemostatic therapy is indicated. Shaded traces are the standard 
deviation of two clotting events measured in 60 sec intervals over 15 min.  
 
Figure 4-5 rFVIIa response in CTI-inhibited WB from 8 factor-deficient patients 
(#50-57; Table 2. Eight patients were examined with respect to ex vivo rFVIIa 
addition in the microfluidic hemostasis model with high or low CTI-inhibited WB.): 
Platelet and fibrin accumulation at t = 15 min or just prior to full channel occlusion 
sorted by residual factor activity and aPTT results  
(A), Average final platelet mass as measured by platelet surface fluorescence at 0 or 4 nM rFVIIa in 8 intrinsic 
clotting factor deficient patients. Error bars are standard deviation of a minimum of 4 clotting events. (B), 
Average final fibrin mass as measured by surface fibrin fluorescence at 0 or 4 nM rFVIIa in 8 intrinsic clotting 
factor deficient patients. Error bars are standard deviation of a minimum of 4 clotting events. (*p<0.05, 
**p<0.01, ns: non-significant) 
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4.3.5 Contact activation and rFVIIa enhance platelet and fibrin deposition in healthy 
blood  
Eight healthy donors were subsequently tested in the same manner as the 
coagulopathic patients to further investigate the role of the contact pathway in exogenous 
rFVIIa function. Consistent with the platelet response to rFVIIa in hemophilic patients, 
healthy donor platelet deposition increased due to rFVIIa addition independent of the 
contact pathway (high or low CTI) (Figure 4-6A, upper panels). However, the contact 
pathway (low CTI) was required to generate sufficient levels of thrombin for robust fibrin 
formation (Figure 4-6A, lower panels). Similar to some hemophilic patients (#54, 56, 57), a 
combination of the contact pathway and ex vivo rFVIIa resulted in peak platelet deposition 
at 7 min followed by a drastic drop in signal. This is indicative of increasing shear stresses on 
the clots which eventually causes them to tear from the collagen surface, restructure, and 
embolize downstream.  
Recombinant FVIIa significantly increased total platelet accumulation at 15 min or 
prior to full channel occlusion in low CTI, showing efficacy in enhancing platelet deposition 
independent of the contact pathway (Figure 4-6B; p<0.01). Total fibrin accumulation 
increased by three fold with rFVIIa when FXIIa was engaged (Figure 4-6C; p<0.01), while 
no increase was observed when FXIIa was strongly inhibited.   
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Figure 4-6 Healthy donor WB (n = 8 donors) platelet and fibrin accumulation 
response to rFVIIa  
(A), Platelet and fibrin fluorescence over time as a function of rFVIIa concentrations in high or low CTI. 
Dashed line indicates full channel occlusion (B), Average final platelet mass at t = 15 min or just prior to full 
channel occlusion in the presence or absence of ex vivo rFVIIa in high or low CTI-inhibited WB. (C), Average 
final fibrin mass at t = 15 min in the presence or absence of ex vivo rFVIIa in high or low CTI-inhibited WB. 
Bars are average and standard deviation from n = 8 healthy donors and  16 clotting events.  (*p<0.05, 
**p<0.01, ns: non-significant) 
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4.4 Discussion  
Microfluidic models of hemostasis comprised of high or low CTI anti-coagulated WB 
perfused over collagen at venous shear rates were used to assess platelet and fibrin 
deposition in response to exogenous rFVIIa. Under these conditions, we investigated the 
role of rFVIIa under flow. We observed significantly increased platelet adhesion in the 
presence of rFVIIa but an inability of rFVIIa to potentiate fibrin formation unless the 
contact pathway was engaged.  
Results from hemophilic patients (#50,51,54,55,56,57) indicate that rFVIIa function 
on platelets generate low "signaling" levels of thrombin to amplify platelet deposition but 
these levels were insufficient to generate fibrin. If contact engagement was blunted in the 
case of severe FXI or FVIII-deficiency (Figure 4-1,Figure 4-2) or at high CTI in FVIII or 
FIX-deficient patients (Figure 4-3A, B, lower left), rFVIIa did not lead to ample fibrin 
formation. However, with engagement of the contact pathway (low CTI), rFVIIa may 
crosstalk with the contact pathway to facilitate strong fibrin production in FVIII or FIX-
deficient patients (Figure 4-3A, B lower right).  
In addition, rFVIIa can generate FXa on the platelet surface and to a very minimal 
extent in solution[81].  In severely FVIII-deficient WB (< 1%), thrombin made distally from 
platelet-bound rFVIIa (4 nM added) is sufficient to promote greater platelet activation but is 
insufficient to generate fibrin (Figure 4-2).  In moderately hemophiliac blood (3% FVIII or 
5% FIX), strong inhibition of the contact pathway prevented fibrin formation although 
platelet deposition was still enhanced by rFVIIa (Figure 4-3).  The initiation of the contact 
pathway in low CTI dramatically enhanced fibrin formation in moderate hemophiliac blood 
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(3% FVII or 5% FIX) treated with rFVIIa (Figure 4-3).  Similar results were found in mild 
hemophilic blood (15% FVIII) (Figure 4-3) and even in healthy WB (Figure 4-6) where 
strong inhibition of the contact pathway significantly blunted fibrin production following 
exogenous rFVIIa treatment.   
Recombinant FVIIa can enhance FXa generation at the site of bleeding by a variety of 
pathways. If TF is exposed to WB, formation of the extrinsic tenase TF/rFVIIa would be 
extremely procoagulant. Furthermore, the heterogeneous response to rFVIIa amongst 
hemophiliacs can also be potentially attributable to variable quantities of circulating lipids or 
procoagulant TF-containing microparticles, two variables known to put hemophiliacs at risk 
for cardiovascular diseases as they age[82,83]. However, hemophiliacs bleed into joints, 
which are presumably sites of low cellularity and low TF[84].  The results derived from FXI-
deficient blood (Figure 4-1) argue against bloodborne TF as a kinetically significant trigger 
that produces detectable changes in our intrinsically driven microfluidic hemostasis model. 
In contrast to the present study, prior work by Onasoga-Jarvis et al. perfused rFVIIa-
supplemented hemophiliac blood over TF-containing collagen to drive thrombin and fibrin 
production [77].  
We predict that for in vivo situations where wall-derived TF and contact activation are 
both minimal, rFVIIa can promote hemostasis in severe hemophilia via platelet activation by 
low levels of thrombin (distal of platelet bound rFVIIa) in the absence of substantial fibrin 
generation.  When the contact pathway is engaged through FXII[85], collagen[86], activated 
platelets[87], or nucleic acid[88], it can promote the efficacy of rFVIIa by providing 
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additional FXa or by inactivation of an inhibitor, such as recently reported FXIa-mediated 
cleavage of  tissue factor pathway inhibitor (TFPI)[89].  
A level of 4 nM rFVIIa enhanced platelet deposition under flow by 2 to 3-fold in all 
patients tested (Figure 4-5A; p<0.05). At <10% factor level (aPTT > 45 sec), the contact 
pathway alone (no rFVIIa) at either high or low CTI produced essentially no fibrin (Figure 
4-5B). However, for <10% factor level, low CTI inhibition of WB potentiated the ability of 
rFVIIa to promote fibrin formation. Distinct from hemophilia, conditions of trauma that 
promote contact activation may enhance the ability of rFVIIa to cause fibrin generation. 
Furthermore, while incidences of venous thrombosis are rare in factor-deficient patients[90], 
we quantified partial movement and remodeling of clots at low CTI with ex vivo rFVIIa in 3 
hemophilic patients. As embolized thrombi are clinically significant, future work should 
assess the risk of venous thromboembolism with rFVIIa under a pressure relief flow regime 
in this microfluidic device[37]. In pressure relief mode, full channel occlusion is a natural 
endpoint as flow diversion to open channels allows thrombi to grow to full occlusion.    
This work highlights the ability of rFVIIa to generate low levels of FXa on platelets to drive 
platelet deposition via thrombin even when that thrombin is sufficient to drive fibrin 
deposition under flow. If the contact pathway is not engaged and TF is absent, rFVIIa may 
display its efficacy in severe hemophiliacs (<1%) by enhancing only platelet function.  
 
 
 
 
76 
 
5 RECOMBINANT FACTOR VIIA ADDITION TO SEVERE 
HEMOPHILIC BLOOD PERFUSED OVER 
COLLAGEN/TISSUE FACTOR CAN SUFFICIENTLY BYPASS 
THE FACTOR IXA/VIIIA DEFECT IN ORDER TO RESCUE 
FIBRIN  
5.1 Introduction 
Hemophilia A and B are X-linked genetic disorders resulting in deficiencies in 
coagulation factor VIII (FVIII) or factor IX (FIX), respectively[72]. These deficiencies cause 
a wide range of bleeding phenotypes depending on severity [75,91–93]. Current treatment 
strategies for hemophilic patients include recombinant clotting factors or bypass therapies. 
Bypass therapies such as activated prothrombin complex concentrates (aPCC) or 
recombinant factor VIIa (rFVIIa) were developed to treat hemophilic patients who develop 
inhibitors[74]. Bypass therapies can supplant FXa generation from the intrinsic tenase 
(FIXa/FVIIIa) by increasing prothrombinase levels or by activating FX on the platelet 
surface via rFVIIa. Though rFVIIa is approved for treating hemophilia patients with 
antibodies to FIX or FVIII, its mechanism of action is complex[94]. Past work has indicated 
that rFVIIa requires tissue factor to function and its requisite high doses are due to its 
competition with endogenous FVII for TF[95,96]. Other studies indicate that rFVIIa can 
also bind monocytes and activated platelets to generate FXa independent of TF[97–99].   
Thus, further studies can help elucidate the roles of intrinsic tenase, extrinsic tenase, 
and rFVIIa in platelet rich thrombus formation and fibrin generation in hemophilic patients 
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under the hemodynamics conditions found in vivo. In hemophilia, deficits in thrombin 
generation impact platelet activation[100], fibrin formation[101], and clot stabilization[102]. 
In vitro flow models with perfusion of human blood deficient in FVIII or with inhibition of 
FVIII resulted in decreased platelet aggregation and fibrin formation at low shear 
conditions[103–105]. With in vivo models of vascular injury (ferric chloride or laser injury), 
mice deficient in FVIII or FIX produce unstable thrombi that fail to reach full vessel 
occlusion[106–108].  While the extrinsic pathway is classically thought of as the arm of the 
coagulation cascade that mitigates deficits in hemophilia A and B, TF expression varies 
greatly in human tissues[109,110]. High TF levels may compensate for a lack of FVIII or 
FIX in some but not all subendothelial vascular beds. Studies have shown bleeding in 
hemophilia is common in the joints where TF expression is considered to be low[110]. The 
contribution of FXa and thrombin stemming from residual intrinsic tenase in various TF-
laden backgrounds has not been studied extensively using hemophilic blood. Previous 
studies only assessed the most severe cases of human FVIII or FIX deficiency (<1%) often 
with FXIIa function uncontrolled or utilized blood from mice deficient in FVIII or 
FIX[104,105,111]. Few have examined how mild or moderate deficiencies in FVIII or FIX 
levels affect platelet adherence, clot stability, and fibrin formation under flow in the presence 
or absence of bypass therapy[77] and surface TF.  
Previously we have developed a contact pathway-driven microfluidic model that 
evaluated the role FVIII and FIX in patients with congenital bleeding disorders[23,24].  
Platelet adhesion and fibrin formation under flow was significantly reduced in whole blood 
from these patients at <1% critical factor level activity[23]. Furthermore, in a second study 
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we concluded that rFVIIa generates low levels of ‘signaling’ thrombin sufficient to enhance 
platelet deposition on collagen, but is insufficient to drive fibrin polymerization unless the 
contact pathway is engaged. In this present study, we aimed to unify our previous two 
studies and firmly establish the role of the intrinsic tenase and rFVIIa in the regulation of 
platelet-fibrin thrombus development under flow. We measured healthy or hemophilic WB 
perfusion over collagen type I surfaces bearing well-controlled low or high concentrations of 
lipidated tissue factor at an initial venous wall shear rate of 100 s-1. We also measured the 
differential effect of exogenously added rFVIIa on platelet deposition, fibrin initiation, and 
fibrin accumulation. This study confirms that FIXa/FVIIIa is required for fibrin generation 
under healthy WB flow, even when TF is abundant at the wall. In severe hemophilic blood 
with CTI-inhibited FXIIa, high levels of rFVIIa are required to rescue fibrin formation 
through the combined generation of FXa via TF/rFVIIa and platelet/rFVIIa function.  
 
5.2 Materials and Methods 
Blood was drawn from healthy donors (n = 5) and hemophilic patients (n = 10) under 
Internal Review Board approval of the University of Pennsylvania. Data regarding patient 
bleeding phenotype and recent therapy was collected (Table 3)  
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Patient 
ID# Diagnosis 
Residual 
Coagulation 
Factor %* 
aPTT 
(Sec) PT 
Platelets 
(103/µL) 
Timing 
of Most 
Recent 
Therapy  
Replacement 
Therapy 
Dosage 
62 
Severe 
Hemophilia A 3 56.1 13.3 172 3 days 
rFVIII (35 
IU/kg) 
63 
Severe 
Hemophilia A 32 32.7 12.9 291 5 hrs 
rVIII (25 
IU/kg) 
64 
Severe 
Hemophilia B 14 34.4 13.7 252 96 hrs 
rFIX 
(unknown) 
65 
Severe 
Hemophilia B 6 51.2 14.9 200 3 days 
rFIX (47 
IU/kg) 
67 
Mild Hemophilia 
A 18 37.4 12.9 244 
None in 
past 5 
years 
rFVIII 
(unknown) 
68 
Moderate 
Hemophilia A 6 50.8 14.1 173 
None in 
past 10 
months N/A 
69 
Moderate 
Hemophilia A 2 53.5 12.5 217 
None 
since 
2012 N/A 
70 
Severe 
Hemophilia A 24 40.1 12.8 273 26 hrs 
rFVIII (50 
IU/kg) 
71 
Moderate 
Hemophilia B 5 51.1 15.9 208 
None in 
past 5 
years N/A 
29 
Severe 
Hemophilia B **<1 133.6 14.5 125 8 hrs 
rFIX (50 
IU/kg) 
 
Table 3. 10 patients were examined with respect to exogenous rFVIIa efficacy by 
perfusion of high CTI inhibited WB on TFlow and TFhigh collagen surfaces.  
Time since last hemostatic therapy, % residual coagulation factor activity, PTT, and platelet count are as 
reported. *Reflects in some cases recent administration of factor concentrate. 
 
Laboratory testing of hemophilic patients included a platelet count, residual coagulation 
factor activity, prothrombin time (PT), and activated partial thromboplastin time (aPTT). 
Residual FVIII, FIX, or FXI activity were measured in Hemophilia A and VWD disease, 
Hemophilia B, or Hemophilia C diagnoses respectively. The aPTT test assesses intrinsic 
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pathway function by measuring the time to clot formation in platelet-poor plasma in the 
presence of exogenous intrinsic pathway activators such as kaolin[112]. aPTT values 
(reference range: 20.9-34.4 sec) were negatively correlated with residual factor activity levels 
as previously established[23]. Healthy donors were self-reported free of oral medication for 7 
days and abstained from alcohol 48 h prior to blood donations. 
WB was drawn into 40 µg/ml CTI (Haematologic Technologies, Essex Junction, 
VT) containing polypropylene plastic syringes, a material which activates the contact 
pathway minimally.  At 40 µg/ml, CTI will almost completely abolish contact pathway 
activation and prevent visible clotting for 30 to 45 min allowing studies of surface-trigged 
TF-dependent coagulation under flow with minimal participation of FXIIa[80]. This 
concentration of CTI allows sufficient time for completion of all assays with no clotting in 
the 35 µL entrance reservoirs of the microfluidic devices. 
Preparation of TF bearing collagen surfaces  
Glass slides were first functionalized with Sigmacote (Sigma, St. Louis, MO) to create 
a hydrophobic surface. Acid-insoluble equine type I collagen fibrils (Chrono-Par, Chrono-
log, Havertown, PA) were introduced into a previously described single channel microfluidic 
patterning device (250 µm by 1 cm) [33,34]. This patterning device was then filled with 5 µL 
of Dade Innovin PT reagent (Siemens Healthcare USA, Malvern, PA. 20 nM stock 
concentration) diluted 300 or 5 fold with 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic 
acid (HEPES)-buffered saline (HBS, 20 mM HEPES, 160 mM NaCl, pH 7.4) to obtain low 
or high TF surface concentrations. TF surface concentrations were measured by the staining 
of TF vesicles with  fluorescein isothiocynate labeled annexin V as previously described[113]. 
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In all microfluidic experiments TF bearing collagen surfaces were incubated for 30 minutes 
in the absence of flow and then washed with 5 µl of 0.5% bovine serum albumin (BSA) in 
HBS. Nominal low and high TF surface concentrations ([TF]wall) were ~0.1 and ~2 
molecules per µm2, respectively, as previously reported[113]. This single channel patterning 
device was then removed to allow placement of microfluidic flow devices onto the 
micropatterned TF bearing collagen strip.   
Extrinsic pathway triggered microfluidic flow assay on TF bearing collagen surfaces  
An 8-channel microfluidic device was fabricated in polydimethylsiloxane (PDMS, 
Sylgard 184, Ellsworth Adhesives) according to previously described techniques[33,64]. The 
device has 8 channels fed by 8 wells with perfusion by withdrawal from a single outlet into a 
syringe pump (PHD 2000, Harvard Apparatus, Holliston, MA). This 8-channel device was 
placed over TF bearing collagen surfaces and reversibly sealed by house vacuum. The 
channels (250 µm by 60 µm) of the device run perpendicularly over a 250 µm wide strip of 
patterned equine fibrillar collagen type I bearing TF. This forms platelet and prothrombotic 
protein interaction zones measuring 250 µm by 250 µm. A customized stage insert held two 
microfluidic devices allowing replicate testing of 4 conditions in 60 sec intervals. Microfluidic 
devices were mounted on an inverted microscope (IX81, Olympus, Center Valley, PA). 
Microfluidic channels were spaced in close proximity to allow two channels to be imaged 
simultaneously with a 10X objective lens equipped with a charged-coupled device (ORCA-
ER, Hamamatsu, Bridgewater, NJ). Prior to initiation of the flow assay, all channels were 
blocked with 0.5% bovine serum albumin (BSA) in HBS.  
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Blood samples were treated with fluorescently conjugated non-function blocking 
anti-CD41a antibody (clone VI-PL2, Becton Dickson, Franklin Lakes, NJ, 0.125 µg/ml final 
concentration) to label platelets and fluorescently conjugated anti-fibrin antibody (clone 
T2G1, Dr. Mortimer Poncz laboratory, Children's Hospital of Philadelphia, 0.5 µg/ml final 
concentration) to label fibrin. WB samples were also treated with vehicle HBS or indicated 
concentrations of rFVIIa. Recombinant FVIIa (NovonSeven, Novo Nordisk, Plainsboro NJ, 
1 mg/ml final concentration) was reconstituted in histidine diluent. WB samples were treated 
with detection antibodies and rFVIIa 5 min prior to initiation of flow assays. A dilution of 
rFVIIa was made to the final desired concentration in HBS within 1 hr of the tests. Whole 
blood perfusion in microfluidic devices started within 15 min of venipuncture. Blood 
samples were perfused at an initial local wall shear rate of 100s-1 (1 µL/min per channel) for 
15 min. In constant flow rate mode the local wall shear rate monotonically increases as 
thrombi grow to the channel height[37].  
Platelet and fibrin accumulation analysis  
Platelet and fibrin fluorescence intensities, which are proportional to the total platelet 
and fibrin masses respectively were measured in 60 sec intervals for 15 min through ImageJ 
software (ImageJ, National Institute of Health, Bethesda, MD). The initial image was taken 
as background and subsequent images were background-corrected. Platelet and fibrin masses 
were measured in an area comprising of 70% center zone of the 250 µm by 250 µm TF 
collagen surface due to the slightly non-uniform shear profiles along the side of the 
microfluidic channels[33,34]. Platelet adhesion and fibrin formation was not observed 
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upstream or downstream of the TF collagen strip prior to full channel occlusion.  Statistical 
significance was assessed using a two tailed Student's t test.  
 
5.3 Results 
5.3.1 Surface-triggered extrinsic pathway under flow does not rescue platelet 
adherence or fibrin generation at <3% factor activity.  
The hemostatic potential of surface-triggered TF under flow to rescue deficits in 
FVIII or FIX was evaluated through perfusion of hemophilic or healthy WB over collagen 
bearing TFlow or TFhigh surfaces. 
 
Figure 5-1 Comparison of severely and moderately factor-deficient (1-3%) patients 
against healthy donor response to TFlow or TFhigh bearing collagen surfaces 
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(A & B), Platelet adherence and fibrin deposition dynamics measured by platelet and fibrin fluorescence 
respectively. WB inhibited with 40 µg/ml CTI was perfused over TFlow bearing collagen surfaces at 100 s-1. (B 
& C), Platelet adherence and fibrin deposition dynamics over time. WB inhibited with 40 µg/ml CTI was 
perfused over TFhigh bearing collagen surfaces at 100 s-1. Lines with shaded traces and points are the mean and 
standard deviation of 6 clotting events measured in 60 sec intervals over 15 min for three distinct hemophilic 
patients (red) or 10 clotting events measured in 60 sec intervals over 15 min for five distinct healthy subjects 
(black).  
 
High CTI-inhibited WB from two severely factor-deficient patients and one 
moderately factor-deficient patient (#62, 69, 29) with 3, 2, and <1 % factor activity 
respectively produced no detectable levels of fibrin (Figure 5-1B,D, red lines) as opposed 
to healthy controls where robust platelet deposition and fibrin generation was measured 
regardless of surface TF concentration (Figure 5-1B, D: black lines). Fully consistent with 
TF/FVIIa as the primary trigger of coagulation in this microfluidic model, time to fibrin 
initiation in healthy donors decreased when surface TF concentration increased (Figure 
5-1B, D: black lines). Platelet deposition over time was also elevated on TFhigh collagen 
surfaces indicating that thrombin generation was occurring at a concentration sufficient to 
drive platelet deposition and facilitate fibrin formation (Figure 5-1C,D: black line). 
Interestingly, at < 3% factor activity, hemophilic patient platelet deposition was reduced 
compared to healthy blood independent of surface TF concentration (Figure 5-1A, C: red 
lines).   
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Figure 5-2 Comparison of 3-14% clotting factor activity patients against healthy 
donor response to TFlow or TFhigh bearing collagen surfaces  
(A & B), Platelet adherence and fibrin deposition dynamics measured by platelet and fibrin fluorescence 
respectively. WB inhibited with 40 µg/ml CTI was perfused over TFlow bearing collagen surfaces at 100 s-1. (B 
& C), Platelet adherence and fibrin deposition dynamics over time. WB inhibited with 40 µg/ml CTI was 
perfused over TFhigh bearing collagen surfaces at 100 s-1. Lines with shaded traces and points are the mean and 
standard deviation of 6 clotting events measured in 60 sec intervals over 15 min for three distinct hemophilic 
patients (red) or 10 clotting events measured in 60 sec intervals over 15 min for five distinct healthy subjects 
(black).  
5.3.2 Extrinsic pathway triggered coagulation under flow partially restores platelet 
adhesion and fibrin generation at 3-14% factor activity.  
Perfusion of moderately and mildly FVIII or FIX-deficient patient WB (#64, 65, 68, 71) 
resulted in poorly detectable or low levels of fibrin accumulation under flow on TFlow or 
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TFhigh surfaces, respectively (Figure 5-2C,D: red lines). Additionally, significant decreases in 
platelet adhesion on TF collagen surfaces were again observed in these patients independent 
of surface TF concentration (Figure 5-2A, B: red lines). However, these levels of platelet 
adhesion were higher than those observed with the 1-3% factor activity group (Figure 5-1A, 
C: red lines). These results indicate that engagement of the intrinsic tense (FIXa/FVIIIa  
FXa) in combination with FXa production from TF/FVIIa under flow on TFhigh collagen 
surfaces was sufficient to initiate some fibrin formation and produce low amounts of fibrin 
accumulation (Figure 5-1D: red lines). 
 
 
Figure 5-3 Comparison of >14% clotting factor activity against healthy donor 
response to TFlow or TFhigh bearing collagen surfaces 
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(A & B), Platelet adherence and fibrin deposition dynamics measured by platelet and fibrin fluorescence 
respectively. WB inhibited with 40 µg/ml CTI was perfused over TFlow bearing collagen surfaces at 100 s-1. (B 
& C), Platelet adherence and fibrin deposition dynamics over time. WB inhibited with 40 µg/ml CTI was 
perfused over TFhigh bearing collagen surfaces at 100 s-1. Lines with shaded traces and points are the mean and 
standard deviation of 6 clotting events measured in 60 sec intervals over 15 min for three distinct hemophilic 
patients (red) or 10 clotting events measured in 60 sec intervals over 15 min for five distinct healthy subjects 
(black).  
 
 
Figure 5-4 Total platelet or fibrin accumulation for different clinical severities of 
hemophilia 
(A & B), Maximum platelet or fibrin accumulation on TFlow bearing collagen surfaces at 100 s-1 measured by 
platelet or fibrin fluorescence at t = 15 min or just prior to full channel occlusion. Data is ordered by severity 
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of factor deficiency (1-3%, 3-14% & >14%) and compared to mean healthy subject maximum platelet or fibrin 
accumulation.  (C & D), Maximum platelet or fibrin accumulation on TFhigh bearing collagen surfaces at 100s-1 
measured by platelet or fibrin fluorescence at t = 15 min or just prior to full channel occlusion. Data is ordered 
by severity of factor deficiency (1-3%, 3-14% & > 14%) compared to mean healthy subject maximum platelet 
or fibrin accumulation. Error bars are the standard deviation of 6 clotting events for each clinical severity of 
hemophilia and 10 clotting events for five healthy subjects. (** p < 0.01, * p < 0.05, ns: non-significant) 
 
5.3.3 Platelet adhesion is partially rescued by the extrinsic pathway independent of 
TF concentration while fibrin formation is fully restored on TFhigh collagen 
surfaces at >14% factor activity 
Platelet deposition from WB of mildly FVIII or FIX-deficient patients (#63, 67, 70) 
remained attenuated in comparison to the platelet deposition from healthy controls although 
it was not statistically significant with low surface TF concentrations (Figure 5-3A, C). 
Interestingly, we observed residual defect in fibrin production at >14% factor activity in the 
presence of TFlow collagen surfaces (Figure 5-3B: red line). Time to fibrin initiation and 
total fibrin accumulation under flow was fully restored with TFhigh collagen surfaces (Figure 
5-3: red line). The influence of FVIIIa and FIXa become more prominent as residual 
clotting factor levels reach >14%.  
In examining total platelet and fibrin accumulation under flow at 15 min for all 
cohorts, platelet and fibrin accumulation on TFlow and TFhigh surfaces was highly defective 
for blood from patients with 1-3% normal factor level when compared to healthy blood 
(Figure 5-4A-D).  High levels of TF do not rescue clotting in severely factor-deficient 
patients (Figure 5-4D) whose blood generated essentially no fibrin.  
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Figure 5-5 Effect of in vitro rFVIIa (0-20 nM) in severely FVIII-deficient patient  
(A & B), Platelet adherence and fibrin deposition in the presence or absence of exogenous rFVIIa measured by 
platelet and fibrin fluorescence at t = 15 min or just prior to full channel occlusion. WB treated with exogenous 
rFVIIa (0-20 nM) and inhibited with 40 µg/ml CTI was perfused over TFlow bearing collagen surfaces at 100 s-
1.   (C & D), Platelet adherence and fibrin deposition in the presence or absence of exogenous rFVIIa 
measured by platelet and fibrin fluorescence. WB treated with exogenous rFVIIa (0-20 nM) and inhibited with 
40 µg/ml CTI was perfused over TFhigh bearing collagen surfaces at 100 s-1. Lines with shaded traces and points 
are the mean and standard deviation of 2 clotting events measured in 60 sec intervals over 15 min for each 
concentration of rFVIIa (colored) or 10 clotting events measured in 60 sec intervals over 15 min for five 
distinct healthy subjects (gray).  
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Figure 5-6 Total platelet or fibrin accumulation in response to in vitro rFVIIa (0-20 
nM) for different clinical severities of hemophilia  
(A & B), Maximum platelet or fibrin accumulation in the presence or absence of exogenous rFVIIa measured 
by platelet or fibrin fluorescence. WB treated with exogenous rFVIIa (0-20 nM) and inhibited with 40 µg/ml 
CTI was perfused over TFlow bearing collagen surfaces at 100s-1. Data is ordered by severity of factor deficiency 
(1-3%, 3-14% & >14%) and compared to mean healthy subject maximum platelet or fibrin accumulation.  (C 
& D), Maximum platelet or fibrin accumulation in the presence or absence of exogenous rFVIIa measured by 
platelet or fibrin fluorescence. WB treated with exogenous rFVIIa (0-20 nM) and inhibited with 40 µg/ml CTI 
was perfused on TFhigh bearing collagen surfaces at 100s-1. Data is ordered by severity of factor deficiency (1-
3%, 3-14% & >14%) and compared to mean healthy subject maximum platelet or fibrin accumulation.  Data is 
ordered by severity of factor deficiency (1-3%, 3-14% & > 14%) compared to mean healthy subject maximum 
platelet or fibrin accumulation. Error bars are the standard deviation of 6 clotting events for each clinical 
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severity of hemophilia and 10 clotting events for five healthy subjects. (** p < 0.01, * p < 0.05, ns: non-
significant) 
 
5.3.4 Exogenous rFVIIa enhances platelet deposition on collagen with TFlow and 
TFhigh, but only fully restores fibrin accumulation at 20 nM on TFhigh collagen 
in a severely FIX-deficient patient 
Perfusion of WB from a severely FIX-deficient patient (#29; <1% FIX) showed 
negligible fibrin accumulation that was only partially rescued by even 20 nM rFVIIa on 
TFlow/collagen (Figure 5-5B).  Addition of rFVIIa strongly enhanced platelet deposition at 
either TF concentration (Figure 5-5. 5A,C).  The combination of high exogenous rFVIIa 
(20 nM) and TFhigh/collagen was able to fully restore fibrin initiation and accumulation under 
flow (Figure 5-5D).    
The effect of exogenously added rFVIIa was tested on patients with a range of 
hemophilic severity using TFlow and TFhigh surfaces.  A level of 20 nM rFVIIa significantly 
increased final platelet and fibrin accumulation at 1-3% factor activity (Figure 5-6) to levels 
commensurate with that observed with untreated healthy blood.  With increasing rFVIIa 
supplementation, healthy whole blood also displayed increased platelet and fibrin deposition 
on TFlow and TFhigh(Figure 5-6). 
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Figure 5-7 Signaling pathways of hemophilic blood when triggered by surface 
TF/collagen in the presence or absence of rFVIIa.  
In hemophilic blood clotting under flow conditions over TF, most FXa comes from the intrinsic tenase 
(FIX/FVIIIa) even when some FXa can be initially generated by the extrinsic tenase TFwall/FVIIa and 
platelet/rFVIIa. 
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 Condition    Clotting at 100 s-1  
Phenotype Surface Contact 
pathway 
rFVIIa Platelets Fibrin [ref.] 
   No (high 
CTI) 
0 low none [24] 
Severe  Collagen No (high 
CTI) 
+ modest 
rescue 
none   
(< 3%)   Yes (low 
CTI) 
0 Low none   
   Yes (low 
CTI) 
+ slight rescue ~none   
   No (high 
CTI) 
0 modest none [24] 
Moderate  Collagen No (high 
CTI) 
+ rescue none   
(3-10%)   Yes (low 
CTI) 
0 modest very low   
   Yes (low 
CTI) 
+ rescue rescue   
 Collagen + 
[TF]low 
  0 very low none * 
Severe  Collagen + 
[TF]low 
No (high 
CTI) 
+ rescue  rescue  
(<3 %) Collagen + 
[TF]high 
  0 very low none  
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 Collagen + 
[TF]high 
  + rescue rescue  
 Collagen + 
[TF]low 
  
No (high 
CTI) 
  
  
0 modest modest * 
Moderate Collagen + 
[TF]low 
+ modest modest  
(3-10%) Collagen + 
[TF]high 
0 moderate moderate  
 Collagen + 
[TF]high 
+ moderate moderate  
Table 4. Clotting potential of severe or moderate hemophilic A or B blood when 
triggered by the low or high levels of contact activation or extrinsic activation in the 
presence and absence of rFVIIa. 
Rescue indicates return to response levels of healthy blood.  Low CTI: 4 µg/mL corn trypsin inhibitor; High CTI: 
40 µg/mL corn trypsin inhibitor.  Mild hemophilic blood (>14-15%) preforms without large functional deficit 
when compared to healthy blood in this assay under conditions of contact or extrinsic activation with reduced 
sensitivity to added rFVIIa. *, this study. 
 
5.4 Discussion and Conclusion 
Microfluidic assays consisting of high CTI (40 µg/ml)-inhibited WB perfusion on 
TFlow or TFhigh /collagen surfaces at venous wall shear rates were used to evaluate platelet 
deposition and fibrin formation in hemophilic patients.  A broad cohort of patients were 
tested representing a large spectrum of clinical phenotypes of hemophilia A or B (severe, 
moderate, and mild(Table 3). Under these ex vivo hemodynamic conditions, we observed 
significantly decreased platelet deposition and fibrin formation on TFlow and TFhigh collagen 
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surfaces in severe hemophilic samples.   Taken together, these results indicate that in healthy 
blood clotting under flow conditions over TF, most Factor Xa comes from the intrinsic 
tenase (FIXa/FVIIIa) even when some FXa can be initially generated by the extrinsic tenase 
TF/FVIIa  (Figure 5-7).  
With respect to factor-deficient patients at 1-3% factor activity (Figure 5-1), we 
observed severe deficits in platelet adherence and fibrin formation that was not rescued by 
perfusion on TFhigh collagen surfaces. With the intrinsic tenase severely blunted as in the case 
of severe FVIII or FIX-deficiency, surface TF-triggered coagulation failed to produce 
adequate levels of thrombin for detectable fibrin formation (Figure 5-1B,D). At high 
surface TF concentrations of ~ 2 TF molecules/µm2 as measured in a prior study [113], the 
extrinsic tenase could not support fibrin formation when critical residual clotting factor 
activity was <3% (Figure 5-1D). Interestingly, we did not observe similar trends when we 
tried to recreate the conditions of acquired severe hemophilia in these microfluidic assays 
through the use of function-blocking antibodies against FVIII or FIX (data not shown) 
added to healthy blood. Under flow conditions on TFlow or TFhigh collagen surfaces, normal 
blood treated with function-blocking antibodies against FVIII or FIX only displayed 
decreases in fibrin formation on TFlow collagen surfaces while no effect was seen on platelet 
deposition. This suggests large functional differences between true factor deficiencies, factor 
deficiencies plus inhibitors, and laboratory experiments with antibodies added to healthy 
blood.  
At 3-14% factor activity, TF collagen surfaces were able to partially restore platelet 
adhesion and fibrin formation under flow, yet these levels were still significantly below 
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healthy WB controls (Figure 5-2). This restoration of platelet adhesion and fibrin generation 
was likely due to sufficient intrinsic tenase (FVIIIa/FIXa) functioning on platelets to 
generate sufficient FXa for thrombin and fibrin production. Finally, at >14% factor activity, 
platelet adhesion was moderately suppressed while TFhigh/collagen fully restored fibrin 
formation (Figure 5-3). This is consistent with previous studies which report adequate local 
thrombin concentrations that support fibrin formation under flow in the case of mild FVIII 
deficiencies and high surface TF concentrations[77]. These findings are also consistent with 
previous studies that report FVIII/FIX dependent enhancement of platelet procoagulant 
activity as a limiting step in fibrin formation under flow[111].  
We also assessed the role of rFVIIa in platelet deposition and fibrin formation under 
flow in hemophilic and healthy WB samples. Results from a severe hemophilic patient 
indicate that rFVIIa amplifies platelet deposition but was not fully sufficient to support 
fibrin generation if the contact pathway was inhibited  (Figure 5-5) [24]. However, a 
combination of 20 nM exogenous rFVIIa and TFhigh/collagen facilitated strong fibrin 
production in the severely FVIII-deficient patient (Figure 5-5D). A consideration of final 
platelet and fibrin deposit size in the presence of exogenous rFVIIa indicates enhancement 
of platelet and fibrin accumulation in the severely factor-deficient hemophilic patients tested 
(Figure 5-6). A similar trend was observed when rFVIIa was exogenously added to the WB 
of healthy donors followed by perfusion on TFlow and TFhigh collagen surfaces (Figure 5-6). 
In summary, we took a systems approach by modulating the following inputs: contact 
pathway engagement, the procoagulant surface trigger, and exogenous concentrations of 
rFVIIa. We then explored the impact of these inputs and found distinct changes in platelet 
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deposition and fibrin generation under flow as a function of these inputs (Table 4). Based 
on this study and our earlier study[24], rFVIIa cannot rescue fibrin deposition via the cellular 
pathway alone, unless FXIIa or TF is participating.  
Distinct from the studies of Swieringa et al. who added TF directly into blood prior to 
perfusion, the micropatterning of TF-rich collagen surfaces generates localized regions of 
thrombosis in microfluidic channels which ensures that blood does not come into contact 
with extraneous prothrombogenic surfaces prior to the region of interest. This enables study 
of platelet deposition in conjunction with surface-triggered coagulation akin to the laser 
cremaster injury[114–116]. In contrast, addition of exogenous TF into blood fails to recreate 
the hemodynamic aspects of thrombosis which are highly dependent on surface presentation 
of TF to the flowing blood[35]. Furthermore, the present work extends previous studies by 
directly examining the contribution of platelet bound rFVIIa on platelet and fibrin formation 
under flow in a wide range of hemophilic patients[77].  
In conclusion, our microfluidic assay results from WB of FVIII or FIX-deficient 
patients indicate a critical role of the intrinsic tenase in driving platelet adhesion and fibrin 
formation on TF-laden collagen substrates at venous shear rates (Figure 5-7). FVIII/FIX 
dependent thrombin production on the platelet surface and the subsequent thrombin 
activation of platelets along with fibrin formation are potent, key pathways in thrombus 
formation under flow.  
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6 EX VIVO RECAPITULATION OF TRAUMA-INDUCED 
COAGULOPATHY UNDER FLOW AND PRELIMINARY 
ASSESSMENT OF PLATELET FUNCTION FOLLOWING 
TRAUMA USING MICROFLUIDIC TECHNOLOGY   
6.1 Introduction 
Trauma is the leading cause of death in people under the age of 36 years old[117]. 
Many severely injured patients exhibit trauma induced coagulopathy (TIC), a hemorrhagic 
state that accounts for 40% of trauma deaths[117]. TIC is multifactorial and associated with 
tissue injury, inflammation, shock, hemodilution, acidosis, hypoxia, and hypothermia[117]. 
Tissue injury and shock result in hyperfibrinolysis due to the acute release of tissue 
plasminogen activator (tPA) from endothelial cells. Systemic fibrinolysis results in fibrinogen 
consumption and limits clot formation and stability at the site of vascular injury, resulting in 
increased bleeding risk[118]. Furthermore, blood loss followed by resuscitation with colloids 
or packed red blood cells (PRBCs) leads to the hemodilution of clotting factors. 
Current research in TIC has focused on coagulation factors and proteases, with the 
role of platelet function during trauma not as well-defined[119,120]. Platelet function studies 
of trauma patients have been difficult to implement due to the technical complexities of 
current platelet function tests. Although recent advances in platelet aggregometry and 
thromboelastography (TEG) have enabled important studies of platelet function and clot 
strength in trauma patients [121–125]. These techniques, however, are closed systems lacking 
flow or are comprised of poorly defined flow fields. 
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Microfluidic systems are open systems where blood flows over a zone of defined 
procoagulant surface, thereby recreating the unique spatial and compositional attributes of 
blood clotting found in vivo [23]. Microfluidic technology in conjunction with 
micropatterning techniques enable low volume and high throughput testing of platelet 
function and fibrin generation over a range of physiological shear stresses [34,37,126–128].  
Microfluidic whole blood assays have been previously used to evaluate platelet and clotting 
function in hemophiliacs and healthy donors taking antiplatelet therapeutics [23,24,77,129].  
In regards to current resuscitation strategies, the administration of PRBCs with or 
without fresh frozen plasma (FFP) and the optimal FFP:PRBCs ratio remain active areas of 
investigation [130]. Prospective studies have shown that platelets may serve as the third 
component of resuscitation strategy [130–133]. PRBC administration not only increases 
hemoglobin, but also contributes biorheologically by driving platelet margination towards 
the vessel wall.    
In this study, we applied microfluidic technology to investigate resuscitation-driven 
hemodilution, hyperfibrinolysis, and plasmin-inhibitor therapy, all topics relevant to TIC risk 
and treatment. Additionally, we evaluated platelet function under flow using whole blood 
from trauma patients during the acute phase of TIC.  
 
6.2 Methods 
6.2.1 Microfluidic evaluation of hemodilution and hyperfibrinolysis  
Following approval from the Internal Review Board approval at the University of 
Pennsylvania, healthy donors (n = 15) were recruited to donate whole blood using standard 
100 
 
phlebotomy techniques. Donors were required to refrain from all oral medications for 7 days 
and abstain from alcohol for 48 h prior to donation. Blood was drawn into corn trypsin 
inhibitor (CTI, Haematologic Technologies, Essex Junction, VT, 40 µg/ml final 
concentration) or FPR-chloromethylketone (PPACK, Haematologic Technologies, Essex 
Junction, VT, 100 µM final concentration). CTI inhibits the contact pathway for studies of 
surface-triggered coagulation while PPACK inhibits thrombin generation in order to 
examine platelet function in the absence of thrombin in vitro. Blood samples were treated 
with fluorescently conjugated anti-CD61a antibody (clone VI-PL2, Becton Dickson, 
Franklin Lakes, NJ, 0.125 µg/ml final concentration) to label platelets and fluorescently 
conjugated fibrinogen (Invitrogen, Life Technologies, Carlsbad, CA, 75 µg/ml) to label 
fibrin(ogen) 5 min prior to initiation of flow assays. All healthy donor microfluidic 
experiments were completed within 45 min of phlebotomy.  
Microfluidic fabrication methods and device specifications were previously described  
[24,33,34]. Microfluidic channels ran perpendicularly over a 250 µm wide strip of patterned 
equine fibrillar collagen type I (Chronopar, Chronolog) or Tissue Factor (TF) bearing 
collagen type I surfaces (Dade Innovin, Siemens Healthcare USA, Malvern, PA). 
Epifluorescent microscopy and image acquisition were performed in real-time as previously 
described [23,24]. Dilution of the hematocrit to simulate resuscitation-induced hemodilution 
was achieved with exogenous addition of HEPES buffered saline (HBS, 20 mM HEPES, 
160 mM NaCl, pH 7.5), donor specific platelet poor plasma (PPP) or platelet rich plasma 
(PRP). Isolation of PRP or PPP was previously described [24,80]. HBS, PPP or PRP was 
added in 1:3, 1:1, 3:1 ratio to whole blood to obtain Hct levels of 30%, 20%, 10% 
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respectively 5 min prior to initiation of the flow assay. Fibrinolysis was promoted by 
exogenously adding 10X stock solutions of tPA (abcam, Cambridge, MA, 0-50 nM). Blood 
samples were perfused at an initial venous wall shear rate of 200 s-1 or an initial arterial wall 
shear rate of 1222 s-1 in a previously designed pressure relief mode for 20 min [37]. Platelet 
and fibrin accumulation were analyzed as previously described [24].  
6.2.2 Microfluidic Assessment of Trauma patient platelet function 
Following Institutional Review Board approval, blood was collected from trauma 
patients (n = 20) who had sustained injuries requiring evaluation at the Hospital of 
University of Pennsylvania (HUP) Level 1 Trauma Center. Exclusion criteria included failure 
to obtain an initial blood draw and death within 24 h of admission. Patient demographics, 
clinical laboratory test results, and outcomes were recorded (Table 5). All trauma patients 
had Hct levels and platelet counts within physiologic ranges (Table 5). All clinical laboratory 
tests were obtained at the same time as the microfluidic assessment of trauma patient platelet 
function. All trauma patient samples were collected within one hour of injury. A blood 
sample was drawn upon patient arrival using 21-guage or larger needle into a 10 ml plastic 
syringe (Becton Dickson, Franklin Lakes, NJ) containing no anticoagulant. Blood samples 
were aliquoted into vacationers for clinical assays and residual blood was transferred into a 
single vacutainer containing 100 µM PPACK. The effects of this collection method and the 
delay between phlebotomy and inhibition by PPACK (average ~ 3 min) were assessed and 
found to have negligible effects on platelet activation and thrombin generation (Figure 8-16, 
Figure 8-17).  
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1 3 MCC 23 No No None 36 238 22 
N
o 
27.3 15.1 1.3 <10 
PRB
CS 
N N 
2 4 Stroke 83 No No hypertension 40 251 0 
N
o 
22.3 11.7 0.9 72 
FPP 
& 
Platel
ets 
N N 
3 5 Fall 84 
Aspir
in, 
Plavi
x 
No 
peripheral 
vascular 
disease, 
diabetes, 
hypertension, 
chronic 
kidney disease 
36 142 11 
Y
es 
29.8 13.2 1.1 0 None N N 
4 6 MVC 60 
coum
adin 
No 
DVT, 
depression, 
39 186 27 
Y
es 
27.2 19.2 1.7 263 None N N 
5 7 MCC 25 No 
4U 
PRBC 
None 42 126 43 
Y
es 
25.5 14.5 1.2 <10 
PRB
CS 
N N 
6 9 Fall 68 No No 
hypertension, 
diabetes 
34 171 30 
Y
es 
44 15.3 1.3 <10 
PRB
CS 
N N 
7 11 Fall 29 No No 
Haemophilia 
A 
36 281 0 
N
o 
81.6 13.7 1.1 <10 None N N 
8 13 Assault 47 No No 
schizophrenia
, etoh abuse, 
40 207 34 
Y
es 
26 14.5 1.2 178 
PRB
CS & 
FFP 
N N 
9 15 Fall 88 No No 
coronary 
artery disease, 
hypertension 
40 163 5 
N
o 
27.8 14.9 1.2 0 None N N 
10 17 GSW 31 No No None 47 320 26 
N
o 
X X X 139 None N N 
11 19 Fall 47 
Love
nox, 
Aspir
in 
No 
Hypertension, 
cardiomyopat
hy, 
40 295 1 
N
o 
26.9 13.2 1.1 0 None N N 
12 20 Fall 77 No No Atrial Fib 36 142 2 
N
o 
20.3 12.4 1 <10 None N N 
13 22 MVC 28 
Heroi
n 
No asthma 43 188 2 
N
o 
28.4 13.5 1.1 <10 None N N 
14 24 SW 27 No No asthma 39 224 10 
N
o 
25.5 13.7 1.1 <10 None N N 
15 26 MVC 31 No No alcohol abuse 49 245 2 
N
o 
21.9 13.9 1.2 439 None N N 
16 28 Fall 80 
Aspir
in 
No 
hypertension, 
hyperlipidemi
a 
38 58 2 
N
o 
29.5 14.1 1.2 0 None N N 
17 31 Fall 55 No No hypertension 33 247 27 
N
o 
28.9 14.3 1.2 <10 
PRB
C, 
FFP, 
& 
Platel
ets 
N N 
18 34 MVC 26 No 
1U 
PRBC 
asthma 29 93 26 
N
o 
31.2 15.2 1.3 0 
PRB
Cs, 
FFP, 
& 
Platel
ets 
N N 
19 35 SW 45 No No 
Seizure 
disorder, on 
dilantin 
38 193 1 
N
o 
30.9 12.8 1 307 None N N 
20 36 
Pedestr
ian 
Struck 
50 No No None 37 348 1 
N
o 
30.1 13.6 1.1 96 None N N 
Table 5. Twenty trauma patient characteristics and clinical data  
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Twenty trauma patients were examined in WB microfluidic assays with PPACK-inhibited WB perfusion over 
collagen. Trauma patient characteristics and clinical data are as reported, blood products post microfluidic testing 
were administered within the first hour of evaluation by Hospital of University of Pennsylvania (HUP) Level 1 
Trauma Center. Medications altering coagulation, blood product use, pre-existing conditions, Hct, platelet count, 
Injury Severity Score (ISS), diagnosis of traumatic brain injury (TBI), PT, PTT, INR, blood alcohol level, and 
blood products post microfluidic testing are as reported. (MCC, motorcycle crash; MVC, motor vehicle crash; 
GSW: gun shot wound; SW, stab wound.) 
 
PPACK anticoagulated blood samples were treated with fluorescently conjugated anti-
CD61a antibody (clone VI-PL2, Becton Dickson, Franklin Lakes, NJ, 0.125 µg/ml final 
concentration) to label platelets and anti-human CD62P (P-Selectin) antibody (BioLegend, 
San Diego, CA, 4 µg/ml final concentration) to stain for P-Selectin. Blood samples were 
subsequently treated with either HBS or 100X stock solutions of the indicated antagonists.  
MRS 2179 (2'-deoxy-N6-methyladenosine 3', 5'-bisphosphate ammonium salt (MRS 2179, 
Tocris Bioscience, Minneapolis, MN), S-Nitrosoglutathione (GSNO, Santa Cruz 
Biotechnology, Dallas TX), and iloprost (Tocris Bioscience) were the antagonists used and 
dissolved at 0.1 mM, 10 mM, 0.2 mM in HBS respectively. Whole blood perfusion in 
microfluidic devices started within 10 min of blood collection in constant flow mode at 100 
s-1.  
6.2.3 Statistical significance analysis  
Statistical significance was assessed using a two-tailed unpaired Student's t-test. Data 
sets were considered significantly different from each other if the calculated p-value < 0.05. 
Exact p-values are reported in the results where p > 0.001, otherwise p < 0.001 is denoted.     
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6.3 Results  
6.3.1 Hemotocrit reduction: dilution reduces platelet deposition on collagen (no 
thrombin) and platelet-fibrin accumulation on TF/collagen 
Our healthy volunteer study population had a mean age 26.2 ± 1.52y (10M/5F). The 
effect of hematocrit dilution on platelet deposition was evaluated by ex vivo dilution of 
healthy whole blood with either saline, PPP, or PRP (Figure 8-11). In the absence of 
thrombin with PPACK-inhibited whole blood at 200 s-1, platelet deposition was strongly 
inhibited by hemodilution with saline (p < 0.001), PPP (p < 0.001), or PRP (p < 0.001: 10 & 
20% Hct, p = 0.01: 30% Hct) (Figure 6-1A,C,E).  As expected in the microfluidic flow 
assay over collagen, fibrin generation was dependent on thrombin production and was 
negligible in PPACK-inhibited whole blood in the absence of surface-patterned TF on 
collagen (Figure 6-1B, D, F).  
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Figure 6-1 Platelet accumulation on collagen in healthy donors following Hct 
dilution in the absence of thrombin.  
(A & B), Platelet and fibrin fluorescence intensities vs. time with saline dilution of Hct. (C & D), Platelet and 
fibrin fluorescence vs. time with PPP dilution of Hct. (E & F), Platelet and fibrin fluorescence intensities vs. 
time with PRP dilution of Hct.  Shaded traces are the mean and standard deviation of 10 clotting events from 5 
donors.  
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Similarly, in the presence of surface-triggered coagulation (Figure 6-2), we detected 
significant decreases in platelet accumulation for all lowered Hct levels when whole blood 
was diluted with saline (p < 0.001: 10 & 20% Hct, p = 0.0154: 30% Hct), PPP (p < 0.001: 10 
& 20% Hct, p = 0.002: 30% Hct or PRP (p < 0.001: 10% Hct, p = 0.0035: 20% Hct, p = 
0.0316: 30% Hct) (Figure 6-2A, C, E).  Total fibrin accumulation at lower Hct levels was 
also significantly reduced when whole blood was supplemented with saline (p < 0.001: 10, 20 
& 30% Hct) or PPP (p < 0.001: 10% Hct, p = 0.005: 20% Hct, p = 0.0064: 30% Hct) or 
PRP (p < 0.001: 10% & 20% Hct, p = 0.3576: 30% Hct) to reduce Hct (Figure 6-2B, D).  
The reduced fibrin accumulation observed with reduced Hct cannot be due to a reduction in 
coagulation factors since the concentration of coagulation proteins remains constant when 
whole blood is diluted with PPP or PRP (as opposed to saline dilution).  In this experiment, 
reduced platelet deposition was highly correlated with reduced fibrin production as Hct was 
reduced, regardless of how Hct was lowered (Figure 6-2). 
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Figure 6-2 Platelet and fibrin accumulation on TF bearing collagen in healthy donors 
following Hct dilution  
(A & B), Platelet and fibrin fluorescence intensities vs. time with saline dilution of Hct. (C & D), Platelet and 
fibrin fluorescence intensities vs. time with PPP dilution of Hct. (E & F), Platelet and fibrin fluorescence 
intensities vs. time with PRP dilution of Hct. Shaded traces are the mean and standard deviation of 10 clotting 
events from 5 donors.  
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6.3.2 Exogenous tPA activates the lytic state at venous and arterial shear rates and 
promotes hyperfibrinolysis  
Following severe trauma and shock, injured endothelial cells release tPA systemically 
leading to hyperfibrinolysis [117]. To mimic this pathological mechanism, tPA was 
exogenously added to whole blood (Figure 8-11). At venous shear rates (200 s-1), exogenous 
addition of tPA to whole blood had negligible effects on platelet deposition on TF bearing 
collagen surfaces under flow (Figure 6-3A, B; ns). However, the rapid production of 
plasmin at the surface-patterned injury site in conjunction with fibrin formation at 200 s-1 
induced a 'lytic state' with 50 nM ex vivo tPA added. Total fibrin accumulation decreased 
63.9 % by 10 min (Figure 6-3C; p = 0.0044). To reverse the 'lytic state' and stop fibrinolytic 
activity under flow, we added the lysine analogue ε-aminocaproic acid (εACA) to inhibit 
plasmin activity. The inhibition of plasmin by εACA restored total fibrin accumulation to 
levels comparable to control conditions but resulted in delayed fibrin initiation (Figure 
6-4C). At arterial shear rates (1222s-1), embolization occurred with tPA as indicated by a 
significant drop in the platelet signal by 12 min (Figure 6-4). The platelet signal continued to 
decrease approaching zero by the end of the 20 min assay (Figure 6-4B). Exogenous tPA 
addition minimized total fibrin accumulation while treatment with εACA non-significantly 
increased platelet deposition (p = 0.1024) and total fibrin accumulation (p = 0.1132) (Figure 
6-4B, C).  Interestingly, in a few channels of the microfluidic assay at either venous or 
arterial wall shear rates, tPA-mediated fibrinolysis was followed by destabilization of platelet 
deposits which then embolized downstream. This disruption of platelet rich thrombi from 
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the patterned injury site was followed a second round of platelet deposition and renewed 
fibrin generation (Figure 8-14, Figure 8-15).  
 
Figure 6-3 Platelet and fibrin accumulation in response to exogenous tPA ± εACA at 
venous shear rates  
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 200 s-1 over the time course of 
the 20 min assay. (B), Platelet fluorescence intensities vs. time with exogenous tPA ± εACA. (C), Fibrin 
fluorescence intensities vs. time with exogenous tPA ± εACA. Shaded traces are the mean and standard 
deviation of 12 clotting events from 3 donors.  
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Figure 6-4 Platelet and fibrin accumulation in response to exogenous tPA ± εACA at 
arterial shear rates  
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 1222 s-1 over the time course of 
the 20 min assay. (B), Platelet fluorescence intensities vs. time with exogenous tPA ± εACA. (C), Fibrin 
fluorescence intensities vs. time with exogenous tPA ± εACA. Shaded traces are the mean and standard deviation 
of 8 clotting events from 2 donors.  
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6.3.3 Trauma patient platelet function tests: delayed platelet recruitment to collagen 
and attenuated secondary aggregation  
Our 20 trauma patient population had a mean age of 50.2 ± 22.84 and a median 
injury severity score (ISS) of 7.5 with an interquartile range of 25. There were 15% 
penetrating injuries and 25% brain injuries. Rapid platelet function testing of PPACK-
inhibited whole blood from trauma patients (n = 20) revealed a subpopulation of patients 
(14/20) with reduced platelet function upon arrival to a Level 1 Trauma Center (Figure 6-5, 
Figure 8-18). When compared to 7 healthy donors, 14 trauma patients were found to have 
significantly decreased total platelet accumulation measured at 900 sec (Figure 8-19; p < 
0.001). We categorized these subset of patients as 'loss of function'. Patients with statistically 
significant increased total platelet accumulation measured at 900 sec when compared to 
healthy donors were categorized as 'gain of function' (Figure 6-5, Figure 8-19) Visual 
inspection of platelet aggregates formed on collagen surfaces indicate two loss of function 
phenotypes in trauma patients. The first loss of function phenotype in trauma patients was 
characterized by platelets failing to adhere to the collagen surface indicative of dysfunctional 
platelet glycoprotein VI (GPVI) (Figure 6-5B, C, E, K). In a second observed loss of 
function phenotype, platelet aggregate growth beyond the initial monolayer of platelets was 
minimal or completely missing (Figure 6-5D, F-N). Platelet aggregates tended to form 
above the initial monolayer of collagen-adherent platelets but were subsequently washed 
downstream. Clots formed from these patients did not grow to full channel occlusion during 
the duration of the 900 sec assay (Figure 6-5, black arrow). This failure of secondary 
aggregation in these patients may be due to a lack of ADP or thromboxane A2 mediated clot 
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growth. Interestingly, 3 patients exhibited hyper-responsive platelet function in this 
microfluidic assay with two patients forming occlusive clots within the first 400 seconds 
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(Figure 6-5R-T).  
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Figure 6-5 Trauma patient thrombi morphology at 900 sec and platelet deposition 
dynamics at venous shear rates (100 s-1) 
(A & A'), Platelet fluorescence intensities vs. time for representative healthy donor and representative image of 
final platelet accumulation at 900 sec. (B-N & B'-N', blue line), Platelet fluorescence intensities vs. time and 
representative image of final platelet accumulation at 900 sec for trauma patients exhibiting loss of platelet 
function.  (O-Q & O'-Q', yellow line), Platelet fluorescence intensities vs. time and representative images of 
final platelet accumulation at 900 sec for trauma patients exhibiting normal platelet function.  (R-T & R'-T', 
green line), Platelet fluorescence intensities vs. time and representative images of final platelet accumulation at 
900 sec for trauma patients exhibiting gain of platelet function. Shaded traces are the mean and standard 
deviation of 4 clotting evens from each patient. (MCC: Motorcycle Crash, MVC: Motor Vehicle Crash, SW: 
Stab wound, GSW: Gun Shot Wound) 
 
6.3.4 Trauma patient platelets respond less to antagonism by MRS2179 and iloprost 
but increased sensitivity to inhibition by GSNO 
To assess the various pathways that affect trauma platelet signaling under flow, we 
antagonized platelet function in three different manners (Figure 8-12). MRS 2179 was used 
to potently inhibit the platelet ADP receptor, P2Y1. The addition of GSNO was used to 
stimulate nitric oxide production ex vivo and iloprost was used to raise cyclic adenosine 
monophosphate (cAMP) levels in order to reduce platelet aggregation. On average, trauma 
patients with detectable baseline platelet function measured by platelet fluorescence 
responded to all three forms of antagonism (Figure 8-12C). Total platelet accumulation at 
900 sec was reduced 58.8%, 43.83% and 73.80 % by MRS2179, GSNO, and iloprost 
respectively in trauma patients (n = 17, 68 clots, p < 0.001) as compared to 79.2%, 15.2%, 
and 91.81% in healthy donors (n = 6, 24 clots, p < 0.001) (Figure 8-20). Interestingly, 
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trauma patient platelet function responded less to the addition of MRS 2179 or iloprost but 
was more strongly inhibited by production of nitric oxide ex vivo (Figure 8-20; MRS 2179: 
p = 0.003, Iloprost or GSNO: p < 0.001).  
6.3.5 A subpopulation of trauma patient platelets displayed decreased p-selectin 
expression under flow  
P-selectin surface expression was also used as a marker for α-granule secretion and 
irreversible platelet activation in our microfluidic assay (Figure 8-13). A population of 
trauma patients (9/21) exhibited low p-selectin expression in the flow assay (data not shown) 
however, when normalized against the platelet fluorescence signal, a single patient displayed 
a severe deficit in p-selectin expression on a per platelet basis (Figure 8-13B-D). The lack of 
p-selectin expression in patient #9 may be indicative of low levels of platelet activation and 
potential previous degranulation of platelets prior to microfluidic testing.   
 
6.4 Discussion  
Trauma induced coagulopathy is a multi-faceted phenomenon that occurs in a setting 
of shock, hemodilution, hypothermia, and tissue injury. With the use of microfluidic 
technology we evaluated hemodilution and hyperfibrinolysis, two common mechanisms of 
TIC, in order to understand how derangements in platelet deposition and fibrin formation 
contribute to altered hemostasis. Hemodilution of healthy whole blood with saline, PPP, or 
PRP significantly reduced platelet adhesion to collagen in the absence of surface-triggered 
coagulation at all lowered Hct levels (Figure 6-1). Platelet deposition was also significantly 
decreased with this dilution scheme on TF-bearing collagen surfaces (Figure 6-2). RBCs 
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strongly influences platelet margination and enhances platelet accumulation at the collagen 
or collagen/TF micropatterned injury site in these assays. These results indicate a significant 
role for RBCs in mediating the rapid platelet response required to seal vessel injuries. 
Furthermore, RBCs have also been shown to release ADP thus promoting platelet 
aggregation and can potentially sustain thrombin generation [134]. This is could be another 
role in which RBCs support platelet function and coagulation in our microfluidic assays.  
However, ADP release from RBC is expected to be minimal under the venous flow 
conditions tested (Figure 6-2).   
Furthermore, a second mechanism associated with TIC is increased fibrinolytic 
activity. Excessive fibrinolysis impairs clot integrity and causes bleeding. We recapitulated 
this mechanism and rapidly detected changes in fibrin accumulation and clot stability in 
microfluidic assays with exogenous addition of tPA. We promoted a 'lytic state' under flow 
inducing fibrin lysis at venous shear rates that was rescued with ex vivo εACA addition 
(Figure 6-3). At arterial shear rates, the 'lytic state' induced embolism as clots tore from the 
TF bearing collagen surfaces and washed downstream (Figure 6-4). In rare cases, the 'lytic 
state' induced a consumptive coagulopathy with complete fibrin lysis and disintegration of 
platelet aggregates followed by platelet re-adherence and fibrin regeneration on the TF 
bearing collagen surface. This observed process depletes platelets, clotting factors, and other 
plasma proteins in the flowing blood. The deranged hemostasis during hyperfibrinolysis we 
have recreated in the microfluidic assays mimics the coagulopathy of traumatic brain injuries 
[135]. Our results suggest that hyperfibrinolysis and excessive consumption of clotting 
factors work synergistically during TIC. (Figure 8-14, Figure 8-15).  Finally, we were able to 
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detect and quantify changes in fibrin generation and clot stability during this 'lytic state' in <6 
min, a time scale much faster than what is currently capable with TEG. 
In clinical settings, conventional plasma-based assays are used to assess TIC instead of 
microfluidic-based assays. The prothrombin time (PT), partial thromboplastin time (PTT), 
platelet count, and fibrinogen levels are the most commonly used tests for monitoring 
coagulopathy following trauma. These tests, however, examine only a single component of 
the hemostatic process and fail to measure clot strength, fibrinolytic activity or platelet 
function. Furthermore, while TEG with or without platelet mapping is more indicative of 
global hemostasis, the use of FXII activator kaolin and citrated samples are major drawbacks 
with this technology. Kaolin activation of coagulation is non-physiologic as kaolin is not 
found in the body and citrate is known to affect platelet αIIβIIIa integrin function. The fluid 
mechanics of TEG also fail to replicate the hemodynamics of the vasculature. The 
oscillatory movement of a cup in a closed system cannot generate the extraordinary platelet 
concentrations in a clot on the vessel wall. Furthermore, in TEG, the moving cup is a closed 
system where platelet releasates and coagulation factors can accumulate unhindered due to 
the lack of transport-induced washout of these components. Microfluidic assessment of 
trauma patient function detected platelet function defects in < 5 min while a complete TEG 
test may take upward to 60 min [136].   
In whole blood microfluidic assays, on the other hand, platelet deposition and fibrin 
generation must occur under well-controlled hemodynamic conditions and in the presence 
of convective dilution of thrombin, soluble agonists, and plasma proteins. During these 
assays, the biorhelogic phenomena present can either limit or augment local enzyme 
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concentrations. In addition to changes in the local enzyme concentrations, platelet receptor-
ligand bonds must withstand the hydrodynamic shear stress imparted by the following 
blood.  Thus whole blood microfluidic assays provide a much more rigorous physiologic test 
of platelet function and fibrin generation not captured by static clotting assays and TEG 
[137,138].  
To the best of our knowledge, our results are the first real-time platelet function 
testing of whole blood samples from trauma patients using microfluidic technology. One 
previous study by Jacoby et al. has assessed platelet function following trauma using a 
platelet function analyzer (PFA-100) with citrated whole blood.  The PFA-100 is a cartridge-
based flow system that aspirates citrated whole blood in capillaries. It measures aperture 
closure time following blood clotting on a membrane coated with collagen/ADP or 
collagen/epinephrine. Their study reported decreased closure times at initial trauma patient 
presentation indicating increased platelet function and hypercoagulability. Contrary to the 
Jacoby et al. report, we observed noticeable decreases in platelet adhesion to collagen and 
secondary platelet aggregation when we rapidly assessed platelet function in trauma patients 
(n = 20) at 100s -1 over collagen surfaces (Figure 6-5). Furthermore, when comparing our 
microfluidic assay results to clinical patient data, we found no correlation between platelet 
function and injury severity score (ISS), or platelet function and the diagnosis of traumatic 
brain injury (TBI). All 14 patients displaying decreased platelet function had physiological 
Hct levels and platelet counts.  With respect to the clinical static plasma clotting assays, 13 of 
the 14 patients with decreased platelet function were within the normal PTT reference range 
(20.8-34.4) [23]. These results indicate that patient hematocrit levels, platelet counts, and 
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plasma-based clotting tests are largely inadequate in assessing the contribution of platelet 
function to the acute phase of TIC.  
Interestingly, of the 7 patients that did require blood products post microfluidic 
testing, 4 patients had decreased platelet function as initially assessed by whole blood 
microfluidic testing. A single patient (#31) was transfused with 14 units of blood products 
within 12 hrs of arrival. Microfluidic testing of this patient detected decreased platelet 
function upon initial presentation and continuous attenuated platelet function up to 72 hours 
post admission (Figure 8-21).  
Important distinctions exist between assays that evaluate platelets under non-flow 
conditions and microfluidics that allow platelets to accumulate on a surface to levels >200-
fold that of whole blood levels.  We demonstrated that microfluidic assay of trauma patient 
samples is a global test of whole blood clotting function under flow with the capability of 
detecting platelet dysfunction.  In future work, a comparison of microfluidic assay with 
platelet aggregometry or platelet mapping-TEG may provide further insights into platelet 
dysfunction during TIC. Microfluidic assay allows determination of: (1) platelet recruitment 
to the collagen surface, (2) total platelet accumulation, (3) platelet accumulation rate, and (4) 
time to full channel occlusion. These metrics could be compared to platelet mapping-TEG 
metrics such as maximum clot strength (MAThrombin), the contribution of ADP receptors 
(MAADP), and the contribution of the arachidonic acid pathway (MAAA). For example, we 
previously observed a relationship between aPTT and platelet accumulation rates on collagen 
surfaces for hemophilic blood from patients with increase bleeding risks (10). Finally, while 
all trauma patient samples were collected within one hour of injury. Further validation in the 
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whole blood microfluidic assay is required to examine how a variation in time of sample 
collection within the one hour time window affects platelet function under flow as 
derangements in trauma patient platelet function is thought to occur rapidly prior to hospital 
admissions.   
 The high throughput nature of microfluidic whole blood testing however, will enable 
testing of fresh platelets, stored platelets, and other current and novel drugs used to restore 
platelet function during the acute phase of trauma-induced coagulopathy. In a previous 
study, we have shown a novel method to assess the incorporation of culture-derived platelets 
from human peripheral blood cells into developing human thrombi under flow (28). Using 
similar techniques, future studies should test whether stored platelets can incorporate into 
trauma patient thrombi under flow. Successful adherence and incorporation of stored 
platelets into patient thrombi formed ex vivo could indicate the high potential of these 
platelets to restore platelet function in acute traumatic coagulopathy.  
The mechanisms underlying trauma platelet dysfunction have yet to be elucidated 
and require further investigation outside of microfluidic testing. Groups have postulated that 
platelet function downregulation can occur during trauma. Previous studies suggest the 
presence of dysfunctional circulating platelets following activation in response to tissue 
damage [121,123]. Platelet receptor proteolysis may be another putative pathway in which 
platelet function is down-regulated in trauma patients. Previous reports describe proteolysis 
of platelet GPVI and GPIb-IX-V receptors (29,30). Ectodomain shedding of platelet 
adhesion receptors is a plausible physiologic mechanism in which platelets can respond to 
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cases of severe endothelial injury following trauma yet prevent uncontrolled thrombus 
growth that leads to systemic clotting.    
In this study, we have used microfluidic technology to effectively evaluate current 
resuscitation strategies and hyperfibrinolysis showing more rapid detection of impaired 
hemostasis and coagulation than what is capable with current technologies.  Furthermore, 
we also tested trauma patient platelet function using this high throughput method. The fast 
identification of platelet function defects in trauma patients using whole blood microfluidic 
assays indicate a potential novel 15 min test to help guide coagulopathy treatments in the 
future.  
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7 FUTURE WORK 
7.1 A role for FXIIIa-mediated clot stability independent of fibrin 
polymerization  
7.1.1 Introduction 
Factor XIII (FXIII) is a coagulation protein that plays an essential role in physiologic 
hemostasis where it can regulate fibrinolysis[141], wound healing[142], and 
angiogenesis[143]. Clinically, FXIII deficiency results in hemorrhage and impaired wound 
healing[144]. FXIII is a plasma protransglutaminase composed of 2 A (FXIII-A) and 2 B 
(FXIII-B) subunits that circulate as a heterotetrameric zymogen (FXIII-A2B2)[145]. FXIII 
activation occurs when thrombin cleaves an N-terminal activation peptide from FXIII-A, 
and calcium mediates the dissociation of the inhibitory FXIII-B subunits, producing 
FXIIIa[145]. FXIIIa confers clot stability by cross-linking fibrin fibers in the fibrin matrix, 
thus altering its rheologic properties. FXIII originates from a family of transglutaminases 
(TG), TG are known to catalyze the formation of covalent ε-(γ-glutamyl) lysyl bond where a 
lysine ε-amino group is cross-linked to the glutamine of a γ-carboxymide group[141].  
FXIIIa can also cross-link inhibitors of fibrinolysis to fibrin, further enhancing 
fibrin’s insolubility and plasmin resistance. Inhibitors cross-linked to fibrin include α2-
antiplasmin (α2AP), thrombin activatable fibrinolysis inhibitor (TAFI), and plasminogen 
activator inhibitor-2. In all, there are twenty-five FXIIIa substrates that can be divided into 
five categories: coagulation factors, components of the fibrinolytic system, adhesive and 
extracellular matrix proteins, intracellular cytoskeletal proteins, and others[145]. Previous 
work has shown a critical role of cross-linked α2AP in stabilizing fibrin. This was 
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demonstrated by either the rapid lysis of clots formed in the absence of α2AP or when α2AP 
activity is neutralized[146]. Moreover, in addition to being present in plasma, FXIII-A is also 
present in platelets in large quantities[147–149]. The concentration of FXIII-A is 100X 
greater in the platelet cytoplasm than in plasma[150]. Recently, Mitchell et al. have shown 
that activated platelets externalize this pool of FXIII-A onto their membranes and that this 
pool is functional in cross-linking α2AP and confers lytic resistance in platelet rich thrombi 
under flow[151].   
The (patho)physiologic roles for FXIIIa activity derived from either platelet FXIII-A 
(cFXIII) or plasma FXIIIa (FXIIIa) are still not well-understood. Previous research has 
shown that human and murine whole blood clots formed in the absence of plasma FXIII or 
in the presence of a small molecular inhibitor for FXIIIa have reduced red blood cell 
retention and are significantly smaller than control clots[9]. Further work proved that FXIIIa 
mediates red blood cell retention in clots by cross-linking fibrin alpha chains[152]. Using 
microfluidic hemostasis models and whole blood perfusion under flow we aimed to delineate 
the ability of cFXIII and FXIIIa to confer platelet-rich thrombus stability independent of 
polymerized fibrin.   
 
7.1.2 Materials and Methods  
7.1.2.1 Materials  
The following reagents were stored according to manufacturer’s instructions: Corn 
Trypsin Inhibitor (CTI, Haematologic Technologies, Essex Junction, VT), phycoerythrin 
(PE) mouse anti-human monoclonal CD61 (αIIbβ3) antibody (clone VI-PL2, Becton Dickson, 
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Franklin Lakes, NJ). Fibrinogen from human plasma, Alexa Fluor 647 conjugate (Invitrogen 
Life Technologies, Carlsbad, CA). Equine fibrillar collagen type I (Chronopar, Chronolog, 
Havertown, PA), Dade Innovin (Siemens Healthcare USA, Malvern, PA), 1,3,4,5-
Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride  (T101) (Zedira, Darmstadt, 
Germany), Gly-Pro-Arg Pro (Billerica, Massachusetts, EMD Millipore), Sylgard 184 Silicone 
Elastomer Kit (Sylgard, Ellsworth Adhesives, Germantown, WI), Iodacetamide (Sigma 
Aldrich, St. Louis, MO).   
7.1.2.2 Blood Collection and preparation  
Phlebotomy was approved by the University of Pennsylvania Institutional Review 
Board and performed on consenting donors in accordance with the Declaration of Helsinki. 
Donors abstained from alcohol 48 h prior to blood donation and were free of oral 
medication for a minimum of 7 days prior to donation.  
7.1.2.3 Microfluidic Assay  
Whole blood was taken from healthy donors using standard phlebotomy techniques. 
Blood was drawn into 40 µg/ml CTI or FPR-chloromethylketone (PPACK, Haematologic 
Technologies, Essex Junction, VT, 100 µM final concentration). CTI inhibits the contact 
pathway for studies of surface-triggered coagulation while PPACK inhibits thrombin 
generation in order to examine platelet function in the absence of thrombin in vitro. Blood 
samples were treated with 0.125 µg/ml fluorescently conjugated anti-CD61a antibody to 
label platelets and fluorescently conjugated fibrinogen to label fibrin(ogen) 5 min prior to 
initiation of flow assays. All healthy donor microfluidic experiments were completed within 
45 min of phlebotomy. 
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Microfluidic fabrication methods and device specifications were previously described  
[24,33,34]. Microfluidic channels ran perpendicularly over a 250 µm wide strip of patterned 
equine fibrillar collagen type I (Chronopar, Chronolog) or Tissue Factor (TF) bearing 
collagen type I surfaces (Dade Innovin, Siemens Healthcare USA, Malvern, PA). 
Epifluorescent microscopy and image acquisition were performed in real-time as previously 
described [23,24]. 
Blood samples were perfused at an initial venous wall shear rate of 200 s-1 or an 
initial arterial wall shear rate of 800 s-1 in a previously designed pressure relief mode for 20 
min [37]. Platelet and fibrin accumulation were analyzed as previously described [24].  
 
7.1.3 Results  
7.1.3.1 Nonspecific FXIIIa inhibitor confers gross platelet instability in the presence of GPRP at constant 
flow conditions  
To investigate the fibrin-independent role of FXIIIa activity and function, non-
selective FXIIIa inhibitor iodoacetamide was used ex vivo in the presence or absence of 
GPRP, a short four peptide sequence that inhibits fibrin polymerization. Following 
incubation with iodoacetamide and GPRP, whole blood was perfused over a TF/collagen 
surface under venous shear rates. Decreases in platelet fluorescence intensity were observed 
over time in the absence of GPRP indicating a thrombin dependent role of FXIIIa (Figure 
7-1A). The addition of exogenous iodoacetamide had not effect of fibrin initiation and 
accumulation over time (Figure 7-1B). A combination of GPRP and iodoacetamide resulted 
in gross platelet thrombus instability as detected by the sharp changes in platelet 
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fluorescence over time (Figure 7-1B; red line). Exogenous GPRP completely inhibited 
fibrin generation under flow independent of iodoacetamide consistent with previous studies 
under flow (Figure 7-1B) [37]. 
 
 
Figure 7-1 Inhibition of FXIIIa in the presence or absence of fibrin polymerization 
(±GPRP) on TF/collagen surfaces at 200 s-1. 
(A & B), Platelet deposition dynamics measured by platelet fluorescence in the presence or absence of GPRP (5 mM). (C 
& D), Fibrin deposition dynamics measured by fibrin fluorescence in the presence or absence of GPRP (5 mM). Lines with 
shaded traces and points are mean and standard deviation of 4 clotting events measured in 45 sec intervals over 10 min for 
one healthy donor.  
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7.1.4 Discussion 
Here we demonstrate for the first time a potential role for FXIIIa stability of platelet 
rich thrombi under flow in the absence of fibrin. Further work must be done to elucidate the 
mechanisms by which FXIIIa can stabilize platelet rich clots. It is unclear whether the 
weakened clot architecture and thrombus disintegration is due to the cellular form of FXIIIa 
(cFXIIIa) or the plasma-derived form (FXIIIa). More specific FXIIIa inhibitors with micro-
molar affinity such as 1,3,4,5-Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride (T101) 
should be tested ex vivo. T101 can be used exogenously in the presence or absence of 
thrombin inhibitors over collagen or collagen/TF surfaces. Pressure relief conditions can be 
used to build occlusive clots under flow for a more rigorous test of platelet/fibrin clot 
strength and stability. To further elucidate the role of cFXIIIa, GR145503 can be used to 
abate platelet aggregation under flow in order to study platelet GPVI and collagen 
interactions. Finally, fluorescent amine donor substrates can be used to detect 
transglutaminase activity under flow to delineate the contributions of FXIIIa activity 
emanating from platelets or platelet-bound fibrin(ogen).     
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8 APPENDIX 
8.1 Microfluidic ASA Phenotyping Supplemental Material  
8.1.1 Supplemental Discussion 
8.1.1.1 Discussion:  Statistical significant inhibition 
For those subjects with < 25 % inhibition, the % inhibition was too small to be 
statistically significant due to the error in the measurement, but not due to the initial platelet 
deposition size.  Statistical significance of inhibition was not correlated with initial platelet 
deposit size (FI300s) (Fig. S1). The other 12 subjects with ≤ 25 % inhibition displayed 
statistically significant inhibition as a group (27 % ± 15 %; p < 0.001, n = 12).  Eleven of 28 
subjects with less than 25 % inhibition following ASA ingestion did not reach statistical 
significance because of the percent error in the smaller signal, not because their original platelet 
deposition at t = 0 was low. With more sampling at the 0 µM ex vivo ASA condition (eg. 4 
lanes per device), we anticipate that donors with < 25 % inhibition of FI300s following ASA 
ingestion would be detected with statistical significance.  In fact, the microfluidic approach 
detected only 1 out of 28 donors (donor # 253) that failed to display any decrease at all in 
platelet deposition after ASA ingestion (Fig. 3A). 
8.1.1.2 Discussion:  Timing of primary versus secondary phase of platelet accumulation 
The starting time for the secondary aggregation phase (150 sec) is a phase in which a 
significant platelet monolayer has already deposited on the collagen surface, thus the majority 
of the collagen surface has been covered with adherent platelets (Fig. S2). The effect of COX-
1 inhibitors added ex vivo to whole blood after 150 sec of platelet deposition on collagen in 
this microfluidic device is a time-scale consistent with previous findings in Ref. 19 (Flamm et 
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al., Blood. 2012). Thus, growth in platelet coverage in two dimensions is significant between 
60 -150 sec while after 150 sec, thrombus growth in the third dimension becomes significant 
under flow mediated by soluble agonists such as thromboxane A2 and ADP in this device. 
8.1.1.3 Discussion:  R value and future studies 
 The R-value in Fig. 4 helps to internally normalize each donor (since we cannot 
normalize to a pooled plasma result, for example). The R-value also has the property of scoring 
the effect of ASA on platelet deposition with R = 1 representing the cut-off between native 
blood (R > 1 for almost all donors) and ASA ingestion (R < 1 for most but not all donors).   
The results in Fig. 4F set the stage to identify individuals (blue points) worthy of future study 
who derive no functional response to aspirin (possibly due to higher ADP release or ADP 
sensitivity), despite the expectation of their COX-1 being fully acetylated and thromboxane 
synthesis being strongly inhibited.  Ideally, such a future study would involve both healthy 
donors and patients with cardiovascular risk. 
8.1.1.4 Discussion:  Receiver-Operator Curve Analysis 
A rigorous approach to assay validation was completed using an objective receiver-
operator curve (ROC) approach. Two cases were tested in this approach and are presented as 
follows.  
CASE I:  0 µM ASA (Period 1 and 2) vs. 26-hr ASA ingestion    
The R-value is a metric of secondary aggregation that normalizes the late stage platelet 
deposition rate to early stage deposition rate for each blood sample.  Receiver Operator Curve 
(ROC) analysis was conducted with JLABROC4v1.0.1 (Dr. J. Eng, Johns Hopkins Univ., 
available through public domain software at 
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www.rad.jhmi.edu/jeng/javarad/roc/JROCFITi.html based on LABROC4, Dr. C. Metz, 
Univ. Chicago). In comparing 56 measurement of the R-value for subjects not taking ASA (at 
t = 0 during Period 1 and 2) [true full COX-1 activity] to 28 individual measurements of R-
value for subjects taking 325 mg ASA [true full COX-1 inhibition], the receiver-operator curve 
had an area under curve (ROC AUC) = 0.741, indicative of an adequate, but not outstanding 
diagnostic discrimination between the two populations (Fig. S3).  Interestingly, the assay had 
high discrimination (high true positive rate with low false positive rate) at an R-value ~ 1 where 
the true positive fraction TPF was 71 % (sensitivity) and the false positive fraction FPF was 
36 % (specificity = 1 – FPF = 64 %).    
 INPUT DATA 
Scores from the 28 actually negative cases:   
   (True INHIBITION of ASA:  t = 26 hr following ASA ingestion) 
    1.1233     0.6034     0.7836     0.9767     0.7722 
    0.8585     0.8080     0.7077     1.6151     0.8603 
    0.9088     0.8099     1.2039     1.3272     0.8068 
    1.5131     0.7501     0.9849     0.8680     0.7233 
    0.9317     0.4908     0.8485     0.4195     0.6296 
    0.8973     0.9438     1.7459  
Scores from the 56 actually positive cases: 
  (True Full COX1 activity:  Period 1 and 2 at t=0; 0 ASA ) 
    0.7416     0.8656     1.1536     1.2645     1.2050 
    1.1738     0.8545     0.9592     1.3055     1.1071 
    1.1600     1.2014     1.4020     1.3010     1.5024 
    0.8560     1.6547     1.0767     1.3708     1.4339 
    1.4688     0.8096     1.2178     1.0163     1.0863 
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    1.0642     1.1327     1.1241     0.9999     1.0100 
    1.9264     1.2613     0.3817     1.1537     0.6803 
    1.0146     1.4208     1.3810     0.9649     1.4063 
    1.8150     1.2511     1.4529     0.4988     1.1964 
    1.1595     1.5706     1.2382     1.3985     1.1455 
    1.4131     1.2984     1.0613     1.3313     0.9103 
    1.5890    
     OPERATING POINTS CORRESPONDING TO THE INPUT DATA 
   FPF:   0.0000  0.0000  0.0357  0.0357  0.0714 
    TPF:   0.0000  0.0357  0.0357  0.0536  0.0536 
   FPF:   0.0714  0.1071  0.1071  0.1429  0.1429 
    TPF:   0.0893  0.0893  0.3036  0.3036  0.4643 
   FPF:   0.1786  0.1786  0.2143  0.2143  0.2857 
   TPF:   0.4643  0.6429  0.6429  0.8036  0.8036 
   FPF:   0.2857  0.3571  0.3571  0.4643  0.4643 
    TPF:   0.8393  0.8393  0.8571  0.8571  0.8750 
   FPF:   0.5357  0.5357  0.6071  0.6071  0.7857 
    TPF:   0.8750  0.9107  0.9107  0.9286  0.9286 
   FPF:   0.7857  0.8571  0.8571  0.9286  0.9286 
    TPF:   0.9464  0.9464  0.9643  0.9643  0.9821 
   PF:    1.0000  1.0000 
    TPF:   0.9821  1.0000 
 
FINAL ESTIMATES OF BINORMAL ROC PARAMETERS A AND B: 
  A = 0.9531    Std. Error (A) = 0.2659 
  B = 1.0831    Std. Error (B) = 0.2050 
  Correlation (A, B) = 0.2561 
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AREA UNDER ROC CURVE: 
  Area under fitted curve (Az) = 0.7410 
          Estimated std. error = 0.0568 
  Trapezoidal (Wilcoxon) area = 0.7659 
         Estimated std. error = 0.0514 
ESTIMATED BINORMAL ROC CURVE, WITH LOWER AND UPPER BOUNDS 
OF THE ASYMMETRIC 95% CONFIDENCE INTERVAL FOR TRUE-POSITIVE 
FRACTION AT A VARIETY OF FALSE-POSITIVE FRACTIONS: 
   FPF     TPF   95% Conf. Interv. 
  0.005  0.0331  (0.0021, 0.2107) 
  0.010  0.0586  (0.0060, 0.2676) 
  0.020  0.1017  (0.0167, 0.3388) 
  0.030  0.1391  (0.0297, 0.3884) 
  0.040  0.1727  (0.0442, 0.4276) 
  0.050  0.2036  (0.0596, 0.4605) 
  0.060  0.2323  (0.0756, 0.4891) 
  0.070  0.2593  (0.0921, 0.5145) 
  0.080  0.2847  (0.1089, 0.5375) 
  0.090  0.3088  (0.1259, 0.5586) 
  0.100  0.3317  (0.1429, 0.5781) 
  0.110  0.3537  (0.1600, 0.5962) 
  0.120  0.3746  (0.1770, 0.6131) 
  0.130  0.3948  (0.1940, 0.6291) 
  0.140  0.4141  (0.2108, 0.6442) 
  0.150  0.4327  (0.2274, 0.6585) 
  0.200  0.5166  (0.3078, 0.7209) 
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  0.250  0.5882  (0.3823, 0.7719) 
  0.300  0.6501  (0.4506, 0.8147) 
  0.400  0.7515  (0.5692, 0.8818) 
  0.500  0.8297  (0.6671, 0.9298) 
  0.600  0.8901  (0.7489, 0.9627) 
  0.700  0.9358  (0.8187, 0.9834) 
  0.800  0.9689  (0.8799, 0.9947) 
  0.900  0.9904  (0.9357, 0.9992)    
  0.950  0.9969  (0.9636, 0.9999) 
ESTIMATED RELATIONSHIP BETWEEN THE CRITICAL TEST RESULT 
VALUE (WHICH SEPARATES "POSITIVE" RESULTS FROM "NEGATIVE" 
RESULTS) AND ITS CORRESPONDING OPERATING POINT PROJECTED 
ONTO THE FITTED BINORMAL ROC CURVE: 
 
CASE (+ = Full COX1, 0 ASA; - = No COX1, 325 ASA) 
                Critical test       
 CASE  R-VALUE         (FPF, TPF) 
    +         1.9264         (0.0008, 0.0069) 
    +         1.8150          (0.0038, 0.0265) 
    -         1.7459        (0.0071, 0.0443) 
    +         1.6547          (0.0105, 0.0608) 
    -         1.6151          (0.0140, 0.0768) 
    +         1.5890          (0.0176, 0.0922) 
    +         1.5706           (0.0214, 0.1073) 
    -         1.5131          (0.0254, 0.1224) 
    +         1.5024         (0.0294, 0.1370) 
    +         1.4688          (0.0335, 0.1515) 
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    +         1.4529         (0.0379, 0.1660) 
    +         1.4339         (0.0424, 0.1804) 
    +         1.4208          (0.0471, 0.1949) 
    +         1.4131         (0.0519, 0.2094) 
    +         1.4063         (0.0570, 0.2239) 
    +         1.4020          (0.0622, 0.2384) 
    +         1.3985          (0.0675, 0.2529) 
    +         1.3810          (0.0731, 0.2673) 
    +         1.3708        (0.0788, 0.2818) 
    +         1.3313       (0.0847, 0.2962) 
    -         1.3272       (0.0907, 0.3106) 
    +         1.3055        (0.0969, 0.3248) 
    +         1.3010        (0.1032, 0.3389) 
    +         1.2984       (0.1096, 0.3529) 
    +         1.2645        (0.1163, 0.3670) 
    +         1.2613       (0.1231, 0.3810) 
    +         1.2511        (0.1301, 0.3951) 
    +         1.2382      (0.1374, 0.4091) 
    +         1.2178      (0.1448, 0.4231) 
    +         1.2050          (0.1524, 0.4371) 
    -         1.2039         (0.1602, 0.4510) 
    +         1.2014        (0.1681, 0.4647) 
    +         1.1964       (0.1762, 0.4784) 
    +         1.1738       (0.1845, 0.4920) 
    +         1.1600        (0.1930, 0.5057) 
    +         1.1595       (0.2018, 0.5193) 
    +         1.1537         (0.2108, 0.5329) 
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    +         1.1536        (0.2201, 0.5465) 
    +         1.1455         (0.2296, 0.5602) 
    +         1.1327        (0.2394, 0.5738) 
    +         1.1241      (0.2496, 0.5876) 
    -         1.1233        (0.2601, 0.6012) 
    +         1.1071        (0.2705, 0.6145) 
    +         1.0863        (0.2812, 0.6276) 
    +         1.0767         (0.2923, 0.6409) 
    +         1.0642          (0.3037, 0.6541) 
    +         1.0613          (0.3155, 0.6674) 
    +         1.0163          (0.3277, 0.6807) 
    +         1.0146          (0.3402, 0.6939) 
    +         1.0100          (0.3533, 0.7072)      Optimal Discrimination by R value = 1 
    +         0.9999          (0.3668, 0.7205)      (Sensitivity ~ 71 %, Specificity ~ 64 %) 
    -         0.9849          (0.3808, 0.7339) 
    -         0.9767         (0.3948, 0.7466) 
    +         0.9649          (0.4087, 0.7590) 
    +         0.9592          (0.4231, 0.7713) 
    -        0.9438          (0.4382, 0.7836) 
    -         0.9317          (0.4532, 0.7955) 
    +         0.9103          (0.4683, 0.8070) 
    -         0.9088          (0.4838, 0.8183) 
    -         0.8973          (0.4994, 0.8293) 
    -         0.8680       (0.5150, 0.8399) 
    +         0.8656        (0.5308, 0.8501) 
    -         0.8603         (0.5469, 0.8601) 
    -         0.8585         (0.5632, 0.8698) 
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    +        0.8560        (0.5797, 0.8792) 
    +         0.8545       (0.5967, 0.8884) 
    -         0.8485         (0.6144, 0.8976) 
    -         0.8099        (0.6323, 0.9064) 
    +         0.8096        (0.6504, 0.9149) 
    -         0.8080       (0.6691, 0.9232) 
    -         0.8068      (0.6879, 0.9311) 
    -         0.7836        (0.7068, 0.9385) 
    -         0.7722        (0.7258, 0.9455) 
    -         0.7501       (0.7447, 0.9521) 
    +         0.7416        (0.7639, 0.9583) 
    -         0.7233       (0.7840, 0.9644) 
    -         0.7077        (0.8043, 0.9700) 
     +        0.6803       (0.8251, 0.9753) 
     -         0.6296        (0.8472, 0.9804) 
    -         0.6034         (0.8696, 0.9850) 
    +         0.4988      (0.8927, 0.9892) 
    -         0.4908         (0.9186, 0.9931) 
    -         0.4195        (0.9452, 0.9964) 
    +         0.3817        (0.9773, 0.9991) 
    
Fitted ROC Area:   0.741 
Fitted points 
FPF    TPF    Lower  Upper 
0.0000 0.0000 0.0000 0.0000 
0.0050 0.0331 0.0021 0.2107 
0.0100 0.0586 0.0060 0.2676 
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0.0200 0.1017 0.0167 0.3388 
0.0300 0.1391 0.0297 0.3884 
0.0400 0.1727 0.0442 0.4276 
0.0500 0.2036 0.0596 0.4605 
0.0600 0.2323 0.0756 0.4891 
0.0700 0.2593 0.0921 0.5145 
0.0800 0.2847 0.1089 0.5375 
0.0900 0.3088 0.1259 0.5586 
0.1000 0.3317 0.1429 0.5781 
0.1100 0.3537 0.1600 0.5962 
0.1200 0.3746 0.1770 0.6131 
0.1300 0.3948 0.1940 0.6291 
0.1400 0.4141 0.2108 0.6442 
0.1500 0.4327 0.2274 0.6585 
0.2000 0.5166 0.3078 0.7209 
0.2500 0.5882 0.3823 0.7719 
0.3000 0.6501 0.4506 0.8147 
0.4000 0.7515 0.5692 0.8818 
0.5000 0.8297 0.6671 0.9298 
0.6000 0.8901 0.7489 0.9627 
0.7000 0.9358 0.8187 0.9834 
0.8000 0.9689 0.8799 0.9947 
0.9000 0.9904 0.9357 0.9992 
0.9500 0.9969 0.9636 0.9999 
1.0000 1.0000 1.0000 1.0000 
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CASE II:  0 µM ASA (Period 1 and 2) VS. 500 µM ASA Ex Vivo 
In comparing 56 measurement of the R-value for subjects not taking ASA (at t = 0 during 
Period 1 and 2)  [true full COX-1 activity] to 56 individual measurements of R-value for ex 
vivo 500 µM ASA addition [true full COX-1 inhibition], the receiver-operator curve had an 
area under curve (ROC AUC) = 0.783, indicative of a good, but not outstanding diagnostic 
discrimination between the two populations (Fig. S3).  Interestingly, the assay had optimal 
discrimination (best true positive rate and minimum false positive rate) at an R-value ~ 1 where 
the true positive fraction TPF was 75 % (sensitivity) and the false positive fraction FPF was 
33 % (specificity = 1 – FPF = 67 %).    
INPUT DATA 
Scores from the 56 actually negative cases: 
  True Inhibition of COX1 with 500 uM ASA 
    0.5468     0.7292     0.6258     0.8920     0.8226 
    0.9299     0.7806     0.7691     1.1218     0.7727 
    1.1059     0.8476     1.0033     1.0534     0.8654 
    0.8333     0.8730     0.9148     0.8196     1.2122 
    1.3131     0.6908     1.1451     0.2065     0.9521 
    0.8769     1.0290     0.8648     0.9114     1.4386 
    1.0893     0.8516     0.1217     0.8566     0.6950 
    0.6501     0.9521     0.8055     1.2264     0.8961 
    1.6720     0.5441     0.8210     0.4755     0.8776 
    1.1593     0.7903     0.5619     1.1969     1.1594 
    0.8804     0.6476     0.8153     0.8193     0.7628 
    1.3335  
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Scores from the 56 actually positive cases: 
True Full COX1 activity: Period 1 and 2 at t = 0; 0 ASA 
    0.7416     0.8656     1.1536     1.2645     1.2050 
    1.1738     0.8545     0.9592     1.3055     1.1071 
    1.1600     1.2014     1.4020     1.3010     1.5024 
    0.8560     1.6547     1.0767     1.3708     1.4339 
    1.4688     0.8096     1.2178     1.0163     1.0863 
    1.0642     1.1327     1.1241     0.9999     1.0100 
    1.9264     1.2613     0.3817     1.1537     0.6803 
    1.0146     1.4208     1.3810     0.9649     1.4063 
    1.8150     1.2511     1.4529     0.4988     1.1964 
    1.1595     1.5706     1.2382     1.3985     1.1455 
    1.4131     1.2984     1.0613     1.3313     0.9103 
    1.5890  
OPERATING POINTS CORRESPONDING TO THE INPUT DATA 
   FPF:   0.0000  0.0000  0.0179  0.0179  0.0357 
    TPF:   0.0000  0.0357  0.0357  0.1429  0.1429 
  FPF:   0.0357 0.0536 0.0536 0.0714 0.0714 
    TPF:   0.2857 0.2857 0.3036 0.3036 0.4286 
   FPF:   0.0893 0.0893 0.1071 0.1071 0.1250 
    TPF:   0.4286 0.4464  0.4464  0.4821  0.4821 
  FPF:   0.1250  0.1607  0.1607  0.1786  0.1786 
    TPF:   0.5536  0.5536  0.6071  0.6071  0.6429 
   FPF:   0.1964  0.1964  0.2321  0.2321  0.2679 
    TPF:   0.6429  0.6607  0.6607  0.7321  0.7321 
   FPF:   0.2679  0.2857  0.2857  0.3750  0.3750 
    TPF:   0.7857  0.7857  0.8393  0.8393  0.8571 
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   FPF:   0.4821  0.4821  0.5357  0.5357  0.6786 
    TPF:   0.8571  0.8750  0.8750  0.9107  0.9107 
  FPF:   0.6786  0.7857  0.7857  0.8393  0.8393 
    TPF:   0.9286  0.9286  0.9464  0.9464  0.9643 
   FPF:   0.9464  0.9464  0.9643  0.9643  1.0000 
    TPF:   0.9643  0.9821  0.9821  1.0000  1.0000 
 
FINAL ESTIMATES OF BINORMAL ROC PARAMETERS A AND B: 
  A = 1.0714    Std. Error (A) = 0.2145 
  B = 0.9357    Std. Error (B) = 0.1519 
  Correlation (A, B) = 0.3923 
 
AREA UNDER ROC CURVE: 
  Area under fitted curve (Az) = 0.7830 
          Estimated std. error = 0.0423 
  Trapezoidal (Wilcoxon) area = 0.7943 
         Estimated std. error = 0.0425 
 
ESTIMATED BINORMAL ROC CURVE, WITH LOWER AND UPPER BOUNDS 
OF THE ASYMMETRIC 95% CONFIDENCE INTERVAL FOR TRUE-POSITIVE 
FRACTION AT A VARIETY OF FALSE-POSITIVE FRACTIONS: 
 
   FPF     TPF   95% Conf. Interv. 
  0.005  0.0903  (0.0199, 0.2666) 
  0.010  0.1344  (0.0392, 0.3259) 
  0.020  0.1975  (0.0747, 0.3976) 
  0.030  0.2455  (0.1072, 0.4460) 
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  0.040  0.2854  (0.1372, 0.4837) 
  0.050  0.3199  (0.1653, 0.5148) 
  0.060  0.3506  (0.1916, 0.5417) 
  0.070  0.3784  (0.2165, 0.5654) 
  0.080  0.4038  (0.2401, 0.5867) 
  0.090  0.4273  (0.2626, 0.6060) 
  0.100  0.4491  (0.2840, 0.6238) 
  0.110  0.4696  (0.3044, 0.6403) 
  0.120  0.4888  (0.3239, 0.6556) 
  0.130  0.5070  (0.3427, 0.6701) 
  0.140  0.5242  (0.3607, 0.6836) 
  0.150  0.5405  (0.3780, 0.6964) 
  0.200  0.6118  (0.4555, 0.7518) 
  0.250  0.6703  (0.5209, 0.7964) 
  0.300  0.7194  (0.5771, 0.8335) 
  0.400  0.7981  (0.6693, 0.8910) 
  0.500  0.8580  (0.7425, 0.9321) 
  0.600  0.9046  (0.8031, 0.9611) 
  0.700  0.9408  (0.8553, 0.9805) 
  0.800  0.9685  (0.9017, 0.9924) 
  0.900  0.9884  (0.9453, 0.9984) 
  0.950  0.9955  (0.9679, 0.9996) 
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ESTIMATED RELATIONSHIP BETWEEN THE CRITICAL TEST RESULT   
VALUE (WHICH SEPARATES "POSITIVE" RESULTS FROM "NEGATIVE" 
RESULTS) AND ITS CORRESPONDING OPERATING POINT PROJECTED 
ONTO THE FITTED BINORMAL ROC CURVE: 
            Critical test   
  Truth  result value                 (FPF, TPF) 
    +       1.9264       (0.0001, 0.0077) 
    +       1.8150       (0.0008, 0.0293) 
    -       1.6720        (0.0018, 0.0486) 
    +       1.6547      (0.0028, 0.0647) 
    +       1.5890      (0.0041, 0.0801) 
    +       1.5706      (0.0055, 0.0955) 
    +       1.5024       (0.0071, 0.1110) 
    +       1.4688       (0.0090, 0.1264) 
    +       1.4529                   (0.0110, 0.1419) 
    -       1.4386                 (0.0132, 0.1571) 
    +       1.4339       (0.0154, 0.1715) 
    +       1.4208       (0.0178, 0.1856) 
    +       1.4131       (0.0204, 0.1998) 
    +       1.4063       (0.0232, 0.2140) 
    +       1.4020       (0.0261, 0.2282) 
    +       1.3985       (0.0293, 0.2424) 
    +       1.3810       (0.0326, 0.2566) 
    +       1.3708       (0.0361, 0.2707) 
    -       1.3335        (0.0398, 0.2847) 
    +       1.3313       (0.0436, 0.2983) 
    -       1.3131        (0.0474, 0.3116) 
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    +       1.3055       (0.0514, 0.3246) 
    +       1.3010       (0.0556, 0.3375) 
    +       1.2984       (0.0599, 0.3503) 
    +       1.2645       (0.0643, 0.3631) 
    +       1.2613       (0.0690, 0.3759) 
    +       1.2511       (0.0739, 0.3888) 
    +       1.2382       (0.0790, 0.4015) 
    -       1.2264       (0.0843, 0.4141) 
    +       1.2178       (0.0896, 0.4265) 
    -       1.2122        (0.0951, 0.4387) 
    +       1.2050       (0.1007, 0.4507) 
    +       1.2014       (0.1065, 0.4626) 
    -       1.1969        (0.1124, 0.4743) 
    +       1.1964       (0.1184, 0.4858) 
    +       1.1738       (0.1245, 0.4972) 
    +       1.1600       (0.1309, 0.5086) 
    +       1.1595       (0.1375, 0.5200) 
    -       1.1594         (0.1444, 0.5314) 
    -       1.1593       (0.1512, 0.5424) 
    +       1.1537       (0.1581, 0.5531) 
    +       1.1536       (0.1651, 0.5637) 
    +       1.1455       (0.1725, 0.5745) 
    -       1.1451        (0.1800, 0.5852) 
    +       1.1327       (0.1876, 0.5955) 
    +       1.1241      (0.1954, 0.6058) 
    -       1.1218       (0.2035, 0.6162) 
    +       1.1071       (0.2116, 0.6263) 
144 
 
    -       1.1059      (0.2199, 0.6363) 
    -       1.0893         (0.2282, 0.6460) 
    +       1.0863        (0.2364, 0.6554) 
    +       1.0767        (0.2449, 0.6647) 
    +       1.0642        (0.2538, 0.6741) 
    +       1.0613       (0.2629, 0.6837) 
    -       1.0534         (0.2724, 0.6932) 
    -       1.0290         (0.2818, 0.7023) 
    +       1.0163        (0.2911, 0.7111) 
    +       1.0146        (0.3007, 0.7199) 
    +       1.0100        (0.3107, 0.7289) 
    -       1.0033         (0.3210, 0.7378) 
    +       0.9999         (0.3313, 0.7464)        Optimal Discrimination by R value = 1 
    +       0.9649         (0.3418, 0.7549)        (Sensitivity ~ 75 %, Specificity ~ 67 %) 
    +       0.9592         (0.3528, 0.7636) 
    +       0.9521       (0.3697, 0.7765) 
    -       0.9299         (0.3867, 0.7888) 
    -       0.9148         (0.3980, 0.7966) 
    -       0.9114         (0.4092, 0.8042) 
    +       0.9103         (0.4204, 0.8115) 
    -       0.8961         (0.4320, 0.8189) 
    -       0.8920           (0.4437, 0.8261) 
    -       0.8804          (0.4553, 0.8331) 
    -       0.8776          (0.4669, 0.8398) 
    -       0.8769          (0.4785, 0.8464) 
    -       0.8730          (0.4900, 0.8527) 
    +       0.8656         (0.5017, 0.8589) 
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    -       0.8654          (0.5136, 0.8650) 
    -       0.8648          (0.5255, 0.8710) 
    -       0.8566          (0.5375, 0.8769) 
    +       0.8560          (0.5495, 0.8826) 
    +       0.8545          (0.5619, 0.8882) 
    -       0.8516          (0.5744, 0.8938) 
    -       0.8476          (0.5871, 0.8993) 
    -       0.8333           (0.5998, 0.9046) 
    -       0.8226          (0.6125, 0.9097) 
    -       0.8210          (0.6252, 0.9147) 
    -       0.8196          (0.6379, 0.9195) 
    -       0.8193          (0.6506, 0.9242) 
    -       0.8153          (0.6634, 0.9287) 
    +       0.8096         (0.6763, 0.9331) 
    -       0.8055          (0.6893, 0.9374) 
    -       0.7903          (0.7024, 0.9416) 
    -       0.7806          (0.7156, 0.9457) 
    -       0.7727          (0.7288, 0.9496) 
    -       0.7691          (0.7419, 0.9534) 
    -       0.7628          (0.7551, 0.9571) 
    +       0.7416         (0.7684, 0.9606) 
    -       0.7292          (0.7820, 0.9641) 
    -       0.6950          (0.7957, 0.9675) 
    -       0.6908          (0.8094, 0.9707) 
    +       0.6803          (0.8232, 0.9738) 
    -       0.6501          (0.8375, 0.9768) 
    -       0.6476          (0.8519, 0.9798) 
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    -       0.6258          (0.8663, 0.9825) 
    -       0.5619          (0.8806, 0.9851) 
    -       0.5468         (0.8950, 0.9876) 
    -       0.5441          (0.9094, 0.9899) 
    +       0.4988         (0.9240, 0.9921) 
    -       0.4755          (0.9394, 0.9942) 
    +       0.3817         (0.9555, 0.9961) 
    -       0.2065         (0.9734, 0.9980) 
    -       0.1217           (0.9930, 0.9996) 
 
FPF    TPF    Lower  Upper 
0.0000 0.0000 0.0000 0.0000 
0.0050 0.0903 0.0199 0.2666 
0.0100 0.1344 0.0392 0.3259 
0.0200 0.1975 0.0747 0.3976 
0.0300 0.2455 0.1072 0.4460 
0.0400 0.2854 0.1372 0.4837 
0.0500 0.3199 0.1653 0.5148 
0.0600 0.3506 0.1916 0.5417 
0.0700 0.3784 0.2165 0.5654 
0.0800 0.4038 0.2401 0.5867 
0.0900 0.4273 0.2626 0.6060 
0.1000 0.4491 0.2840 0.6238 
0.1100 0.4696 0.3044 0.6403 
0.1200 0.4888 0.3239 0.6556 
0.1300 0.5070 0.3427 0.6701 
0.1400 0.5242 0.3607 0.6836 
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0.1500 0.5405 0.3780 0.6964 
0.2000 0.6118 0.4555 0.7518 
0.2500 0.6703 0.5209 0.7964 
0.3000 0.7194 0.5771 0.8335 
0.4000 0.7981 0.6693 0.8910 
0.5000 0.8580 0.7425 0.9321 
0.6000 0.9046 0.8031 0.9611 
0.7000 0.9408 0.8553 0.9805 
0.8000 0.9685 0.9017 0.9924 
0.9000 0.9884 0.9453 0.9984 
0.9500 0.9955 0.9679 0.9996 
1.0000 1.0000 1.0000 1.0000 
 
8.1.2 Final Platelet Fluorescence (FI300s), Platelet Deposition Rates, R-values 
 
Subject 
ID 
FI300s 
(0 µM 
ASA) 
Period 1 
0 hr 
FI300s 
(0 µM 
ASA) 
Period 2 
0 hr 
F'(300-150s) 
(0  µM 
ASA) 
Period 1 
0 hr 
F'(300-150s) 
(0  µM 
ASA) 
Period 2 
0 hr 
R 
(0 µM 
ASA) 
Period 
1 
0 hr 
R 
(0 µM 
ASA) 
Period 
2 
0 hr 
R 
(500 
µM 
ASA) 
Period 
1 
0 hr 
R 
(500 
µM 
ASA) 
Period 
2 
0 hr 
R 
(0 µM ASA) 
Period 1 
26 hr 
217 3078 5937 10.00 21.60 0.7416 0.9999 0.5468 0.9114 1.1233 
246 4495 4363 13.72 17.79 0.8656 1.0100 0.7292 1.4386 0.6034 
272 11079 9864 44.07 47.81 1.1536 1.9264 0.6258 1.0893 0.7836 
259 6336 9246 26.72 37.94 1.2645 1.2613 0.8920 0.8516 0.9767 
262 8436 12890 35.38 55.55 1.2050 0.3817 0.8226 0.1217 0.7722 
225 7541 2648 30.12 24.02 1.1738 1.1537 0.9299 0.8566 0.8585 
250 5413 5949 18.30 7.94 0.8545 0.6803 0.7806 0.6950 0.8080 
241 10253 2471 36.37 9.58 0.9592 1.0146 0.7691 0.6501 0.7077 
283 10178 6100 44.50 27.75 1.3055 1.4208 1.1218 0.9521 1.6151 
268 4225 7404 16.40 32.43 1.1071 1.3810 0.7727 0.8055 0.8603 
203 2058 1312 8.46 5.06 1.1600 0.9649 1.1059 1.2264 0.9088 
248 4111 5946 16.76 26.76 1.2014 1.4063 0.8476 0.8961 0.8099 
239 8521 6571 36.17 36.43 1.4020 1.8150 1.0033 1.6720 1.2039 
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216 3862 4308 16.76 17.80 1.3010 1.2511 1.0534 0.5441 1.3272 
226 4686 1977 20.91 8.92 1.5024 1.4529 0.8654 0.8210 0.8068 
235 4627 3430 17.27 7.49 0.8560 0.4988 0.8333 0.4755 1.5131 
238 3438 3268 17.31 40.92 1.6547 1.1964 0.8730 0.8776 0.7501 
240 5172 3616 20.74 14.85 1.0767 1.1595 0.9148 1.1593 0.9849 
255 6294 2484 27.70 20.29 1.3708 1.5706 0.8196 0.7903 0.8680 
212 3177 6139 14.75 23.87 1.4339 1.2382 1.2122 0.5619 0.7233 
231 6148 3207 17.55 14.60 1.4688 1.3985 1.3131 1.1969 0.9317 
243 4194 5141 14.43 19.58 0.8096 1.1455 0.6908 1.1594 0.4908 
278 2028 5208 8.85 24.08 1.2178 1.4131 1.1451 0.8804 0.8485 
293 5477 4994 19.70 20.97 1.0163 1.2984 0.2065 0.6476 0.4195 
253 3243 1441 12.87 12.02 1.0863 1.0613 0.9521 0.8153 0.6296 
256 12716 16498 47.96 67.36 1.0642 1.3313 0.8769 0.8193 0.8973 
277 7539 7548 26.62 25.54 1.1327 0.9103 1.0290 0.7628 0.9438 
282 10221 6506 42.15 29.99 1.1241 1.5890 0.8648 1.3335 1.7459 
Average 6020 5588 24 25 1.16 1.21 0.88 0.89 0.93 
Stdev 2888 5576 24 25 0.22 0.34 0.22 0.32 0.31 
 
Table 6. Microfluidic ASA Phenotyping Quantification Metrics  
8.1.3 Total platelet accumulation with no in vitro ASA addition at 0 hr vs. % 
inhibition 
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Figure 8-1  Total platelet accumulation with no ex vivo ASA addition at 0 hr vs. % 
inhibition.   
 
8.1.4  Collagen % surface coverage by platelet with no in vitro addition of agonists 
in PPACK inhibited whole blood 
 
Figure 8-2  % surface coverage by platelets on collagen with no in vitro addition of 
agonists in PPACK treated whole blood in the 8-channel microfluidic device.  
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8.1.5 ROC Curve Case I: 0 µM ASA (Period 1 & 2) vs. 26 h ASA ingestion  
 
Figure 8-3 ROC Curve Case I: 0 µM in vitro ASA (Period 1 and 2) vs. 26 h ASA 
ingestion 
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8.1.6 ROC Curve Case II: 0 µM ASA (Period 1 & 2) vs. 500 µM ASA in vitro 
 
Figure 8-4 ROC Curve Case II: 0 µM in vitro ASA (Period 1 and 2) vs. 500 µM in vitro 
ASA  
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8.2 Detection of platelet sensitivity to inhibitors of COX-1, P2Y1, and 
P2Y12 using a whole blood microfluidic assay: Supplemental 
Material  
8.2.1 Supplemental Materials and Methods  
8.2.1.1 Response to ex vivo 2MeSAMP and MRS2179 dosing at venous and arterial shear rates  
For combined venous (200s-1) and arterial wall shear rate (1000s-1) studies, blood was 
collected from 5 healthy donors; one donor of the 5 tested was not examined in the primary 
study of this work. Blood collection, labeling, addition of antagonists, and exclusion criteria 
for donors for these assays were identical as the main protocol. PPACK treated whole blood 
was perfused through the device within 40 min of phlebotomy. For dose-response testing of 
P2Y12 and P2Y1 antagonists, 8 distinct concentrations of either antagonist previously 
incubated with whole blood is perfused through a single 8 channel device with 3 devices 
tested simultaneously at the same wall shear rate. A custom stage insert holds 3 microfluidic 
devices, allowing 24 simultaneous platelet aggregation events under flow to be imaged in 15 s 
intervals. The protocol is repeated with the second wall shear rate. The order of which wall 
shear rate was tested first was randomized. Final ex vivo concentrations of 2 MeSAMP and 
MRS 2179 used are as indicated [2 MeSAMP: 0, 0.1, 0.5, 1, 5, 10, 50, 100 µM; MRS 2179: 0, 
0.01, 0.05, 0.1, 0.5, 1, 5, 10 µM]. The respective arterial wall shear rate of 1000s-1 was 
established in other assays with the same microfluidic device[34,37,64]. 
 
 
 
153 
 
8.2.2 Healthy donor phenotyping of platelet function response to P2Y1 or P2Y12 
antagonists under flow, baseline final platelet fluorescence values  
Intradonor variability of FI300s(0): Different Devices  
                    
Donor  Device 1  Device 1  Device 2 Device 2  Device 3  Device 3  Average SD  CV% 
1 1545.77 1311.61 1454.20 1465.33 1462.44 1427.59 1444.49 76.23 5.3% 
2 1640.33 2082.70 1452.06 1724.67 1705.70 2142.69 1791.36 267.59 14.9% 
3 2014.25 2308.29 2428.46 2477.85 2942.26 2311.79 2413.82 304.88 12.6% 
4 5037.89 4563.72 3806.69 4905.00 5745.34 5360.22 4902.77 671.39 13.7% 
5 4386.49 4335.76 3090.64 4468.44 5418.45 5067.75 4461.28 798.04 17.9% 
6 3711.38 4644.85 2933.58 3587.71 2991.93 3083.38 3261.60 650.42 19.9% 
7 5733.93 6521.59 4891.77 3956.05 4928.05 3210.83 4862.83 1188.78 24.4% 
8 5733.93 6521.59 4891.77 3956.05 4928.05 3210.83 4873.70 1188.78 24.4% 
9 3441.47 2539.59 2246.24 2417.76 2426.44 2420.57 2614.30 431.38 16.5% 
10 2357.16 2053.67 2276.70 2366.31 1664.21 2792.64 2251.78 374.66 16.6% 
11 13832.1 12883.99 11644.54 10971.13 15391.014 14979.67 13283.74 1778.34 13.4% 
Avg 4494.06 4524.30 3737.88 3845.12 4509.46 4182.54 4196.52 702.77 16.3% 
          
Intradonor variability of FI300s(0): Same Device 
            
Donor  Avg D1 SD D1 CV% D1 Avg D2 SD D2 CV% D2 Avg D3 SD D3 
CV% 
D3 
1 1428.69 165.58 11.6% 1459.76 7.87 0.5% 1445.01 24.64 1.7% 
2 1861.51 312.81 16.8% 1588.37 192.77 12.1% 1924.20 309.00 16.1% 
3 2161.27 207.92 9.6% 2453.15 34.92 1.4% 2627.03 445.81 17.0% 
4 4800.80 335.29 7.0% 3806.69 776.62 20.4% 5552.78 272.32 4.9% 
5 4361.12 35.88 0.8% 3779.54 974.25 25.8% 5243.18 248.10 4.7% 
6 4178.12 660.07 15.8% 3260.65 462.54 14.2% 3037.66 64.66 2.1% 
7 6127.76 556.96 9.1% 4423.91 661.65 15.0% 4069.44 1214.26 29.8% 
8 6127.76 556.96 9.1% 4423.91 661.65 15.0% 4069.44 1214.26 29.8% 
9 2990.53 637.72 21.3% 2332.00 121.28 5.2% 2426.44 4.15 0.2% 
10 2205.41 214.60 9.7% 2321.50 63.36 2.7% 2228.43 797.92 35.8% 
11 13358.04 670.42 5.0% 11307.84 476.17 4.2% 15185.34 290.87 1.9% 
Avg 4509.18 395.84 11.0% 3741.57 403.01 11.0% 4346.27 444.18 13.1% 
 
Table 7. Intradonor variability of platelet fluorescence intensity on collagen 
[FI300s(0)]: same 8-channel device or cross-device coefficient of variability (CV) 
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8.2.3 Healthy donor phenotyping of platelet function response to P2Y1 or P2Y12 
antagonists under flow: Intradonor R(0) variability  
Intradonor variability of R(0): Different Devices  
            
Donor  Device 1  Device 1  Device 2 Device 2  Device 3  Device 3  Average SD  CV% 
1 0.682 0.814 0.867 0.752 0.725 0.609 0.741 0.092 12.4% 
2 1.096 1.269 1.040 1.091 0.983 0.816 1.049 0.149 14.2% 
3 1.657 1.522 1.772 1.713 1.800 2.067 1.755 0.182 10.4% 
4 2.210 2.540 1.170 1.830 1.805 1.469 1.839 0.493 26.8% 
5 1.200 1.141 1.014 1.165 1.396 1.143 1.176 0.125 10.6% 
6 1.219 1.335 1.075 0.942 1.086 1.153 1.095 0.135 12.3% 
7 1.174 1.153 0.803 0.930 0.802 0.949 1.002 0.163 16.3% 
8 1.232 1.127 0.733 0.948 1.193 0.974 1.035 0.187 18.0% 
9 0.914 0.911 0.978 1.169 1.167 1.206 1.028 0.138 13.4% 
10 0.917 0.882 0.948 0.861 0.745 1.447 0.967 0.245 25.3% 
11 1.249 1.074 1.373 1.272 1.083 1.182 1.206 0.116 9.6% 
Avg 1.232 1.252 1.070 1.152 1.162 1.183 1.172 0.184 15.4% 
          
          
Intradonor variability of R(0): Same Device 
                    
Donor  Avg D1 SD D1 CV% D1 Avg D2 SD D2 CV% D2 Avg D3 
SD 
D3 
CV% 
D3 
1 0.748 0.094 12.6% 0.809 0.081 10.1% 0.667 0.082 12.2% 
2 1.182 0.122 10.3% 1.066 0.036 3.3% 0.900 0.118 13.2% 
3 1.590 0.095 6.0% 1.742 0.042 2.4% 1.934 0.189 9.8% 
4 2.375 0.233 9.8% 1.170 0.466 39.8% 1.637 0.238 14.5% 
5 1.170 0.042 3.6% 1.089 0.107 9.8% 1.270 0.179 14.1% 
6 1.277 0.082 6.4% 1.008 0.094 9.3% 1.119 0.047 4.2% 
7 1.163 0.015 1.3% 0.866 0.089 10.3% 0.876 0.104 11.9% 
8 1.179 0.074 6.3% 0.841 0.152 18.1% 1.084 0.155 14.3% 
9 0.912 0.002 0.2% 1.074 0.135 12.6% 1.167 0.027 2.3% 
10 0.900 0.025 2.8% 0.905 0.061 6.8% 1.096 0.496 45.2% 
11 1.162 0.124 10.7% 1.323 0.071 5.4% 1.133 0.070 6.2% 
Avg 1.242 0.083 0.064 1.081 0.121 0.116 1.171 0.155 13.2% 
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Table 8. Intradonor variability of R(0): same 8-channel device or cross-device 
coefficient of variability (CV) 
8.2.4 Concentration-dependent response of platelet function under flow to ex vivo 
2MeSAMP or MRS2179 at initial venous and arterial wall shear rates  
 
Figure 8-5 Response to ex vivo P2Y12 or P2Y1 inhibition by incubation with 
2MeSAMP or MRS2179 respectively at 200 s-1 and 1000 s-1 initial wall shear rates.  
(A, B), Average IC50 curves for 2MeSAMP and MRS 2179 at venous and arterial shear rates. Nine microfluidic 
assays were run at each initial wall shear rate for a total of 3 donors. Each point on the dose response curve is 
an average of 9 clotting events under flow. 95% CI for ex vivo 2MeSAMP addition were 6.62-14.11 µM and 
1.02-30.20 µM at 200 s-1 and 1000s-1 respectively and 0.029-0.164 µM, 0.03-1.87 µM for MRS 2179 at 200 s-1 
and 1000s-1 respectively.  
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8.3 Recombinant factor VIIa enhances platelet deposition from flowing 
hemophilic blood but requires the contact way to promote fibrin 
deposition: Supplemental Material  
8.3.1 Supplemental Material and Methods  
8.3.1.1 Validation of the dependency of fibrin generation on the contact pathway in the microfluidic 
hemostasis model and the role of rFVIIa in a cell free system  
To isolate platelet poor plasma (PPP), WB was collected from healthy donors in 1 
part sodium citrate from Sigma (St. Louis, MO) to 9 parts blood and 4 µg/ml CTI. Samples 
were subsequently centrifuged at 1000 g for 10 min. FXI, FIX, and FVIII-deficient plasma 
samples were purchased from Haematologic Technologies (Essex Junction, VT). Factor-
deficient plasma samples were inhibited with 4 µg/ml CTI. Five minutes prior to 
experimentation, normal pooled plasma (n = 3 donors) or factor-deficient plasma were 
treated with fluorescently conjugated anti-fibrin antibody, recalcified with 10 mM CaCl2, and 
indicated concentrations of rFVIIa were added. Two microfluidic devices were tested 
allowing 16 simultaneous collagen strips to be imaged in 30 sec intervals. Healthy pooled 
plasma, FXI, FIX, or FVIII-deficient plasma samples were tested in replicate on each 8-
channel device. Plasma samples were perfused at an initial local wall shear rate of 100s-1 for a 
total perfusion time of 20 minutes.  
8.3.1.2 FVIIa Fluorogenic Substrate detection 
The fluorogenic FVIIa substrate D-Phe-Pro-Arg-6-amino-1-naphthalenesulfonamide 
(D-FPR-ANSNH C4H9 · 2 HCl) was obtained  from Haematologic Technologies (Essex 
Junction, VT). Prior to experimentation, D-FPR-ANSNH C4H9 2*HCl (50 µM) was added 
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to each well in a 384 well plate (Nunc, Thermo Scientific, Waltham, MA).  A fluoroskan 
(Fluoroskan Ascent, Thermo Scientific, Waltham, MA) detected the fluorescence of the 
released ANSN reporter group. Addition of low or high CTI occurred at 1 min followed by 
addition of rFVIIa at 5 min. Each well was read twice per minute for 90 minutes. Fractional 
conversion of the fluorogenic substrate was determined according to:  
(Equation 8-1) 
                                                                            𝐶 =
𝐹 − 𝐹𝑚𝑖𝑛
𝐹𝑚𝑎𝑥 − 𝐹𝑚𝑖𝑛
                                                       
where C is the fractional conversion, F is the instantaneous fluorescence at any time, Fmin or 
Fmax is the respective minimum or maximum fluorescence for an individual well.  
 
8.3.1.3 Thrombin Fluorogenic Substrate detection 
The fluorogenic thrombin substrate t-Butyloxycarbonyl-β-benzyl-L-aspartyl-L-prolyl-
L-arginine-4 methylcoumaryl-7-amide [Boc-Asp(OBzl)-Pro-Arg-AMC] was obtained from 
Peptide International (Louisville, KY). Lipids, L-α-phosphatidylcholine (PC), L-α-
phosphatidyserine (PS) were purchased from Avanti Polar Lipids (Alabaster, AL).  WB was 
collected in two syringes containing 1 part sodium citrate to 9 parts blood and either 4 
µg/ml or 40 µg/ml CTI.  To isolate platelet poor plasma (PPP), WB was centrifuged at 1000 
g for 10 min. Citrated and high or low CTI-inhibited PPP was diluted 1:10 in HBS and 
recalcified to 10 mM final calcium concentration in all wells. Prior to experimentation all 
wells were pre-loaded with indicated concentrations of rFVIIa and 5 µM PC:PS vesicles. To 
ensure simultaneous detection of thrombin activity, Boc-Asp(OBzl)-Pro-Arg-AMC (10 µM)  
was added simultaneously to all wells with distinct conditions in a 384 well plate and the 
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fluorescence of the released aminomethylcoumarin (AMC) was measured. Each well was 
read twice per minute for 90 minutes and fractional conversion of the substrate was 
determined as previously described.  
8.3.1.4 Assessment of platelet-rFVIIa function in the microfluidic hemostasis model in the complete absence 
of thrombin 
WB was drawn into 4 µg/ml CTI and either 1 µM FXa inhibitor apixaban 
(Selleckchem. Houston, TX) or 100 µM H-D-Phe-Pro-Arg-chloromethylketone 
(Haematologic Technologies. Essex Junction, VT), or a combination of both with low CTI. 
Blood samples were treated with fluorescently conjugated anti-CD41a antibody and 
fluorescently conjugated anti-fibrin antibody to label platelets and fibrin respectively as 
previously mentioned. Blood samples were also treated with vehicle HBS buffer or 4 nM 
rFVIIa. Two microfluidic devices were tested allowing 16 simultaneous thrombi to be 
imaged in 60 sec intervals. Conditions were tested at minimum in replicate with 2 different 
forms of anti-coagulation (ie. Low CTI vs. Low CTI + Apixaban + PPACK) tested on each 
device. Blood samples were perfused at a local wall shear rate of 100s-1. The total perfusion 
time was 15 min for all flow assays. Platelet and fibrin accumulation were analyzed in the 
same manner as previously mentioned.   
8.3.2 Supplemental Discussion  
Though potent thrombin inhibitors have been used in study of rFVIIa, the effect of 
the contact pathway with in vitro flow assays is not often considered[153,154]. Enhancement 
of fibrin formation under flow conditions by rFVIIa have been shown previously[76,154,155]. 
However, these studies used heparin or citrate as anticoagulants, not considering contact 
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pathway-associated thrombin generation as FXII activation is known to occur independently 
of heparin or plasma calcium. In these prior studies, thrombin was most likely already present 
prior to perfusion through activation of the contact pathway. Thus rFVIIa mediated fibrin 
generation could be due to FXIIa in these cases. Interestingly, only a triple cocktail of 
anticoagulants blocking thrombin with a potent thrombin inhibitor (PPACK), FXa inhibitor 
(Apixaban), and FXIIa inhibitor (CTI) completely abolished the platelet effects from rFVIIa 
(Supplemental Figure S4). This establishes a requirement for thrombin in order to observe 
substantial effects from rFVIIa.  
In platelet poor plasma (PPP) under static conditions, contact pathway engagement 
and rFVIIa initiated thrombin faster when compared to strong contact pathway inhibition 
with high CTI (Supplemental Figure S5). Under flow conditions, ex vivo rFVIIa had no 
effect on fibrin generation from healthy PPP or factor-deficient plasma (Supplemental 
Figure S1). We anticipate that potentiation of rFVIIa function by the contact pathway requires 
the platelet surface or platelet-derived products. Future studies would involve carefully 
titrating varying levels of FVIII, FIX, or FXI into hemophillic WB to examine the role of the 
contact pathway in rFVIIa function.   
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8.3.3 Fibrin fluorescence at t = 10 min for low CTI-inhibited recalcified healthy 
pooled plasma, FXI, FIX, or FVIII-deficient plasma ± rFVIIa  
 
 
Figure 8-6. Representative images at 10 min of fibrin fluorescence intensity for low 
CTI-inhibited recalcified healthy pooled plasma, FXI, FIX, or FVIII-deficient 
plasma ± rFVIIa.  
Fibrin initiation and accumulation was observed in the corners of the microfluidic channels in areas of low flow 
where coagulation factors accumulate for healthy pooled plasma (A&E). In healthy pooled plasma, 
accumulation of fibrin fibers was independent of rFVIIa. No fibrin fluorescence signal was detected in all 
factor-deficient plasma samples (B-D, F-H) with or without rFVIIa. The scale bar indicates 50 µm. 
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8.3.4 Detection of CTI interaction with rFVIIa with fluorogenic FVIIa substrate  
 
Figure 8-7 Conversion of fluorogenic FVIIa substrate in the absence or presence of 
low or high CTI with 400 nM rFVIIa  
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8.3.5 Effect of exogenous rFVIIa in two additional severely FVIII-deficient patients 
#57 and #56  
 
Figure 8-8 Effect of exogenous rFVIIa in severely FVIII-deficient patient #57 and 56 
after recovery of critical factor levels to 9 and 10% respectively due to therapy.  
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(A), Platelet and fibrin fluorescence over time in high or low CTI-inhibited WB for patient #57. (B), Platelet 
and fibrin fluorescence in high or low CTI-inhibited WB for patient #56. Timing of recent hemostatic therapy 
is as indicated. Shaded traces are the standard deviation of two clotting events measured in 60 sec intervals over 
15 min. Dashed lines indicate full channel occlusion.  
 
8.3.6 Effect of ex vivo rFVIIa to WB under flow with inhibition of the contact 
pathway, thrombin, and FXa 
 
Figure 8-9 Exogenous rFVIIa addition to WB anti-coagulated with low CTI, PPACK 
and direct FXa inhibitor Apixaban 
(A), Platelet fluorescence dynamics with exogenous rFVIIa addition in thrombin-inhibited flow environment. 
(B), Fibrin fluorescence dynamics with exogenous rFVIIa addition in thrombin-inhibited flow environment. 
Shaded traces are standard deviation of 4 clotting events measured in 30 sec intervals 
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8.3.7 Detection of contact pathway mediated rFVIIa efficacy using fluorogenic 
thrombin substrate  
 
Figure 8-10 Conversion of fluorogenic thrombin substrate in low or high CTI 
inhibited PPP upon addition of indicated concentrations of rFVIIa  
(A), Detection of thrombin activity in recalcified high CTI-inhibited PPP supplemented with rFVIIa and 
PS:PC vesicles.  (B), Detection of thrombin activity in recalcified low CTI-inhibited PPP supplemented with 
rFVIIa and PS:PC vesicles. Traces are average of 4 repeats per condition.   
 
8.4 Ex vivo recapitulation of trauma-induced coagulopathy and 
preliminary assessment of trauma patient platelet function under 
flow using microfluidic technology  
8.4.1 Supplementary Materials and Methods  
8.4.1.1 Blood collection 
Whole blood was collected from healthy donors either into 100 μM PPACK or into 
an empty BD syringe. 1 mL of whole blood from the empty syringe was then aliquoted into 
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four separate tubes containing 10 μL PPACK at 1, 2, 3, and 4 min after the initial blood 
draw to mimic phlebotomy blood collection methods in the HUP trauma and resuscitation 
bay.  
 
8.4.1.2 Validation by flow cytometry that minor delays in anticoagulation do not affect platelet activation  
All fluorescent antibodies were purchased from BD Biosciences. Each well of a flat-
bottom 96 well plate (Corning, Corning, NY, USA) was loaded with 72 μL HBS, 2 μL of 
Cy5 annexin V, 2 μL PE anti-CD62P, and 4 μL FITC PAC-1. Each row received 10 μL of 
1:10 diluted whole blood inhibited at 0, 1, 2, 3, 4 min post-phlebotomy. ADP and collagen 
(final concentration 50 μM and 100 nM respectively) were selected as agonists to stimulate 
platelet activation. Ten minutes prior to flow cytometry analysis, 10 μL of a 10X stock of the 
appropriate agonist or HBS was added, giving a final volume of 100 μL. Accuri C6 flow 
cytometer with CSampler was used for plate handling. The sample flow rate was set to slow, 
and samples were analyzed for 1 min following the 10 minute incubation with agonist(s). 
8.4.1.3 Validation of thrombin inhibition by 100 uM PPACK in whole blood anticoagulated up to 4 
min after initial phlebotomy  
Fluorogenic thrombin substrate Boc-Val-Pro-Arg-methylcoumarinamide (Boc-VPR-
MCA) was obtained from Bachem (King of Prussia, PA). Boc-VPR-MCA diluted in HBS 
was added to each well in a 384 well plate (Corning). Whole blood anticoagulated with 100 
µM PPACK at 0, 1, 2, 3, 4 min post-phlebotomy was diluted in HBS. Diluted whole blood 
was added simultaneously to each row of substrate to ensure a simultaneous detection of 
thrombin activity yielding a final concentration of 9 μM Boc-VPR-MCA and 20% whole 
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blood. A fluoroskan (Fluoroskan Ascent, Thermo Scientific, Waltham, MA) detected the 
fluorescence of the released aminomethylcoumarin (AMC) reporter group. Each well was 
read twice per minute for 45 min. Fractional conversion of the fluorogenic substrate was 
determined according to (Equation 8-1). 
 
8.4.2 Ex vivo protocol to mimic modules of trauma-induced coagulopathy in the 8-
channel device under pressure relief flow regimes 
 
 
 
Figure 8-11 Ex vivo protocol to mimic resuscitation-induced hemodilution and 
hyperfibrinolysis in the 8-channel microfluidic device under pressure relief mode 
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(A), WB is inhibited with 40 µg/ml CTI or 100 µM PPACK and diluted with saline, PPP or PRP to mimic Hct 
lowering. To promote a 'lytic state' exogenous tPA (0-50 nM) was added to whole blood. (B), Flow through a 
cross section of a pair of microfluidic channels was previously modeled using COMSOL. The growing clot 
with variable height was represented by a trapezoidal shape in a single channel[37]. Pressure relief mode was 
recreated by setting the flow rate at the outlet to 4 µl/min. (C), Shear rate calculated at the wall in the center of 
the model clot[37]. (D), Flow rate calculated at the wall in center of the model clot[37].   
8.4.3 Platelet accumulation fluorescence dynamics and total platelet accumulation 
at 900 sec (Healthy subject vs Trauma patient #24: Response to ex vivo 
MRS2179, GSNO, iloprost) 
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Figure 8-12 Platelet accumulation dynamics measured by platelet fluorescence and 
total platelet accumulation morphology at 900 sec in representative healthy donor 
and trauma patient (#24) in response to ex vivo MRS2179, GSNO, or iloprost.  
(A), Total platelet accumulation at 900 sec following ex vivo treatment with antagonists MRS2179, GSNO, or 
iloprost. (B), Platelet fluorescence dynamics in representative healthy donor in the presence of indicated 
concentrations of ex vivo MRS 2179, GSNO, or iloprost. (C), Platelet fluorescence dynamics in trauma patient 
(#24) in the presence of indicated concentrations of ex vivo MRS 2179, GSNO, or iloprost. Shaded traces are 
the mean and standard deviation of 4 clotting events from each healthy donor or patient. 
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8.4.4 P-selectin expression measured by p-selectin antibody staining and platelet 
accumulation in representative healthy donor and trauma patient #9. 
 
 
Figure 8-13 Dynamic p-selectin expression and platelet accumulation in 
representative healthy donor and trauma patient (9).  
(A), Overlay of platelet deposition (red) and p-selectin expression (aqua) over the time course of the flow 
assay. (B), Platelet fluorescence and p-selectin expression dynamics over time in three healthy donors in 
comparison to a trauma patient (#9). Shaded traces are the mean and standard deviation of a minimum of 4 
clotting evens from each donor or patient. 
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8.4.5 Gross thrombus instability due to the lytic state at venous shear rates  
 
Figure 8-14 Disintegration of platelet aggregates and fibrin accumulation in response 
to exogenous tPA ± εACA at venous shear rates.  
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 200s-1.  (B), Platelet 
fluorescence intensities vs. time with exogenous tPA ± εACA added. (C), Fibrin fluorescence intensities vs. 
time with exogenous tPA ± εACA added. Shaded traces are the average and standard deviation of two clotting 
events.  
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8.4.6 Gross thrombus instability due to the lytic state at arterial shear rates  
 
Figure 8-15 Disintegration of platelet aggregates and fibrin accumulation in response 
to exogenous tPA ± εACA at arterial shear rates  
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 1222 s-1 over the time course of 
the 20 min assay. (B), Platelet fluorescence intensities vs. time with exogenous tPA ± εACA added. (C), Fibrin 
fluorescence intensities vs. time with exogenous tPA ± εACA added. Shaded traces are the average and 
standard deviation of two clotting events.  
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8.4.7 Detection of platelet desensitization from stimulation of WB anticoagulated 
with PPACK up to 4 min post phlebotomy with ADP or collagen in flow 
cytometry  
 
 
Figure 8-16 Stimulation of whole blood anticoagulated with 100 µM PPACK up to 4 
min post-phlebotomy with ADP or collagen in flow cytometry 
The percentage of platelets staining positive for PAC-1 expression (A), P-Selectin expression (B), and PS 
exposure (C) upon stimulation with indicated agonists in 1% whole blood samples anticoagulated with 100 µM 
PPACK at 0, 1, 2, 3, 4 min following initial blood draw. These results indicate that platelets were not 
significantly activated for up to 3 minutes in the syringe prior to anticoagulation. Markers are the average and 
standard deviation of 3 measurements from 3 donors.  
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8.4.8 Detection of thrombin using a fluorogenic thrombin-sensitive substrate in WB 
anticoagulated with PPACK up to 4 min post phlebotomy 
 
Figure 8-17 Conversion of fluorogenic thrombin-sensitive substrate in whole blood 
anticoagulated with 100 µM PPACK up to 4 min post-phlembotomy  
To evaluate whether 100 µM PPACK fully inhibits thrombin generation post-phlebotomy, the conversion of 
the thrombin sensitive flurogenic substrate was measured for 45 min. A delay of up to 4 min prior to 
anticoagulation with PPACK does not illicit thrombin generation. Shaded traces are the average and standard 
deviation of 12 measurements from 3 donors.  
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8.4.9 Trauma Patient #36 platelet function under flow at venous shear rates 
 
Figure 8-18 Trauma patient #36  
(A) Total platelet accumulation at 900 sec. (B) Platelet deposition dynamics at venous shear rates (100s-1). 
Shaded trace is the mean and standard deviation of 4 clotting events from patient #36.  
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8.4.10 Comparison of baseline platelet accumulation on collagen (healthy subjects vs. 
trauma patients) 
 
Figure 8-19 Comparison of healthy and trauma patient total platelet accumulation at 
900 sec 
Bars are average and standard deviation from the indictated number of donors or patients tested (n) at 4 
clotting events per donor or patient. **p<0.001 
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8.4.11 Comparison of response to ex vivo addition of MRS2179, GSNO, or iloprost 
(healthy subjects vs trauma patients) 
 
Figure 8-20 Ex vivo addition of GSNO reduced total platelet accumulation more 
significantly in trauma patients then healthy donors 
Trauma patients responded less to ex vivo antagonism with MRS 2179 or iloprost. Bars are average and 
standard deviation from the indictated number of donors or patients tested (n) at 4 clotting events per donor or 
patient. **MRS 2179: p = 0.003, GSNO: p < 0.001, Iloprost: p < 0.001 
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8.4.12 Platelet function measured by platelet fluorescence over time post-admissions 
for massively transfused patient #31 
 
Figure 8-21 Platelet fluorescence vs. time for massively transfused patient #31 
Shaded traces are the average and standard deviation of 4 clotting events. 
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